2571 articles by Ned Pagliarulo

• Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says

  Jan. 28, 2025

• Akero says MASH drug reverses liver damage in study, doubling shares

  Jan. 27, 2025

• The biopharma industry outlook on 2025: Uncertainty and change

  Jan. 24, 2025

• J&J joins Pfizer in detailing impact of Part D redesign

  Jan. 22, 2025

• Ozempic, Ibrance among next drugs picked by Medicare for price talks

  Jan. 17, 2025

• JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

  Jan. 16, 2025

• Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku

  Jan. 14, 2025

• 5 questions facing emerging biotech in 2025

  Jan. 14, 2025

• J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

  Jan. 13, 2025

• Patrizia Cavazzoni, key FDA official, to leave agency

  Jan. 10, 2025

• Intellia to stop work on rare disease therapy, lay off staff

  Jan. 10, 2025

• 5 questions facing pharma in 2025

  Jan. 9, 2025

• J&J says cancer drug combination showed survival benefit over Tagrisso

  Jan. 7, 2025

• Zepbound, Mounjaro shortages are resolved, FDA confirms

  Dec. 19, 2024

• Namandjé Bumpus, FDA’s No. 2 official, to depart agency at end of year

  Dec. 17, 2024

• Pfizer predicts stability, to Wall Street’s relief

  Dec. 17, 2024

• Jazz to search for new chief as CEO plans retirement

  Dec. 16, 2024

• Edgewise weighs fast approval path for muscular dystrophy drug

  Dec. 16, 2024

• Novo Holdings’ purchase of Catalent set to close after regulators’ green light

  Dec. 16, 2024

• AbbVie to acquire Roche spinout Nimble in immune drug deal

  Dec. 13, 2024

• Editas to lay off staff after search for sickle cell partner comes up empty

  Dec. 12, 2024

• Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery

  Dec. 11, 2024

• ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T

  Dec. 10, 2024

• ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

  Dec. 9, 2024

• Gene therapy uptake in sickle cell stays slow, despite patient interest

  Dec. 9, 2024

• Applied’s rare disease drug rejected by FDA

  Dec. 2, 2024

• Sarepta rebuilds drug pipeline with Arrowhead deal

  Nov. 27, 2024

• Roche’s TIGIT-targeting drug for cancer fails its biggest test

  Nov. 26, 2024

• Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

  Nov. 22, 2024

• Lexicon to disband sales team, lay off 60% of staff

  Nov. 22, 2024

• Biotech startups are built on venture capital. Track funding rounds here.

  Nov. 21, 2024

• J&J pill clears skin in two late-stage psoriasis studies

  Nov. 19, 2024

• CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest

  Nov. 18, 2024

• Surviving in biotech’s new normal: 5 tips from industry VCs and CEOs

  Nov. 15, 2024

• Trump names RFK Jr. as his pick to lead HHS

  Nov. 14, 2024

• Neurogene hits a setback in the clinic, days after fundraise

  Nov. 12, 2024

• Moderna earnings beat forecasts, but analysts question whether sales spike will last

  Nov. 7, 2024

• With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

  Nov. 7, 2024

• Sickle cell patient dies in Beam study of base editing therapy

  Nov. 5, 2024

• Viking data provide latest test of oral obesity drug potential

  Nov. 4, 2024

• Jade, another biotech spinout of Paragon, to merge with Aerovate

  Oct. 31, 2024

• Novo takes big step toward ending Ozempic, Wegovy shortages

  Oct. 30, 2024

• Lilly shares fall as obesity drug sales miss forecasts

  Oct. 30, 2024

• GSK to pay $300M to license drug it sees as potential lupus treatment

  Oct. 29, 2024

• Pfizer answers Starboard challenge with beat-and-raise quarter

  Oct. 29, 2024

• Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

  Oct. 28, 2024

• Starboard makes case for change at Pfizer, citing research, M&A missteps

  Oct. 22, 2024

• Editas, changing course again, looks to partner lead CRISPR therapy

  Oct. 22, 2024

• Sanofi, expanding in radiopharma, strikes a joint venture deal

  Oct. 17, 2024

• Wave sees RNA editing validation in early trial results

  Oct. 16, 2024

• Pfizer drug for hemophilia approved by FDA

  Oct. 14, 2024

• New data underline cancer risk of Bluebird therapy for brain disease

  Oct. 10, 2024

• Lilly names Mount Sinai scientist as first chief AI officer

  Oct. 9, 2024

• Startup led by John Maraganore raises $135M to build ‘future of RNAi’

  Oct. 8, 2024

• Intellia starts late-stage test of CRISPR therapy for rare swelling disease

  Oct. 7, 2024

• Medicare tweaks rules for second round of drug price talks

  Oct. 3, 2024

• 4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

  Sept. 19, 2024

• Ascendis trial data piles pressure on BioMarin

  Sept. 17, 2024

• ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact

  Sept. 16, 2024

• TIGIT drug from iTeos shrinks lung tumors in trial

  Sept. 14, 2024

• BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

  Sept. 11, 2024

• Relay breast cancer drug shows potential in early trial

  Sept. 9, 2024

• Lykos CEO to depart after FDA rejection, layoffs

  Sept. 5, 2024

• AI specialist Recursion says lead drug is safe, but efficacy less clear

  Sept. 3, 2024

• Lilly rolls out Zepbound vials at a discount price

  Aug. 27, 2024

• Updated COVID shots from Pfizer, Moderna cleared by FDA

  Aug. 22, 2024

• BridgeBio sends rare disease drugs to new company

  Aug. 21, 2024

• J&J drug combo for lung cancer approved by FDA

  Aug. 20, 2024

• Lilly’s tirzepatide cuts diabetes risk, study data show

  Aug. 20, 2024

• Novo plans new plant as it races to meet drug demand

  Aug. 19, 2024

• Medicare reveals results of drug price negotiations

  Aug. 15, 2024

• Acelyrin shifts from main drug, lays off staff

  Aug. 13, 2024

• Galderma wins FDA approval for skin condition treatment

  Aug. 13, 2024

• FDA approves Ascendis drug for rare endocrine condition

  Aug. 12, 2024

• Apellis plans FDA filing after drug success in kidney trial

  Aug. 8, 2024

• Lilly boosts outlook on rising Zepbound revenue

  Aug. 8, 2024

• BioMarin pares Roctavian spending as it narrows sales focus

  Aug. 6, 2024

• Zepbound, Mounjaro back in supply as Lilly resolves shortage

  Aug. 5, 2024

• Jim Wilson, prominent gene therapy researcher, to depart UPenn

  Aug. 1, 2024

• GSK cuts vaccine forecasts, while predicting faster overall growth

  July 31, 2024

• Incyte trims cancer drug pipeline in R&D refocus

  July 30, 2024

• Boehringer adds to cancer drug pipeline with deal for startup Nerio

  July 29, 2024

• Bristol Myers’ beat completes strong week of pharma earnings

  July 26, 2024

• Startup led by former J&J executives raises $165M for cancer, immune disease drugs

  July 23, 2024

• US government declines to clear Bluebird fertility support for Zynteglo patients

  July 22, 2024

• In strengthening Spravato sales, a positive sign for psychedelic drugs

  July 17, 2024

• Gilead’s CMO to depart next year

  July 17, 2024

• Vertex sues US over limits on providing fertility services to Casgevy patients

  July 16, 2024

• Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

  July 15, 2024

• UniQure, with sale of plant, outsources Hemgenix manufacturing

  July 1, 2024

• Rocket gene therapy rejected by FDA over manufacturing

  June 28, 2024

• 2seventy slims down with sale of hemophilia assets to Novo

  June 27, 2024

• Wave, with new data, plots path forward for Huntington’s drug

  June 25, 2024

• Novo fills in positive picture for preventive hemophilia drug

  June 24, 2024

• Twice-yearly shots of Gilead HIV drug effective in large prevention study

  June 20, 2024

• Radiopharma drugmaker Telix pulls US IPO plans

  June 14, 2024

• Pfizer gene therapy for Duchenne fails to meet goals of key trial

  June 12, 2024

• Regenxbio CEO to step down after 15 years

  June 12, 2024

• Ipsen drug for rare liver disease approved by FDA

  June 11, 2024

• Germany’s ITM raises $205M as radiopharma field booms

  June 6, 2024

• BridgeBio data show sustained benefit for achondroplasia drug

  June 4, 2024

• Gilead’s Trodelvy misses goal in bladder cancer study

  May 31, 2024

• Novartis study points to larger role for targeted leukemia drug

  May 31, 2024

• J&J antidepressant eases symptoms, improves sleep in key trial

  May 29, 2024

• Insmed shares double as lung drug data convince Wall Street

  May 28, 2024

• Lilly to pour $5B more into expanding Zepbound, Mounjaro production

  May 24, 2024

• Cytokinetics secures up to $575M in royalty deal, frustrating investors

  May 23, 2024

• Pfizer expands cost cuts with new $1.5B target

  May 22, 2024

• BIO to restructure, lay off staff in shakeup of lobbying group

  May 20, 2024

• Dyne shares jump on trial data for muscle disease drugs

  May 20, 2024

• Lilly’s once-weekly insulin matches daily shots in late-stage tests

  May 16, 2024

• Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170

  May 15, 2024

• FogPharma, Artbio join forces to design a different radiopharma drug

  May 14, 2024

• Novavax gets a lifeline with Sanofi vaccine pact

  May 10, 2024

• Takeda targets ‘efficiency’ in restructuring, pipeline cuts

  May 9, 2024

• Verve moves forward with backup base editing therapy

  May 7, 2024

• Bluebird, Vertex prep for first commercial use of sickle cell gene therapies

  May 6, 2024

• Why selling to Novartis made sense for Mariana

  May 3, 2024

• BridgeBio spinout launches with $200M for KRAS cancer drugs

  May 2, 2024

• Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

  May 1, 2024

• Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb

  April 30, 2024

• Prime gets FDA green light to begin first trial test of ‘prime editing’

  April 29, 2024

• Bristol Myers to cut 6% of workforce, trim drug pipeline

  April 25, 2024

• Moderna turns to AI to change how its employees work

  April 24, 2024

• Novartis raises forecasts as top drug sales beat Wall Street estimates

  April 23, 2024

• Bristol Myers taps startup to boost cell therapy production

  April 22, 2024

• Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

  April 18, 2024

• J&J sees mixed performance from new multiple myeloma drugs

  April 16, 2024

• Ultragenyx says Angelman therapy is working, but safety questions remain

  April 15, 2024

• FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use

  April 5, 2024

• Merck puts KRAS cancer drug competitor to the test

  April 4, 2024

• Verve pauses base editing trial, shifts strategy after treatment side effect

  April 2, 2024

• Gilead bets on Xilio cancer drug as biotech restructures

  March 28, 2024

• Stoke shares surge on updated results for Dravet drug

  March 26, 2024

• Novo to acquire heart failure drug in $1B deal for Cardior

  March 25, 2024

• With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease

  Feb. 29, 2024

• Janux shares triple on early cancer immunotherapy data

  Feb. 27, 2024

• Minerva schizophrenia drug rejected by FDA

  Feb. 27, 2024

• J&J secures EMA backing for earlier CAR-T use in multiple myeloma

  Feb. 23, 2024

• Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’

  Feb. 22, 2024

• AstraZeneca gets new Tagrisso OK as drug succeeds in another trial

  Feb. 20, 2024

• Ipsen drug approved by FDA for early pancreatic cancer

  Feb. 14, 2024

• Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex

  Feb. 14, 2024

• Gilead to buy CymaBay in $4.3B deal for liver disease drug

  Feb. 12, 2024

• Obesity drug mania takes over Amgen’s earnings call

  Feb. 7, 2024

• Merck keeps deal focus with Keytruda patent cliff on horizon

  Feb. 1, 2024

• New CMS pilot to test payment scheme for pricey sickle cell gene therapies

  Jan. 31, 2024

• Regeneron to acquire 2seventy’s cell therapy pipeline

  Jan. 30, 2024

• Non-opioid drug from Vertex cuts pain in major trial tests

  Jan. 30, 2024

• Sarepta data show new Duchenne drug’s potency, but highlight side effects

  Jan. 29, 2024

• RayzeBio drew other pharma interest before Bristol Myers deal

  Jan. 25, 2024

• Lilly gene therapy finding puts focus on hearing loss treatment pipeline

  Jan. 24, 2024

• Sanofi to buy Inhibrx in deal worth up to $2.2B

  Jan. 23, 2024

• Novartis details first-line data for radiopharma drug Lutathera

  Jan. 19, 2024

• Gene therapy biotech Jaguar spins out manufacturing company

  Jan. 18, 2024

• BridgeBio strikes drug royalty deal for cash infusion

  Jan. 18, 2024

• FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia

  Jan. 16, 2024

• The biopharma industry outlook on 2024: Guarded optimism for a rebound

  Jan. 16, 2024

• Backed by billionaires, a new biomedical institute tests an unorthodox approach

  Jan. 12, 2024

• 5 questions facing pharma in 2024

  Jan. 10, 2024

• JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense

  Jan. 10, 2024

• GSK to buy asthma drug startup Aiolos for $1B

  Jan. 9, 2024

• Year of biotech layoffs leaves industry looking for spark

  Jan. 8, 2024

• J&J to acquire ADC drug developer Ambrx for $2B

  Jan. 8, 2024

• FDA authorizes Florida to import drugs from Canada

  Jan. 5, 2024

• Lilly launches online service for home delivery of weight loss drug

  Jan. 4, 2024

• 5 FDA decisions to watch in the first quarter

  Jan. 4, 2024

• 10 clinical trials to watch in the first half of 2024

  Jan. 2, 2024

• Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval

  Dec. 22, 2023

• Bristol Myers to acquire brain drug developer Karuna for $14B

  Dec. 22, 2023

• Biogen holds onto Tecfidera market in Europe for a little longer

  Dec. 19, 2023

• Point radiopharma drug results disappoint in prostate cancer study

  Dec. 18, 2023

• At ASH, doctors acclaim new sickle cell gene therapies, but are cautious on details

  Dec. 13, 2023

• ASH23: Pharma branding, Editas’ high bar and clinical trial diversity

  Dec. 11, 2023

• ‘No tolerance for failure’: An oral history of the first CRISPR medicine

  Dec. 10, 2023

• ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media mentions

  Dec. 9, 2023

• Pricey new gene therapies for sickle cell pose access test

  Dec. 8, 2023

• CRISPR therapy for sickle cell approved by FDA in gene editing milestone

  Dec. 8, 2023

• AbbVie to buy Cerevel in $8.7B bet on brain drugs

  Dec. 6, 2023

• Novartis gets FDA approval of closely watched rare disease drug

  Dec. 6, 2023

• J&J pitches investors on sales growth from cancer, immune disease drugs

  Dec. 5, 2023

• EyePoint sees stock surge on AMD drug trial data

  Dec. 4, 2023

• Pfizer plans for oral obesity drug hit new setback

  Dec. 1, 2023

• Novartis sees brighter sales future as R&D revamp continues

  Nov. 28, 2023

• Regeneron, Sanofi to seek new Dupixent approval in US after COPD success

  Nov. 27, 2023

• Freeline, after cuts, agrees to take-private deal with Syncona

  Nov. 22, 2023

• Bristol Myers faces FDA delay on cancer cell therapy decision

  Nov. 20, 2023

• World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia

  Nov. 16, 2023

• Anthos blood thinner bests Xarelto on safety in mid-stage study

  Nov. 13, 2023

• First look at Verve study data offers base editing ‘proof of principle’

  Nov. 12, 2023

• Novo takes aim at obesity drug shortages with $6B manufacturing plan

  Nov. 10, 2023

• Lilly rival to weight loss drug Wegovy approved by FDA

  Nov. 8, 2023

• What if a CRISPR cure isn’t such an easy choice?

  Nov. 8, 2023

• Biogen, Sage set price of postpartum depression pill at $15,900

  Nov. 7, 2023

• Celldex’s reinvention advances with inflammatory disease drug data

  Nov. 6, 2023

• November brings new flurry of biotech layoffs

  Nov. 3, 2023

• Vertex, CRISPR therapy for sickle cell passes FDA panel test

  Oct. 31, 2023

• A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy

  Oct. 31, 2023

• Lilly buys out Beam in heart drug alliance with Verve

  Oct. 31, 2023

• Sarepta gene therapy for Duchenne misses main goal of key study

  Oct. 30, 2023

• Novartis bet on kidney disease drug yields positive study data

  Oct. 30, 2023

• Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs

  Oct. 27, 2023

• FDA staff focus on ‘off-target’ risk in review of Vertex, CRISPR sickle cell therapy

  Oct. 27, 2023

• Bristol Myers says new drugs sales will grow more slowly

  Oct. 26, 2023

• Excision gives first look at gene editing therapy for HIV

  Oct. 25, 2023

• Seagen trial data impresses at ESMO, lifting Merck, Pfizer in the process

  Oct. 23, 2023

• Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary

  Oct. 23, 2023

• Verve gets FDA green light to run base editing study in US

  Oct. 23, 2023

• Merck allies with Daiichi Sankyo in major bet on antibody cancer drugs

  Oct. 20, 2023

• Beam to lay off 100 employees, seek partners in research restructuring

  Oct. 19, 2023

• After long journey, Ardelyx gets FDA OK for kidney disease drug

  Oct. 18, 2023

• J&J again bumps forecasts on strong immune drug sales

  Oct. 17, 2023

• The top biopharma conferences in 2024

  Oct. 16, 2023

• Pfizer to cut costs, lay off staff on waning demand for COVID products

  Oct. 13, 2023

• Akero drug for NASH misses goal in mid-stage study

  Oct. 10, 2023

• Bristol Myers to buy KRAS cancer drug developer Mirati for $4.8B

  Oct. 8, 2023

• FDA panel finds KRAS drug data unreliable, in blow to Amgen

  Oct. 6, 2023

• Orchard sells to Kyowa Kirin in gene therapy buyout

  Oct. 5, 2023

• Sanofi buys into Teva gut disease drug

  Oct. 4, 2023

• Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

  Oct. 3, 2023

• 5 FDA decisions to watch in the fourth quarter

  Oct. 2, 2023

• Structure boosted by early data for experimental obesity drug

  Sept. 29, 2023

• J&J cancer drug combo beats Tagrisso in closely watched trial

  Sept. 28, 2023

• BrainStorm’s ALS therapy not effective, FDA panel finds

  Sept. 27, 2023

• Former Novartis executive Tsai to lead UK heart drug startup

  Sept. 27, 2023

• Immunovant data show potential for autoimmune disease drug

  Sept. 26, 2023

• Eisai’s Alzheimer’s drug Leqembi approved in Japan

  Sept. 25, 2023

• FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

  Sept. 25, 2023

• J&J to phase out Janssen name in corporate rebrand

  Sept. 15, 2023

• Actio, a precision medicine startup, launches with $55M and a mouse lab partnership

  Sept. 12, 2023

• 2Seventy CEO Leschly to step down as company cuts staff, spending

  Sept. 12, 2023

• Ex-Sanofi executive Sibold joins Madrigal as new CEO

  Sept. 11, 2023

• Otsuka partners with Shape in deal to design eye gene therapies

  Sept. 8, 2023

• Astellas withdraws lawsuit challenging Medicare drug price program

  Sept. 7, 2023

• Catalent expands board in deal with activist investor Elliott

  Aug. 29, 2023

• Medicare names first 10 drugs for price negotiations

  Aug. 29, 2023

• AstraZeneca the latest pharma to challenge drug pricing law

  Aug. 25, 2023

• Royalty Pharma buys into Ferring’s cancer treatment in first gene therapy deal

  Aug. 24, 2023

• Boehringer sues to block US drug price program

  Aug. 22, 2023

• Boehringer moves Wegovy competitor into late-stage testing

  Aug. 17, 2023

• Gilead allies with targeted drug startup Tentarix in latest research bet

  Aug. 15, 2023

• Taysha gets cash lifeline from new investor RA Capital

  Aug. 14, 2023

• Amylyx ALS drug sales tick higher after fast US launch

  Aug. 11, 2023

• Lilly market value soars on higher sales, obesity drug potential

  Aug. 8, 2023

• Novartis sickle cell drug’s approval formally revoked by EU regulators

  Aug. 4, 2023

• Amgen says KRAS drug met goal in late-stage colon cancer trial

  Aug. 3, 2023

• Vertex taking ‘flexible’ approach to payment talks for experimental CRISPR therapy

  Aug. 2, 2023

• Pfizer weighs cutting costs as COVID drug sales ebb

  Aug. 1, 2023

• BridgeBio explores path forward for muscular disease drug

  July 31, 2023

• Biogen to acquire rare disease drugmaker Reata for $7.3B

  July 28, 2023

• Gene editing biotech Homology hits reset and seeks a sale

  July 28, 2023

• Biogen to eliminate 1,000 jobs in further cost cuts

  July 25, 2023

• Roche buys into Alnylam heart drug in cardiovascular research bet

  July 24, 2023

• Mirati’s KRAS-blocking cancer drug hits setback in Europe

  July 21, 2023

• J&J shares jump on strong sales, boosted outlook

  July 20, 2023

• Wilson Bryan, former FDA gene therapy leader, joins consulting firm

  July 19, 2023

• Argenx raises $1.1B on heels of rare disease drug data

  July 19, 2023

• Novartis raises drug sales forecast, plans new stock buybacks

  July 18, 2023

• Lilly to buy Versanis, adding to obesity drug pipeline

  July 14, 2023

• Startup Tenpoint raises $70M to develop regenerative medicines for the eye

  July 12, 2023

• Avrobio halts gene therapy research and considers a sale

  July 12, 2023

• Bristol Myers licenses Prothena, Evotec brain drugs, inching back into neuroscience

  July 11, 2023

• Novartis to appeal district court ruling on heart drug patent

  July 10, 2023

• Nanobiotix licenses cancer treatment to J&J, extending runway

  July 10, 2023

• Bausch + Lomb bulks up OTC business with J&J deal

  July 6, 2023

• Spyre, a new biotech spinout, launches via merger with Aeglea

  June 22, 2023

• Argenx wins FDA approval for under-the-skin injection of rare disease drug

  June 21, 2023

• Verve partners with Lilly on gene editing therapy for heart disease

  June 15, 2023

• Pfizer refiles Seagen deal paperwork with regulators

  June 14, 2023

• Study of 2seventy Bio’s AML cell therapy paused after patient death

  June 14, 2023

• Medicare sets next tranche of drugs to face price hike penalties

  June 9, 2023

• Armed with new gene therapy tools, a biotech startup promises a better way to target muscle diseases

  June 8, 2023

• Closing ASCO: AstraZeneca’s ‘very special’ meeting, more CAR-T survival data and Pfizer’s PARP play

  June 6, 2023

• AstraZeneca study points to new uses for targeted cancer drug Enhertu

  June 5, 2023

• J&J sees trial data supporting earlier CAR-T use in multiple myeloma

  June 5, 2023

• Bristol Myers data make case for earlier use of bone marrow disease drug

  May 25, 2023

• ASCO puts spotlight on advancing antibody-drug conjugate pipeline

  May 25, 2023

• Novartis buys rare disease gene therapy from Avrobio

  May 22, 2023

• Gilead picks former Roche executive to run cell therapy unit Kite

  May 17, 2023

• Siren emerges from stealth with plans to marry gene therapy to cancer immunotherapy

  May 17, 2023

• Biotech startup Ray raises $100M for vision-restoring gene therapies

  May 16, 2023

• FDA panel narrowly backs approval of Sarepta’s Duchenne gene therapy

  May 12, 2023

• Gilead acquires San Diego startup for early-stage cancer, immune drugs

  May 9, 2023

• EQRx resets strategy, abandoning plans to disrupt drug pricing

  May 8, 2023

• Catalent cuts outlook, delays results as it reveals new hurdles

  May 8, 2023

• Apellis reports strong start for new vision loss drug

  May 5, 2023

• Lilly drug slows Alzheimer’s decline in large study

  May 3, 2023

• Travere set back by study failure of kidney disease drug

  May 2, 2023

• Initial launches with $75M and a new idea for targeting problematic proteins

  May 1, 2023

• AbbVie weathers first months of biosimilar challenge to top-selling Humira

  April 28, 2023

• Sangamo to lay off 120 as it pares pipeline

  April 27, 2023

• Morphic shares swing on study data for drug viewed as ‘oral Entyvio’

  April 25, 2023

• J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market

  April 25, 2023

• Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs

  April 24, 2023

• Startup Abdera raises $110M to fuel radiopharmaceutical research

  April 20, 2023

• J&J study data show dramatic benefit to multiple myeloma cell therapy

  April 19, 2023

• GSK to buy Bellus Health and its chronic cough drug for $2B

  April 18, 2023

• Biotech leader Vagelos to retire as Regeneron board chair

  April 17, 2023

• Biotech layoffs gather pace as industry downturn persists

  April 10, 2023

• Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca

  April 7, 2023

• FDA withdraws preterm birth drug’s approval, denying maker’s request for delay

  April 6, 2023

• Seagen, Astellas win expanded FDA approval for bladder cancer drug

  April 4, 2023

• Pharma partner Sartorius eyes gene therapy market with $2.6B deal

  March 31, 2023

• Mathai Mammen, former J&J executive, to become FogPharma CEO

  March 30, 2023

• Bluebird, awaiting FDA feedback, says it’s likely to miss filing goal for sickle cell gene therapy

  March 29, 2023

• Pfizer returns cancer immunotherapy rights to Merck KGaA

  March 27, 2023

• BrainStorm files ALS drug application over FDA protest

  March 27, 2023

• Stuart Peltz, founder of PTC, retires after 25 years as CEO

  March 24, 2023

• Former Seagen CEO Siegall returns to biotech as head of early-stage startup

  March 23, 2023

• Biohaven strikes a deal to take TYK2 drugs in a new direction

  March 22, 2023

• FDA staff signal support for Biogen ALS drug, but highlight data hurdles

  March 20, 2023

• FDA reversal sets up high-stakes hearing on Sarepta gene therapy

  March 17, 2023

• Pfizer to buy Seagen in $43B cancer drug deal

  March 13, 2023

• Cancer drug startup Cargo raises $200M to solve CAR-T relapse

  March 1, 2023

• Theravance, under pressure from activist investor, cuts back research, trims staff

  Feb. 28, 2023

• Billy Dunn, FDA official in charge of neuroscience drug reviews, to leave agency

  Feb. 27, 2023

• EQRx, having redrawn strategy, to trim workforce by 18%

  Feb. 24, 2023

• Sickle cell pipeline narrows as gene therapy developers rethink research plans

  Feb. 23, 2023

• Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

  Feb. 21, 2023

• Gilead’s Shaw to step down from role running cell therapy unit

  Feb. 17, 2023

• PureTech, tweaking research, trims a ‘small number’ of positions

  Feb. 14, 2023

• AstraZeneca sees run of growth continuing in 2023

  Feb. 9, 2023

• Bayer names former Roche executive Bill Anderson as new CEO

  Feb. 8, 2023

• Idorsia shares sink on ‘unexpected’ failure of drug study

  Feb. 6, 2023

• FDA approves Gilead’s Trodelvy for expanded use in breast cancer

  Feb. 3, 2023

• Roche promotes from within to replace pharma head

  Feb. 2, 2023

• GSK secures FDA approval of anemia drug, but with limitations

  Feb. 2, 2023

• FDA approves cancer drugs from Lilly, Menarini

  Jan. 30, 2023

• FDA advisers back agency plan to simplify COVID-19 vaccination

  Jan. 26, 2023

• Bristol Myers says CAR-T therapy curbed leukemia in long-running study

  Jan. 26, 2023

• Merck reports one success, one setback from late-stage Keytruda trials

  Jan. 25, 2023

• Finch to lay off 95% of staff, scrap microbiome drug study

  Jan. 24, 2023

• FDA weighs shift in COVID vaccination strategy

  Jan. 23, 2023

• FDA rejects Lilly Alzheimer’s drug, citing insufficient data

  Jan. 20, 2023

• Editas, in next restructuring step, to sell cell therapy work to Shoreline

  Jan. 19, 2023

• Large study of J&J’s HIV vaccine stopped after shot found ineffective

  Jan. 18, 2023

• 5 questions facing gene therapy in 2023

  Jan. 12, 2023

• JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

  Jan. 10, 2023

• New Biogen CEO seeks to ‘redefine’ company after challenging year

  Jan. 10, 2023

• Editas to cut jobs, narrow research focus in restructuring

  Jan. 9, 2023

• Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

  Jan. 9, 2023

• 5 FDA decisions to watch in the first quarter

  Jan. 9, 2023

• Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

  Jan. 6, 2023

• Bluebird bolsters balance sheet with sale of second regulatory fast pass

  Jan. 6, 2023

• FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022

  Jan. 3, 2023

• Disappearing IPOs, building startups and closing deals: Views from an up-and-down year in biotech

  Jan. 3, 2023

• Merck builds out cancer drug pipeline with Kelun-Biotech deal

  Dec. 22, 2022

• Doubts around cancer drug target persist after Gilead, Arcus study results offer ‘mixed picture’

  Dec. 20, 2022

• FDA lifts hold on Bluebird’s sickle cell gene therapy

  Dec. 19, 2022

• Third Harmonic halts study of lead drug over safety risk

  Dec. 15, 2022

• Kymera shares jump on Sanofi’s decision to advance protein-degrading drug

  Dec. 14, 2022

• Mirati’s KRAS-blocking cancer drug approved by FDA

  Dec. 13, 2022

• J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

  Dec. 12, 2022

• Gene therapy approval won, Bluebird takes on next challenge: selling it

  Dec. 12, 2022

• Amgen to buy Horizon in year’s biggest biotech deal

  Dec. 12, 2022

• Esperion, without data, says cholesterol pill lowered heart risk in study

  Dec. 7, 2022

• Gene therapy approvals bring validation as field closes year on high

  Dec. 6, 2022

• Novartis prostate cancer drug succeeds in study key to company’s sales hopes

  Dec. 5, 2022

• SQZ CEO steps down as company restructures, cuts jobs

  Dec. 1, 2022

• Lilly’s Alzheimer’s drug bests Aduhelm in plaque clearance study

  Dec. 1, 2022

• Large pharmas probe takeover of Horizon Therapeutics

  Nov. 30, 2022

• What to make of Eisai and Biogen’s Alzheimer’s drug results

  Nov. 29, 2022

• State of Play: A closer look at hotspots of emerging biotech research

  Nov. 29, 2022

• FDA approves first gene therapy for hemophilia B

  Nov. 22, 2022

• GSK to pull blood cancer drug from US market after study failure

  Nov. 22, 2022

• Merck KGaA outlines plan to rev up drug R&D

  Nov. 21, 2022

• Editas to seek partner for CRISPR medicine after lackluster study results

  Nov. 17, 2022

• Biogen names former Sanofi head Viehbacher to replace Vounatsos as CEO

  Nov. 10, 2022

• Arrowhead capitalizes on Amgen drug progress with royalty rights deal

  Nov. 9, 2022

• BioMarin signals lengthier FDA review for hemophilia gene therapy

  Nov. 8, 2022

• GSK myeloma drug comes up short in confirmatory test

  Nov. 7, 2022

• Amgen to test new way to lower heart risk with large drug trial

  Nov. 7, 2022

• Bispecific cancer drugs and gene therapy advances: What to watch at this year’s ASH meeting

  Nov. 4, 2022

• RA Capital backs another startup hunting for a better antidepressant

  Nov. 2, 2022

• Lilly sales of new diabetes drug accelerate on rising patient demand

  Nov. 1, 2022

• Merck reveals chairman succession as earnings beat forecasts

  Oct. 27, 2022

• Novartis sales of Zolgensma gene therapy slow as market shifts

  Oct. 25, 2022

• Novartis rival to AstraZeneca rare disease drugs succeeds in study

  Oct. 24, 2022

• Pfizer planning steep price hike for COVID-19 vaccine

  Oct. 21, 2022

• Gilead, working to improve cancer cell therapy, partners with California startup

  Oct. 20, 2022

• AbbVie to buy UK biotech DJS for $255M

  Oct. 20, 2022

• FDA opens case to withdraw controversial drug for preterm births

  Oct. 17, 2022

• 5 questions facing drugmakers as third quarter earnings begin

  Oct. 17, 2022

• ‘We have to find a way’: FDA seeks solutions to aid bespoke gene therapy

  Oct. 13, 2022

• Odyssey recruits new investors to fund precision drug research

  Oct. 13, 2022

• Omicron boosters from Pfizer, Moderna cleared by FDA for younger children

  Oct. 12, 2022

• Vertex, after setbacks, moves forward with second-generation rare disease drug

  Oct. 11, 2022

• BIO’s McMurry-Heath steps down as head of biotech lobby

  Oct. 11, 2022

• Cytokinetics pushes on with late-stage study of ALS drug

  Oct. 10, 2022

• Biohaven starts life as new company following Pfizer buyout

  Oct. 5, 2022

• KalVista stops work on rare disease drug over safety concerns

  Oct. 4, 2022

• Former Spark CEO Marrazzo joins epigenetics startup’s board

  Oct. 4, 2022

• 5 FDA decisions to watch in the fourth quarter

  Oct. 3, 2022

• Sanofi partners with Scribe to gain gene editing tools for cell therapy work

  Sept. 27, 2022

• Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

  Sept. 21, 2022

• Merck to resume testing of closely watched HIV drug, but at lower dose

  Sept. 20, 2022

• Back-to-back gene therapy approvals give Bluebird shot at survival

  Sept. 19, 2022

• Bluebird wins FDA approval of gene therapy for rare brain disorder

  Sept. 17, 2022

• Alnylam, Regeneron to advance NASH drug after early signs of potential

  Sept. 15, 2022

• Amgen data supports KRAS cancer drug, but survival benefit remains in question

  Sept. 12, 2022

• How a top FDA official’s words helped push a closely watched ALS drug toward approval

  Sept. 9, 2022

• Relay impresses with early study data for targeted cancer drug

  Sept. 8, 2022

• Sarepta to restart Duchenne drug study after FDA lifts hold

  Sept. 6, 2022

• Sangamo presses ahead with Fabry disease gene therapy

  Sept. 1, 2022

• Amgen says KRAS drug beat chemo in lung cancer study

  Aug. 31, 2022

• ‘Treg’ startup Sonoma expands with plans for manufacturing plant

  Aug. 24, 2022

• Pfizer, BioNTech submit omicron booster for FDA clearance

  Aug. 22, 2022

• Pharvaris studies of rare disease drug put on hold by FDA

  Aug. 22, 2022

• With $2.8M gene therapy, Bluebird sets new bar for US drug pricing

  Aug. 18, 2022

• Bluebird gene therapy approved by FDA for rare blood disease

  Aug. 17, 2022

• Moderna, after firing newly hired CFO, finds replacement in PerkinElmer executive

  Aug. 17, 2022

• Novartis bid to repurpose rare disease drug for cancer falls short in third trial

  Aug. 15, 2022

• Amgen’s low tax rates draw attention of top Democratic senator

  Aug. 12, 2022

• Novartis reports deaths of two patients treated with Zolgensma gene therapy

  Aug. 11, 2022

• GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns

  Aug. 11, 2022

• Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma

  Aug. 10, 2022

• J&J’s head of R&D departs as pharma’s leadership turns over

  Aug. 9, 2022

• Samantha Truex on biotech hiring, competing for funding and Upstream’s next steps

  Aug. 9, 2022

• Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati

  Aug. 8, 2022

• Pfizer buys sickle cell drugmaker Global Blood for $5.4B

  Aug. 8, 2022

• FDA approves AstraZeneca, Daiichi drug in breast cancer first

  Aug. 5, 2022

• Acadia turned back by FDA on second attempt to get psychosis drug approved

  Aug. 5, 2022

• Lilly takes long view on Alzheimer’s drug as FDA starts expedited review

  Aug. 5, 2022

• IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations

  Aug. 2, 2022

• Strand CEO on founder-led biotech, venture capital and the market’s retreat

  Aug. 2, 2022

• Concert to seek approval for hair loss drug after second study success

  Aug. 1, 2022

• AbbVie cancer drug sales fall as AstraZeneca competitor gains ground

  July 29, 2022

• Alnylam reveals longer wait for anticipated drug trial results

  July 28, 2022

• Editas treats first patient in sickle cell trial as FDA lifts partial hold

  July 28, 2022

• Bristol Myers CAR-T sales rise despite production problems

  July 27, 2022

• Versant partners with AbCellera to arm startups with better antibodies

  July 27, 2022

• BridgeBio advances drug for dwarfism after study data

  July 26, 2022

• Seagen, Astellas claim positive results in study key to cancer drug's success

  July 26, 2022

• China-based biotech licenses Sanofi's RNA drug technology

  July 25, 2022

• AstraZeneca, Daiichi breast cancer drug set for speedy FDA review

  July 25, 2022

• Astellas to bring research units under one roof in new West Coast center

  July 22, 2022

• Freeline gives detailed look at hemophilia gene therapy results

  July 21, 2022

• Novartis forecasts improving generic drug business as it weighs unit's future

  July 19, 2022

• Ultragenyx buys gene therapy partner after new study results

  July 19, 2022

• Drug deals, launches in focus as pharma earnings begin

  July 18, 2022

• Novo strikes $110M deal for regulatory fast pass

  July 15, 2022

• Novartis, BeiGene cancer drug faces delay as FDA puts off approval decision

  July 14, 2022

• Atara shares sink after update on multiple sclerosis trial

  July 13, 2022

• Verve starts first human test of gene editing treatment for heart disease

  July 12, 2022

• 10 clinical trials to watch in the second half of 2022

  July 5, 2022

• 5 FDA decisions to watch in the third quarter

  June 29, 2022

• J&J-backed gene therapy for the eye clears early study test

  June 28, 2022

• Relay details new research plans in quest to design better cancer drugs

  June 27, 2022

• Bristol Myers CAR-T therapy cleared by FDA for earlier lymphoma use

  June 23, 2022

• Novartis hunting for sickle cell cure with Precision deal

  June 22, 2022

• Mixed results for PTC Duchenne drug put spotlight on EU approval

  June 21, 2022

• FDA authorizes Pfizer, Moderna COVID-19 vaccines for young children

  June 17, 2022

• Pfizer study results show Paxlovid benefit less clear in lower-risk patients

  June 15, 2022

• Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost

  June 14, 2022

• FDA staff supportive of Pfizer, Moderna COVID vaccines in young children

  June 13, 2022

• FDA advisers offer unanimous support to second Bluebird gene therapy

  June 10, 2022

• FDA panel backs Bluebird gene therapy despite safety risks

  June 9, 2022

• Bluebird's future in balance as FDA weighs gene therapy approvals

  June 9, 2022

• ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy

  June 6, 2022

• FDA extends review of Amylyx ALS drug, delaying approval decision

  June 3, 2022

• Former AbbVie executive Severino joins Flagship-backed startup as CEO

  June 2, 2022

• Upstream Bio, a richly funded startup, reveals its lead drug and research plans

  June 2, 2022

• Sage, Biogen drug meets goal in postpartum depression study

  June 1, 2022

• BioMarin delays planned FDA filing for hemophilia gene therapy

  May 31, 2022

• Mirati matches Amgen with updated data for KRAS-blocking cancer drug

  May 26, 2022

• 3 cancer drug studies to watch at next month's ASCO meeting

  May 26, 2022

• Former Editas CEO Bosley joins UK venture capital firm

  May 26, 2022

• FDA starts clock on review of CSL, UniQure gene therapy

  May 25, 2022

• Springworks shares fall despite drug trial's success

  May 24, 2022

• Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs

  May 24, 2022

• Concert drug helps regrow hair in study, boosting shares

  May 23, 2022

• Bayer backs out of Atara cell therapy deal

  May 20, 2022

• Ultragenyx strikes deal with struggling Abeona for rare disease gene therapy

  May 17, 2022

• Bristol Myers' Opdivo comes up short in bladder cancer trial

  May 16, 2022

• BridgeBio sale of FDA voucher good news for Bluebird, other biotech sellers

  May 13, 2022

• Bristol Myers acquires BridgeBio drug aimed at emerging cancer target

  May 12, 2022

• Former Novartis exec joins ADC Therapeutics as CEO after brief stint as Rafael head

  May 9, 2022

• J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic

  May 9, 2022

• Novartis suspends production of two radiopharmaceutical drugs over quality concerns

  May 6, 2022

• Intercept sells international rights to liver drug in $400M deal

  May 5, 2022

• Moderna vaccine sales surpass expectations as company looks to fall boosters

  May 4, 2022

• Vertex surprised by FDA halt of diabetes cell therapy study

  May 2, 2022

• Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug

  April 22, 2022

• Drug price hikes moderate as rebates rise, report finds

  April 21, 2022

• AbbVie ends research alliance on BioArctic Parkinson's drug

  April 20, 2022

• Satellite Bio launches with new approach to bioengineering tissues

  April 20, 2022

• Gilead gets cell therapy boost with FDA clearance of Maryland factory

  April 19, 2022

• GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

  April 13, 2022

• Versant-backed startup launches with plans to broaden cell therapy's reach

  April 13, 2022

• AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach

  April 11, 2022

• FDA advisers grapple with how to update COVID-19 vaccines

  April 6, 2022

• Novartis breast cancer drug approved for ultra-rare condition

  April 6, 2022

• Merck counting on heart drugs to boost business next decade

  April 5, 2022

• CAR-T treatment moves earlier as FDA widens approval of Gilead's Yescarta

  April 4, 2022

• Sanofi API spinout takes step toward market listing

  April 1, 2022

• 5 FDA decisions to watch in the second quarter

  March 31, 2022

• Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

  March 31, 2022

• Orchard turns to layoffs in cutting gene therapy research

  March 30, 2022

• FDA clears second COVID booster for older adults, immunocompromised

  March 29, 2022

• Pfizer inflammatory disease drug hits goal in second study

  March 29, 2022

• As biotech retreats, gene therapy companies retrench and redraw plans

  March 24, 2022

• Vertex plans path to FDA for top drug prospect

  March 22, 2022

• Bristol Myers melanoma drug approved by FDA in immunotherapy advance

  March 21, 2022

• Alnylam sues Pfizer, Moderna over technology used in COVID vaccines

  March 17, 2022

• FDA sets out advice to developers of gene editing medicines

  March 16, 2022

• Passage Bio to cut jobs in latest biotech restructuring

  March 15, 2022

• Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

  March 14, 2022

• Novartis turns cell therapy skill into contract manufacturing deal

  March 10, 2022

• AbbVie holds off another Humira challenger with Alvotech deal

  March 9, 2022

• Novo sees fast growth ahead of obesity drugs despite production hurdles

  March 4, 2022

• Amid biotech downturn, Atlas raises $450M to build new drug startups

  March 3, 2022

• 'We have to make a stand': Biotech leaders vow to break ties with Russia over Ukraine war

  March 1, 2022

• J&J, Legend cell therapy approved by FDA for multiple myeloma

  Feb. 28, 2022

• Moderna sued for allegedly infringing patents tied to COVID-19 vaccine

  Feb. 28, 2022

• Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down

  Feb. 23, 2022

• Adagio pledges to press forward with COVID drug as CEO to resign

  Feb. 22, 2022

• BioMarin says gene therapy hold will endure as FDA questions cancer risk

  Feb. 18, 2022

• Bristol Myers gets FDA decision date for earlier use of CAR-T therapy

  Feb. 17, 2022

• Third Harmonic, led by former Audentes CEO, launches with $155M in funding

  Feb. 16, 2022

• Amgen sees potential for KRAS drug in treating pancreatic cancer

  Feb. 15, 2022

• EMA follows FDA in scrutinizing safety of certain immune drugs

  Feb. 14, 2022

• ProQR eye drug comes up short in key study, surprising company and investors

  Feb. 11, 2022

• Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback

  Feb. 10, 2022

• Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill

  Feb. 8, 2022

• Al Sandrock, former top Biogen scientist, to join drug discovery startup's board

  Feb. 8, 2022

• Pressed by Wall Street, pharma executives signal openness to M&A

  Feb. 7, 2022

• In England, Orchard secures rare agreement on gene therapy coverage

  Feb. 4, 2022

• Intellia, expanding in gene editing, buys startup Rewrite for $45M

  Feb. 3, 2022

• Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods

  Feb. 1, 2022

• Biogen buys into fast-advancing Roche cancer drug

  Feb. 1, 2022

• Pfizer stops development of once-promising heart drug, handing back rights to partner Ionis

  Jan. 31, 2022

• Biogen, facing pressure on all sides, sells stake in biosimilars business

  Jan. 28, 2022

• Atara sells cell therapy plant to Fujifilm for $100M

  Jan. 27, 2022

• Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug

  Jan. 26, 2022

• J&J 'constantly looking' at biotech M&A, but focused on small, mid-sized deals

  Jan. 25, 2022

• Gene editing startup Metagenomi raises $175M to advance research pipeline

  Jan. 25, 2022

• Merck drug for chronic cough rejected by FDA

  Jan. 24, 2022

• Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.

  Jan. 21, 2022

• Top Merck executive to depart company for CEO role at ingredients maker

  Jan. 20, 2022

• GSK loses R&D chief Barron to high-powered startup amid investor pressure

  Jan. 19, 2022

• Bluebird faces longer wait for FDA verdict on experimental gene therapies

  Jan. 18, 2022

• 5 questions facing gene therapy in 2022

  Jan. 13, 2022

• JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year

  Jan. 12, 2022

• JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

  Jan. 11, 2022

• Amgen partners with Arrakis to develop drugs aimed at RNA

  Jan. 11, 2022

• JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies

  Jan. 10, 2022

• BioMarin plans return to FDA with updated data on hemophilia gene therapy

  Jan. 10, 2022

• Pfizer expands into gene editing with Beam research deal

  Jan. 10, 2022

• AstraZeneca adds to rare disease drug pipeline with Neurimmune deal

  Jan. 7, 2022

• German Merck buys manufacturer of key component in mRNA medicines

  Jan. 6, 2022

• Novartis turns to Alnylam in research deal aimed at liver failure

  Jan. 6, 2022

• Pfizer, BioNTech bet mRNA can make a better shingles vaccine

  Jan. 5, 2022

• 5 FDA approval decisions to watch in the first quarter

  Jan. 5, 2022

• Avrobio stops work on rare disease gene therapy after unexpected study results

  Jan. 4, 2022

• Sanofi to buy cancer immunotherapy biotech for $1B

  Dec. 21, 2021

• Bluebird hit with another hold for sickle cell gene therapy

  Dec. 20, 2021

• FDA OKs drugs from Amgen, Argenx, Intra-Cellular in year-end push

  Dec. 20, 2021

• Spark expands in Philadelphia, with new facility meant to be Roche's gene therapy hub

  Dec. 17, 2021

• EU regulator says member countries can use Pfizer's experimental COVID pill

  Dec. 16, 2021

• Flush with cash, large drugmakers turn to share buybacks, deals

  Dec. 16, 2021

• Sanofi, GSK say COVID vaccine works as booster, but delay key study results

  Dec. 15, 2021

• Two cancer cell therapy studies succeeded. Why did a third fail?

  Dec. 14, 2021

• CAR-T therapy trials show promise for earlier use in lymphoma

  Dec. 12, 2021

• Moderna reveals first study results for seasonal flu vaccine

  Dec. 10, 2021

• Lilly deepens research ties in China with biotech deal

  Dec. 10, 2021

• AstraZeneca antibody cleared by FDA for preventive use against COVID-19

  Dec. 8, 2021

• Omicron cuts Pfizer vaccine's potency, but data show booster may restore protection

  Dec. 8, 2021

• Acadia shares rise on study success for Rett syndrome drug

  Dec. 7, 2021

• A serial biotech entrepreneur launches his next startup with high-dollar backing

  Dec. 7, 2021

• Biohaven to seek FDA approval for second migraine drug after study success

  Dec. 6, 2021

• Former Immunomedics executive charged with insider trading around trial data

  Dec. 3, 2021

• Early tests suggest Vir, GSK antibody could hold up versus omicron

  Dec. 2, 2021

• Vertex, needing research spark, finds promising results in small study of kidney disease drug

  Dec. 1, 2021

• GSK hires away top Pfizer vaccine scientist

  Nov. 30, 2021

• Vaccine makers move quickly to confront omicron threat

  Nov. 29, 2021

• GSK dives into NASH, RNA interference with Arrowhead deal

  Nov. 23, 2021

• Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy

  Nov. 22, 2021

• Biogen seeking more information in investigation of Aduhelm patient's death

  Nov. 19, 2021

• FDA approves Merck's Keytruda as first immunotherapy for early kidney cancer

  Nov. 18, 2021

• European drugs regulator signals rejection likely for Biogen's Aduhelm

  Nov. 17, 2021

• Pfizer asks FDA to authorize COVID-19 pill

  Nov. 16, 2021

• Pfizer will allow generic drugmakers to produce promising COVID-19 pill

  Nov. 16, 2021

• Biden nominates Robert Califf to return as FDA head

  Nov. 12, 2021

• Cortexyme plans path forward for Alzheimer's drug that failed study

  Nov. 12, 2021

• J&J, world's largest drugmaker, plans to split in two

  Nov. 12, 2021

• Pfizer buys into Biohaven's fast-selling migraine medicine

  Nov. 9, 2021

• Mirati gives first look at KRAS drug combination in lung cancer

  Nov. 8, 2021

• Beam gets green light to begin first clinical test of base editing

  Nov. 8, 2021

• Moderna cuts vaccine sales, delivery targets for 2021

  Nov. 4, 2021

• Pfizer gene therapy research delayed by trial changes, safety questions

  Nov. 3, 2021

• Pfizer sales of COVID-19 vaccine climb, with tens of billions more expected next year

  Nov. 2, 2021

• Takeda reels in a cell therapy research partner with 'build-to-buy' deal

  Oct. 27, 2021

• FDA advisers support Pfizer's coronavirus vaccine for young children

  Oct. 26, 2021

• Cortexyme drug fails in Alzheimer's trial, but company sees validation of unorthodox approach

  Oct. 26, 2021

• Novartis to consider sale or separation of Sandoz business

  Oct. 26, 2021

• Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

  Oct. 25, 2021

• What to watch at the FDA's high-stakes meeting on COVID-19 vaccines for kids

  Oct. 22, 2021

• Bluebird, winding down in Europe, withdraws another rare disease gene therapy

  Oct. 21, 2021

• J&J foresees end to not-for-profit sales of coronavirus vaccine

  Oct. 19, 2021

• Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat

  Oct. 18, 2021

• AstraZeneca immunotherapy combo extends survival in liver cancer trial

  Oct. 15, 2021

• Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

  Oct. 14, 2021

• Relay’s targeted cancer drug could be safer than its competitors. Is it more effective?

  Oct. 8, 2021

• Intergalactic Therapeutics launches with $75M to build a new type of gene therapy

  Oct. 7, 2021

• Takeda halts studies of touted sleep disorder drug over safety concern

  Oct. 6, 2021

• J&J asks FDA to clear booster dose of its coronavirus vaccine

  Oct. 5, 2021

• Gilead wins approval of CAR-T therapy in adult leukemia

  Oct. 4, 2021

• 5 FDA approval decisions to watch in the fourth quarter

  Oct. 1, 2021

• GSK, Merck KGaA end cancer drug partnership after study results disappoint

  Oct. 1, 2021

• After long wait, Editas reveals first data for CRISPR gene editing treatment

  Sept. 29, 2021

• Eisai, Biogen to test FDA by asking for approval of second Alzheimer's drug

  Sept. 28, 2021

• Biohaven's pipeline takes a hit as drug for rare neurological disease falls short in trial

  Sept. 27, 2021

• CDC recommends Pfizer booster shots for many, overruling advisers on broad use

  Sept. 23, 2021

• AstraZeneca strikes deal with university spinoff to turn RNA into drugs

  Sept. 23, 2021

• US buying 500M more doses of Pfizer coronavirus vaccine for donation to world

  Sept. 22, 2021

• Novartis pushes further into gene therapy for the eye with deal for Swiss startup

  Sept. 21, 2021

• ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up

  Sept. 20, 2021

• FDA advisers support booster dose of Pfizer vaccine in older or high-risk adults

  Sept. 17, 2021

• Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention

  Sept. 17, 2021

• Amgen to advance KRAS drug combination after improved results in colon cancer

  Sept. 16, 2021

• US stocks up on COVID-19 antibody drugs amid shortage concerns

  Sept. 15, 2021

• Fourth trial volunteer dies in Astellas gene therapy study

  Sept. 14, 2021

• Departing FDA officials, WHO leaders argue against broad rollout of COVID-19 booster shots

  Sept. 13, 2021

• Apellis eye drug succeeds in one key study, but falls short in its twin

  Sept. 9, 2021

• 'The sky is not falling.' Cautious optimism follows FDA meeting on gene therapy risks

  Sept. 7, 2021

• At FDA meeting, gene therapy experts wrestle with field's blindspots

  Sept. 3, 2021

• What to expect at the FDA's two-day meeting on gene therapy safety

  Sept. 1, 2021

• Hint of benefit in Alzheimer's drug study fuel stock surge for Swiss biotech

  Aug. 31, 2021

• Pfizer drug bests Sanofi, Regeneron's Dupixent in head-to-head study

  Aug. 30, 2021

• BioMarin wins European approval to sell drug for dwarfism

  Aug. 27, 2021

• Gilead wins reversal of $1.2B penalty in CAR-T patent case

  Aug. 26, 2021

• Pfizer taps McKinsey executive to lead dealmaking efforts

  Aug. 26, 2021

• Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

  Aug. 23, 2021

• Cell, gene therapy company funding reaches new heights, despite setbacks

  Aug. 19, 2021

• US to offer coronavirus boosters to all Americans in aggressive plan to counter delta's spread

  Aug. 18, 2021

• Merck wins approval for cancer drug acquired in 2019 biotech buyout

  Aug. 16, 2021

• VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug

  Aug. 12, 2021

• Biotech M&A has plateaued. Track the deals that are happening here.

  Aug. 10, 2021

• SeaGen builds cancer drug pipeline with China biotech deal

  Aug. 9, 2021

• Startup EQRx to take drug price mission public through $1.8B SPAC deal

  Aug. 6, 2021

• Moderna says vaccine protective through six months, but warns boosters needed this fall

  Aug. 5, 2021

• HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

  Aug. 4, 2021

• Sarepta adds another gene therapy to its ever-expanding pipeline

  Aug. 4, 2021

• Sanofi bets $3.2B on mRNA with deal to buy Translate Bio

  Aug. 3, 2021

• Caribou raises $304M in one of gene editing's most lucrative IPOs

  July 23, 2021

• Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'

  July 22, 2021

• J&J predicts faster coronavirus vaccine sales amid debate over boosters

  July 21, 2021

• Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion

  July 20, 2021

• Cytokinetics heart drug succeeds in mid-stage study, boosting shares

  July 19, 2021

• Questions on new Alzheimer's drug benefit, price loom large at ICER meeting

  July 16, 2021

• Galapagos shares sink as first data from touted drug program disappoints

  July 15, 2021

• Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

  July 12, 2021

• Novo, in rare deal, buys rights to Prothena amyloidosis treatment

  July 12, 2021

• FDA, under fire for Alzheimer's drug approval, seeks investigation of review process

  July 9, 2021

• Biohaven beats expectations with fast sales of migraine drug

  July 8, 2021

• FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

  July 8, 2021

• A well-funded cancer drug startup brings on GSK's Axel Hoos as CEO

  July 7, 2021

• Moderna puts seasonal flu vaccine ambitions to the test

  July 7, 2021

• Lilly, Boehringer say diabetes drug first to succeed in hard-to-treat heart failure

  July 6, 2021

• 5 FDA decisions to watch in the third quarter

  July 2, 2021

• CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study

  July 1, 2021

• Beam, Apellis partner in deal to expand gene editing's reach

  June 30, 2021

• ICER stands by view on Biogen's Aduhelm, says sharp price cut needed

  June 30, 2021

• Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal

  June 29, 2021

• Gilead matches Bristol Myers in showing benefit to earlier CAR-T treatment

  June 28, 2021

• FDA advisers vote down Incyte cancer drug as agency takes tougher line

  June 25, 2021

• Reversing course, Lilly to seek fast approval for experimental Alzheimer's drug

  June 24, 2021

• Third Rock-backed startup launches to develop cell therapies for MS, diabetes

  June 23, 2021

• FDA documents show how controversial Alzheimer's drug decision was reached

  June 22, 2021

• Blackstone to invest $250M in cell therapy startup backed by Intellia, Cellex

  June 22, 2021

• GSK, Vir build case for COVID-19 antibody drug with new study data

  June 21, 2021

• US to invest $3B in research quest for COVID-19 pill

  June 18, 2021

• Gene editing biotech Verve to raise $267M in large IPO

  June 17, 2021

• Sage antidepressant succeeds in key study, but data raise questions

  June 15, 2021

• Novavax says vaccine 90% effective against COVID-19 in large trial

  June 14, 2021

• Blood disease treatment from CRISPR, Vertex shows promise in more patients

  June 11, 2021

• Bristol Myers says CAR-T therapy beat chemo, transplant in lymphoma study

  June 10, 2021

• Beigene expands into cancer cell therapy with Shoreline pact

  June 9, 2021

• The FDA approved Biogen's Alzheimer's drug. The company now has years to confirm it works.

  June 8, 2021

• Bluebird cleared by FDA to resume studies of sickle cell gene therapy

  June 7, 2021

• ASCO21: An immunotherapy debate, an NK cell question and the next precision drugs

  June 7, 2021

• Bristol Myers sued over delayed approval of cancer cell therapy

  June 4, 2021

• Novartis prostate cancer drug extends survival in key test of radiopharmaceutical therapy

  June 3, 2021

• Bayer buys a biotech and its offshoot in bet on radiopharmaceuticals

  June 3, 2021

• MorphoSys to buy Constellation in $1.7B deal, aided by unusual funding

  June 2, 2021

• Sanofi rare disease drug hits another setback

  June 1, 2021

• In first, FDA approves KRAS-blocking cancer drug from Amgen

  May 28, 2021

• Centessa raises $330M in third largest biotech IPO this year

  May 28, 2021

• 'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA

  May 27, 2021

• Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs

  May 20, 2021

• Closely watched Bristol Myers immunotherapy shows benefit in melanoma

  May 19, 2021

• FDA seeking more consistency from cell, gene therapy developers, top official says

  May 19, 2021

• Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target

  May 18, 2021

• Novartis challenge to Amgen's Enbrel patents ends at Supreme Court's door

  May 18, 2021

• Sanofi, GSK say revamped coronavirus vaccine is strong enough for final test

  May 17, 2021

• Biogen gene therapy misses goal in eye disease study

  May 14, 2021

• CDC panel endorses Pfizer vaccine for 12- to 15-year-olds

  May 12, 2021

• Ginkgo Bioworks to go public through $2.5B SPAC deal

  May 11, 2021

• FDA authorizes Pfizer's coronavirus vaccine for younger teens

  May 10, 2021

• Amgen asks FDA for approval of key asthma drug

  May 10, 2021

• Pharma erupts as Biden administration backs waiver of vaccine patent rights

  May 6, 2021

• ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug

  May 5, 2021

• Pfizer forecasts $26B in coronavirus vaccine revenue this year

  May 4, 2021

• Avrobio changes course after FDA closes path for speedy gene therapy approval

  May 3, 2021

• FDA faces tough choice after panel backs speedy cancer drug approvals

  April 30, 2021

• Emergent CEO defends company from criticism of error that ruined vaccine doses

  April 30, 2021

• Merck, GSK vaccine sales hit by pandemic as competitors' business booms

  April 29, 2021

• BioMarin partners with Allen Institute to develop gene therapies for the brain

  April 28, 2021

• Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens

  April 27, 2021

• Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine

  April 26, 2021

• FDA, CDC support resuming use of J&J vaccine after advisory panel vote

  April 23, 2021

• GSK immunotherapy wins FDA approval, joining crowded cancer drug class

  April 23, 2021

• A look ahead at the FDA meeting that could decide the future of 6 cancer drug approvals

  April 22, 2021

• FDA cites Emergent for failings at plant that contaminated J&J doses

  April 22, 2021

• The next 2 months in biotech and pharma will be busy. Here's what to watch.

  April 20, 2021

• Bluebird to withdraw gene therapy from Germany after dispute over price

  April 20, 2021

• Relay buys AI startup to aid unorthodox drug discovery quest

  April 16, 2021

• GSK stops studies testing closely watched cancer immunotherapy

  April 15, 2021

• The US paused use of J&J's vaccine. What happens next?

  April 13, 2021

• US recommends pause in J&J vaccinations due to concerns over rare blood clots

  April 13, 2021

• Lilly, Arch join Deerfield in backing new gene therapy biotech Jaguar

  April 13, 2021

• 5 takeaways from AACR, one of the year's top meetings on cancer drugs

  April 12, 2021

• Lilly gene-targeted drug shows potential for use across cancers

  April 11, 2021

• Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine

  April 9, 2021

• Lilly claims promising finding in failed study of COVID-19 drug

  April 8, 2021

• Bluebird executive joins Flagship startup Tessera as CMO

  April 7, 2021

• New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

  April 6, 2021

• J&J to oversee vaccine production at Emergent factory that ruined doses

  April 5, 2021

• Manufacturing mix-up could blunt supply boost from J&J vaccine

  April 1, 2021

• Audentes CEO exits as Astellas rebrands a gene therapy buyout

  April 1, 2021

• Akebia tries for FDA approval of anemia drug after mixed data

  March 30, 2021

• UniQure says hemophilia gene therapy likely not cause of study volunteer's cancer

  March 29, 2021

• FDA approves first CAR-T cell therapy for multiple myeloma

  March 27, 2021

• Slaoui steps down from two more biotechs after harassment claim

  March 25, 2021

• Moncef Slaoui, who led US Warp Speed effort, accused of sexual harassment

  March 24, 2021

• FDA won't review Novo diabetes drug in latest case of regulatory pushback

  March 23, 2021

• AstraZeneca may have used 'outdated' data to describe vaccine's efficacy, NIH says

  March 23, 2021

• Bluebird's top doctor to depart as company grapples with safety review

  March 17, 2021

• Record funding flowed into cell, gene therapy companies last year

  March 16, 2021

• Elevate Bio raises half a billion dollars to fuel cell, gene therapy expansion

  March 15, 2021

• Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots

  March 11, 2021

• Bluebird says gene therapy 'very unlikely' cause of cancer case in trial

  March 10, 2021

• Biotech's deal refusals led to pricey buyout by Merck

  March 5, 2021

• Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime

  March 4, 2021

• FibroGen shares sink as FDA meeting decision suggests another delay for top drug

  March 2, 2021

• J&J's 1-dose coronavirus vaccine becomes third available in US

  Feb. 27, 2021

• FDA panel backs J&J's coronavirus vaccine, clearing way for shot's authorization

  Feb. 26, 2021

• Bluebird reveals new details on cancer cases in gene therapy trial

  Feb. 26, 2021

• A play-by-play of the FDA meeting on J&J's vaccine

  Feb. 26, 2021

• Top Moderna executive to leave company later this year

  Feb. 25, 2021

• Former AveXis executives launch gene therapy startup with uncommon targets

  Feb. 25, 2021

• FDA review supports safety, efficacy of J&J coronavirus vaccine

  Feb. 24, 2021

• Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M

  Feb. 23, 2021

• FDA lays out shortened path for testing vaccines against new coronavirus variants

  Feb. 22, 2021

• Why this week's FDA meeting on J&J's coronavirus vaccine will be important

  Feb. 22, 2021

• Pfizer set to double weekly production of coronavirus vaccine

  Feb. 19, 2021

• Bluebird stops studies of sickle cell gene therapy after new cancer cases

  Feb. 16, 2021

• 10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model

  Feb. 16, 2021

• A gene therapy pipeline takes shape for a cluster of rare diseases

  Feb. 12, 2021

• US secures 200 million more vaccine doses from Pfizer, Moderna

  Feb. 12, 2021

• FDA clears Lilly's COVID-19 antibody cocktail for emergency use

  Feb. 10, 2021

• Editas names new CEO in latest executive shakeup

  Feb. 8, 2021

• Bristol Myers finally wins FDA approval for cancer cell therapy

  Feb. 5, 2021

• Gilead sales propped up by COVID-19 drug Veklury

  Feb. 5, 2021

• J&J asks FDA for emergency clearance of coronavirus vaccine

  Feb. 4, 2021

• Ken Frazier, veteran pharma leader, to step down as Merck CEO

  Feb. 4, 2021

• Jazz Pharma to buy GW Pharma, maker of CBD-based epilepsy drug, for $7.2B

  Feb. 3, 2021

• Pfizer forecasts $15B sales boost from coronavirus vaccine orders

  Feb. 2, 2021

• Bayer agrees to help CureVac produce coronavirus vaccine

  Feb. 1, 2021

• Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy

  Feb. 1, 2021

• J&J says single dose of coronavirus vaccine 66% effective in large trial

  Jan. 29, 2021

• Amgen study data bolster prospects of KRAS-blocking cancer drug

  Jan. 28, 2021

• Lilly strikes deal to acquire drug for chronic pain

  Jan. 28, 2021

• Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

  Jan. 26, 2021

• J&J says study data on coronavirus vaccine due 'early next week'

  Jan. 26, 2021

• Moderna to study vaccine booster aimed at coronavirus variant

  Jan. 25, 2021

• Pricing challenge looms for Novartis as cholesterol drug's US fate remains unclear

  Jan. 22, 2021

• Lilly's antibody drug prevents COVID-19 in study, but hurdles to use remain

  Jan. 20, 2021

• Beam, Verve stockpile cash as investors bank on gene editing progress

  Jan. 19, 2021

• JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's research and Pfizer's deep pockets

  Jan. 12, 2021

• Bluebird to split company, spin off cancer drug business

  Jan. 11, 2021

• BioMarin tries to get hemophilia gene therapy back on track with positive data

  Jan. 11, 2021

• 5 questions facing gene therapy in 2021

  Jan. 8, 2021

• 5 FDA approval decisions to watch in the 1st quarter

  Jan. 5, 2021

• How an all-or-nothing bet on 3 Bristol Myers drugs came undone

  Jan. 4, 2021

• Pfizer, BioNTech win EU vaccine approval as UK grapples with new coronavirus variant

  Dec. 22, 2020

• FDA delays decision on Novartis cholesterol therapy

  Dec. 21, 2020

• Changing identity, Agios to sell cancer drug business to Servier

  Dec. 21, 2020

• FDA panel endorses Moderna's coronavirus vaccine

  Dec. 17, 2020

• A play-by-play of the FDA meeting on Moderna's coronavirus vaccine

  Dec. 17, 2020

• FDA scientists back safety, efficacy of Moderna's coronavirus vaccine

  Dec. 15, 2020

• Relay Therapeutics, fresh off IPO, partners with Roche in cancer drug deal

  Dec. 14, 2020

• Viatris to lay off staff, shutter plants in major restructuring

  Dec. 11, 2020

• FDA advisers back Pfizer, BioNTech vaccine, clearing way for emergency approval

  Dec. 10, 2020

• A play-by-play of the historic FDA meeting on Pfizer and BioNTech's coronavirus vaccine

  Dec. 9, 2020

• Vaccine Developers of the Year: BioNTech and Moderna

  Dec. 9, 2020

• FDA scientists appear supportive of Pfizer, BioNTech's coronavirus vaccine

  Dec. 8, 2020

• Lilly to pit Loxo cancer drug against top-selling rival after strong study results

  Dec. 7, 2020

• Vaccine production in focus as Moderna, Pfizer await FDA decision

  Dec. 4, 2020

• 4 storylines to track at the year's biggest meeting on blood diseases

  Dec. 3, 2020

• Merck, expanding coronavirus work, buys a small biotech and its COVID-19 drug

  Nov. 23, 2020

• Trump administration pushes last-ditch plans to lower drug prices

  Nov. 20, 2020

• Pfizer, BioNTech ask FDA for emergency approval of coronavirus vaccine

  Nov. 20, 2020

• UniQure's gene therapy for hemophilia B meets goal in key study

  Nov. 19, 2020

• New coronavirus vaccine data bolster Pfizer, BioNTech claims of strongly effective shot

  Nov. 18, 2020

• Trial success for 2 coronavirus vaccines backs up early research bets

  Nov. 17, 2020

• Moderna close to having results from key coronavirus vaccine trial

  Nov. 12, 2020

• Pfizer and BioNTech's coronavirus vaccine works. Here's what we still don't know.

  Nov. 10, 2020

• 5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug

  Nov. 9, 2020

• FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt

  Nov. 6, 2020

• BioMarin, stung by FDA rejection, pressed on path forward for 2 key drugs

  Nov. 6, 2020

• Biogen surges as FDA reviewers appear supportive of Alzheimer's drug approval

  Nov. 4, 2020

• Bristol Myers bet pays off as psoriasis drug beats Amgen rival in study

  Nov. 3, 2020

• AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer

  Nov. 2, 2020

• Axovant shares sink on manufacturing delay for Parkinson's gene therapy

  Oct. 30, 2020

• Gilead lifted by fast sales of COVID-19 drug Veklury. Will they last?

  Oct. 29, 2020

• US to pay Lilly $375M for supply of COVID-19 drug

  Oct. 28, 2020

• 5 takeaways from the FDA's closely watched coronavirus vaccine meeting

  Oct. 24, 2020

• AstraZeneca, J&J cleared to restart major coronavirus vaccine studies

  Oct. 23, 2020

• Ultragenyx expands into Duchenne gene therapy with Solid Bio deal

  Oct. 23, 2020

• At key meeting, FDA advisors debate if early coronavirus vaccine approvals may compromise trials

  Oct. 23, 2020

• Moderna enrolls final volunteers into key coronavirus vaccine study

  Oct. 22, 2020

• Merck, with more study data, builds case for pneumonia vaccine successor

  Oct. 20, 2020

• Intellia cleared to start key CRISPR drug study in UK

  Oct. 19, 2020

• Gilead's COVID-19 drug doesn't prevent deaths, large WHO study finds

  Oct. 16, 2020

• Fujifilm to help Lilly make COVID-19 antibody drug

  Oct. 15, 2020

• FDA approves Regeneron antibody drug as first Ebola virus treatment

  Oct. 14, 2020

• NIH study of Lilly COVID-19 antibody drug paused for safety review

  Oct. 13, 2020

• J&J halts studies of coronavirus vaccine due to participant's illness

  Oct. 13, 2020

• Mallinckrodt, beset by opioid drug suits, files for bankruptcy

  Oct. 12, 2020

• US backs AstraZeneca COVID-19 antibody drug with $486M in funding

  Oct. 9, 2020

• Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL

  Oct. 9, 2020

• Amgen and Cytokinetics claim heart drug success, but results widely disappoint

  Oct. 8, 2020

• FDA releases coronavirus vaccine guidelines that White House resisted

  Oct. 6, 2020

• FDA told coronavirus vaccine makers of stricter standards for early approval

  Oct. 6, 2020

• Trump treated for COVID-19 with Regeneron, Gilead drugs

  Oct. 2, 2020

• Merck research chief Roger Perlmutter to retire, leaving immunotherapy legacy

  Oct. 2, 2020

• Gilead to distribute COVID-19 drug Veklury in US, taking over from federal government

  Oct. 2, 2020

• Private equity-backed Covis to buy AMAG Pharma in $650M deal

  Oct. 1, 2020

• Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge

  Oct. 1, 2020

• 5 FDA approval decisions to watch in the 4th quarter

  Sept. 29, 2020

• J&J, beginning final test, shares first data on coronavirus vaccine

  Sept. 25, 2020

• Drugmakers push forward on large-scale production of coronavirus vaccines

  Sept. 24, 2020

• Trump undercuts FDA on coronavirus vaccine authorization plans

  Sept. 24, 2020

• J&J begins largest Phase 3 study of a coronavirus vaccine

  Sept. 23, 2020

• Blueprint's bet on itself pays off with rare disease drug data

  Sept. 22, 2020

• Merck matches Roche in search for next cancer immunotherapy

  Sept. 21, 2020

• Amgen's KRAS drug can shrink tumors for months, but new data leave room for improvement

  Sept. 20, 2020

• Moderna and Pfizer, having shown speed with coronavirus vaccines, see opportunity in seasonal flu

  Sept. 17, 2020

• Vaccine makers, in bid for transparency, disclose detailed plans of coronavirus vaccine trials

  Sept. 17, 2020

• Pfizer says coronavirus vaccine study still on track for October readout

  Sept. 15, 2020

• Takeda adds to cell therapy push with new manufacturing site

  Sept. 15, 2020

• Lilly says its arthritis drug helps speed COVID-19 recovery

  Sept. 14, 2020

• Gilead to buy cancer drugmaker Immunomedics for $21B

  Sept. 13, 2020

• How biotech and pharma companies pay their CEOs, and their workers

  Sept. 9, 2020

• Studies of AstraZeneca coronavirus vaccine put on hold for safety review

  Sept. 8, 2020

• Amarin loses appeal of court ruling on heart drug patents

  Sept. 3, 2020

• Intercept, facing long road ahead for NASH drug, lays off quarter of workforce

  Sept. 2, 2020

• NIH panel says data doesn't support plasma use for COVID-19

  Sept. 2, 2020

• Relay Therapeutics set out to change how drugs are designed. Can it continue what Vertex began?

  Aug. 24, 2020

• In major surprise, FDA rejects high-profile therapies from BioMarin, Gilead

  Aug. 19, 2020

• Sanofi, seeking control of key drug, to buy Principia for $3.7B

  Aug. 17, 2020

• Europe, trailing US, UK, reaches first coronavirus vaccine deal

  Aug. 14, 2020

• CanSino rides coronavirus vaccine progress to lucrative Shanghai market debut

  Aug. 13, 2020

• Moderna gets $1.5B from US for coronavirus vaccine supply

  Aug. 11, 2020

• Russia, with scant study data, approves coronavirus vaccine

  Aug. 11, 2020

• US puts Kodak loan on hold after stock scrutiny

  Aug. 10, 2020

• Pfizer to help Gilead produce COVID-19 drug remdesivir

  Aug. 7, 2020

• GSK wins US approval for first-of-its-kind blood cancer drug

  Aug. 6, 2020

• Moderna sets high price in early coronavirus vaccine supply deals

  Aug. 5, 2020

• Novartis says CAR-T cancer therapy works in second lymphoma type

  Aug. 4, 2020

• Bausch Health to pay $45M to settle US charges over Valeant-era accounting

  Aug. 3, 2020

• Merck nears clinical tests for coronavirus vaccine candidates

  July 31, 2020

• US promises $2.1B to Sanofi, GSK in latest coronavirus vaccine deal

  July 31, 2020

• Pfizer spinoff Cerevel to raise $445M in merger with blank-check company

  July 30, 2020

• US taps camera makers for help manufacturing drugs, vaccines

  July 28, 2020

• AstraZeneca turns again to Daiichi Sankyo for a major cancer drug deal

  July 27, 2020

• Early coronavirus vaccine data leave many questions, but some lessons, too

  July 23, 2020

• US to pay nearly $2B for supply of Pfizer, BioNTech coronavirus vaccine

  July 22, 2020

• Biogen to study use of key SMA drug after Novartis gene therapy

  July 21, 2020

• CanSino coronavirus vaccine clears mid-stage test, but data show its limits

  July 20, 2020

• J&J, on the cusp of starting coronavirus vaccine trials, sets high bar for success

  July 16, 2020

• Researchers publish long-awaited study data on Moderna coronavirus vaccine

  July 14, 2020

• Sanofi turns to MD Anderson to help fuel cancer drug push

  July 14, 2020

• Beigene, already flush with cash, raising $2B from investors

  July 13, 2020

• In the UK, a coronavirus study shows how to get fast, powerful data during a pandemic

  July 10, 2020

• 5 FDA approval decisions to watch in the 3rd quarter

  July 8, 2020

• Novavax gets $1.6B in US funding for coronavirus vaccine

  July 7, 2020

• J&J, with new deal, plans for long-term manufacture of coronavirus vaccine

  July 6, 2020

• Novartis to pay $678M to settle claims over 'sham' doctor events

  July 2, 2020

• Coronavirus vaccine from Pfizer, BioNTech shows early potential

  July 1, 2020

• FDA insists it 'will not cut corners' in coronavirus vaccine approvals

  June 30, 2020

• Large UK study finds no benefit to HIV antiviral in COVID-19

  June 30, 2020

• Gilead sets price for COVID-19 drug remdesivir

  June 29, 2020

• WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses

  June 26, 2020

• Trailing leaders, Sanofi speeds coronavirus vaccine plans

  June 23, 2020

• Gilead to launch studies of inhaled version of COVID-19 drug remdesivir

  June 22, 2020

• Merck gives 1st look at Phase 3 results for its Prevnar competitor

  June 22, 2020

• Chinese biotech to test GSK, Dynavax adjuvants in coronavirus vaccine study

  June 19, 2020

• With new proposal, Trump administration tries to encourage 'value-based' drug deals

  June 18, 2020

• 'Warp Speed' plan for coronavirus vaccines comes into focus

  June 17, 2020

• FDA revokes emergency clearance for hydroxychloroquine, citing new data, risks

  June 15, 2020

• Sinovac claims progress with early coronavirus vaccine study

  June 15, 2020

• New CRISPR, gene therapy results strengthen potential for treatment of blood diseases

  June 12, 2020

• US invests in drug vials to support coronavirus vaccine push

  June 9, 2020

• Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.

  June 9, 2020

• Lilly gets a 2nd COVID-19 antibody into clinical trials with Junshi's help

  June 8, 2020

• Case for hydroxychloroquine in COVID-19 fades as key UK study finds no benefit

  June 5, 2020

• 'Warp Speed' push for coronavirus vaccine accelerates as White House reportedly narrows field

  June 4, 2020

• Hydroxychloroquine offers no COVID-19 protection after exposure, study shows

  June 3, 2020

• US government promises Maryland drug manufacturer $628M to make coronavirus vaccines

  June 2, 2020

• COVID-19 could slow progress in reducing cancer death, NCI head warns

  June 1, 2020

• Facing vial shortage, pharmas explore workarounds for coronavirus vaccines

  May 28, 2020

• Coronavirus vaccine developers plan to enroll tens of thousands in late-stage tests

  May 28, 2020

• Merck makes COVID-19 drug plans clear with flurry of deals

  May 26, 2020

• New study details show remdesivir speeds COVID-19 recovery, but doesn't help sickest patients

  May 23, 2020

• Coronavirus study in China shows CanSino's vaccine spurs immune responses

  May 22, 2020

• Biotech companies raise cash as coronavirus updates lift stocks

  May 19, 2020

• 'Operation Warp Speed,' unveiled by Trump, aims for coronavirus vaccine by year's end

  May 15, 2020

• Cancer biotech stocks shift on glimpse of ASCO data

  May 14, 2020

• Roche unveils first data for new type of cancer immunotherapy

  May 13, 2020

• Surprise setback for Bristol, Bluebird as FDA rejects cell therapy application

  May 13, 2020

• Trump administration: States to decide which hospitals get Gilead's COVID-19 drug

  May 11, 2020

• Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo

  May 9, 2020

• Moderna plans earlier start to late-stage test of coronavirus vaccine

  May 7, 2020

• Ousted BARDA director claims retaliation for pushing back on unproven coronavirus drugs

  May 5, 2020

• Alexion, seeking to broaden business, to buy Portola for $1.4B

  May 5, 2020

• With new estimate, ICER sets terms of debate on pricing Gilead's COVID-19 drug

  May 4, 2020

• Gilead's remdesivir, shown to hasten COVID-19 recovery, cleared for emergency use by FDA

  May 1, 2020

• Gilead may have a drug for COVID-19. Wall Street asks whether it will profit

  May 1, 2020

• 'We really did need a win.' Gilead drug no knockout in COVID-19, but results spur optimism

  April 30, 2020

• Gilead drug for COVID-19 clears crucial clinical test

  April 29, 2020

• Pharmas boosted by drug stockpiling, but warn of COVID-19 impact

  April 28, 2020

• Regeneron, Sanofi immunotherapy extends survival in previously untreated lung cancer

  April 27, 2020

• Sanofi CEO cautions arthritis drug a 'long shot' in COVID-19, says study results 'imminent'

  April 24, 2020

• Leaked data on Gilead's remdesivir suggest drug didn't help patients with COVID-19

  April 23, 2020

• Immunomedics wins long-sought FDA approval for breast cancer drug

  April 22, 2020

• Coronavirus vaccine from BioNTech, Pfizer set to enter testing in Germany

  April 22, 2020

• BARDA director says he was ousted for 'clashes' with HHS over unproven therapies

  April 21, 2020

• Novartis, launching COVID-19 trial, seeks to prove hydroxychloroquine's worth

  April 20, 2020

• US government to back Moderna's coronavirus vaccine with up to $483M

  April 16, 2020

• As Ebola drug review starts, Regeneron hopes to chart similar path for coronavirus therapy

  April 16, 2020

• AstraZeneca to study leukemia drug as COVID-19 treatment

  April 15, 2020

• In rare move, Sanofi and GSK ally on coronavirus vaccine development

  April 14, 2020

• Early data on Gilead coronavirus drug raises hope, but answers few questions

  April 11, 2020

• Pfizer accelerates clinical trial plans for coronavirus drug

  April 9, 2020

• Sage to lay off half of workforce in cost-cutting retrenchment

  April 7, 2020

• Inovio begins first human test of experimental coronavirus vaccine

  April 7, 2020

• Gilead working to quickly boost production of experimental coronavirus drug

  April 6, 2020

• Incyte, Novartis to test repurposed cancer drug in COVID-19

  April 3, 2020

• Amgen, partnering with Seattle's Adaptive, begins coronavirus drug search

  April 2, 2020

• Amarin shares slump as surprising court defeat puts Vascepa at risk

  March 31, 2020

• No sanctions for Novartis as FDA ends review of gene therapy violations

  March 30, 2020

• FDA clears emergency use of malaria pills to treat COVID-19

  March 30, 2020

• For CAR-T, coronavirus brings uneven impact to studies, treatment

  March 27, 2020

• AstraZeneca turns again to UK's Silence in renewed RNAi push

  March 25, 2020

• Coronavirus forces ASCO, cancer research's top meeting, to move online

  March 24, 2020

• Gilead, flooded with requests, suspends access to experimental coronavirus drug

  March 23, 2020

• Drugmakers boost production of malaria pill touted by Trump as coronavirus treatment

  March 20, 2020

• Despite 'heroic' effort, coronavirus study finds little benefit to repurposed HIV drug

  March 18, 2020

• Sage redraws its plans for failed antidepressant drug

  March 18, 2020

• Pharma salesforces brought to a halt as coronavirus shutters economy

  March 17, 2020

• Germany's CureVac, the subject of a reported US overture, thrust into coronavirus spotlight

  March 16, 2020

• With AbCellera deal, Lilly becomes latest pharma to start coronavirus program

  March 13, 2020

• CureVac CEO replaced in midst of biotech's coronavirus push

  March 12, 2020

• Facing coronavirus risk, a top cancer group postpones annual meeting

  March 11, 2020

• 2 newer multiple myeloma drugs fall short in bid for wider market

  March 10, 2020

• As US coronavirus cases mount, top drugmakers tell employees to work from home

  March 9, 2020

• Coronavirus spread threatens spring slate of medical meetings

  March 6, 2020

• A closer look at the Ebola drug that's become the top hope for a coronavirus treatment

  March 5, 2020

• In a CRISPR first, Editas therapy used to fix genes in the body

  March 4, 2020

• High prices fuel pharma profits. New research provides more context

  March 3, 2020

• Sanofi wins US approval for myeloma drug key to its cancer ambitions

  March 2, 2020

• Cell therapy developer Unum restructures, cutting staff in pivot

  March 2, 2020

• Karyopharm shares jump on positive study data for multiple myeloma drug

  March 2, 2020

• FDA reports first drug shortage due to coronavirus impact

  Feb. 28, 2020

• Gilead commits to in-house development of coronavirus treatment hopeful

  Feb. 27, 2020

• Amgen heart drug passes interim check, setting up year-end readout

  Feb. 26, 2020

• US begins first study of coronavirus treatment, testing Gilead's remdesivir

  Feb. 25, 2020

• As shortages draw spotlight, Sanofi to spin out drug ingredient business

  Feb. 24, 2020

• Chinese biotech enlists GSK in coronavirus vaccine effort

  Feb. 24, 2020

• With supply tight, Novartis readies gene therapy plant for production

  Feb. 21, 2020

• GSK taps Immatics' cell therapy science in research deal

  Feb. 20, 2020

• Tocagen restructuring leads to reverse merger with Forte

  Feb. 20, 2020

• Biotech executives, having pledged fair pricing, criticize drugmaker for steep hike

  Feb. 19, 2020

• Audentes to spend $110M on new gene therapy plant in North Carolina

  Feb. 18, 2020

• Sanofi starts work on coronavirus vaccine, bringing scale to global research effort

  Feb. 18, 2020

• Bristol-Myers finds FDA receptive to speedy review of key cell therapy

  Feb. 13, 2020

• J&J bolsters coronavirus vaccine work with BARDA partnership

  Feb. 12, 2020

• Sanofi shrinks executive team as new CEO reshapes French drugmaker

  Feb. 12, 2020

• Moderna, raising cash, quickly advances coronavirus candidate

  Feb. 11, 2020

• Biohaven misses a chance to prove it's more than migraine

  Feb. 10, 2020

• AbbVie's plan to replace Humira is ahead of schedule

  Feb. 7, 2020

• In small study, hints of promise for 'natural killer' cell therapy

  Feb. 6, 2020

• Kite isn't flying with investors, and Gilead knows it

  Feb. 5, 2020

• Regeneron partners with US government to develop coronavirus treatment

  Feb. 4, 2020

• Antiviral drugmakers GSK, Gilead join fight against coronavirus' spread

  Feb. 3, 2020

• Biotech lacking diverse leadership, top trade group admits

  Jan. 31, 2020

• Vertex impresses with strong Trikafta launch

  Jan. 30, 2020

• Novartis gives up on Advair generic, leaving Mylan as sole competitor

  Jan. 29, 2020

• Zolgensma sales grow, signaling gene therapy momentum

  Jan. 29, 2020

• FDA, expecting a gene therapy boom, firms up policies

  Jan. 28, 2020

• J&J launches vaccine efforts as coronavirus spreads

  Jan. 27, 2020

• Epizyme drug granted approval by FDA for rare cancer

  Jan. 23, 2020

• AstraZeneca pledges to go 'carbon negative' by 2030

  Jan. 23, 2020

• Drug trial success a consolation prize for Akcea, Ionis

  Jan. 22, 2020

• 5 biopharmas to watch as the decade's last earnings kick off

  Jan. 21, 2020

• BioNTech rescues cancer biotech Neon in bargain buyout

  Jan. 16, 2020

• Lilly expands half-price insulin offerings

  Jan. 15, 2020

• Nationwide Children's, a gene therapy leader, launches manufacturing spinout

  Jan. 15, 2020

• Incyte turns to German Morphosys to refresh cancer pipeline

  Jan. 13, 2020

• A biotech startup launches with unusual goal: invent new drugs, and sell them for less

  Jan. 13, 2020

• Blueprint wins 1st FDA approval with targeted cancer drug

  Jan. 10, 2020

• 5 biotech trends to follow in 2020

  Jan. 9, 2020

• Belgian CDMO Ardena gets new private equity owners

  Jan. 9, 2020

• US cancer death rate drops by most on record

  Jan. 8, 2020

• Trial failure keeps Incyte searching for its next act

  Jan. 3, 2020

• Stealth's rare disease drug falls short in study, sinking shares

  Dec. 20, 2019

• Bladder cancer approval gives Seattle Genetics its second drug

  Dec. 19, 2019

• Trump administration lays out plans to import drugs from abroad

  Dec. 18, 2019

• GSK advances blood cancer drug to FDA, but rivals threaten

  Dec. 17, 2019

• Roche's $4.8B deal for Spark cleared by FTC after long delay

  Dec. 16, 2019

• BioMarin drug for dwarfism meets goal in late-stage study

  Dec. 16, 2019

• In stunning twist, FDA approves Sarepta's Duchenne drug it rejected

  Dec. 12, 2019

• Novartis still hasn't solved its CAR-T manufacturing issues

  Dec. 11, 2019

• For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans

  Dec. 10, 2019

• New drugs for sickle cell excite but, at ASH, a recognition that more is needed

  Dec. 9, 2019

• Drug Launch of the Year: Zolgensma

  Dec. 9, 2019

• Executive of the Year: Josh Bilenker, Loxo Oncology

  Dec. 9, 2019

• Sangamo keeps pressure on rivals with updated hemophilia data

  Dec. 7, 2019

• Myeloma cell therapies, now in pharma hands, move into spotlight

  Dec. 7, 2019

• Trial setback strikes blow to Sage antidepressant ambitions

  Dec. 5, 2019

• Lilly puts its cancer future in Loxo's hands

  Dec. 5, 2019

• Astellas joins gene therapy race with $3B Audentes buy

  Dec. 3, 2019

• FDA denies Lexicon bid to reverse diabetes drug rejection

  Dec. 2, 2019

• Wave faces key test in bid to challenge Sarepta in DMD

  Nov. 27, 2019

• Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations

  Nov. 26, 2019

• Medicines Co. deal caps pharma's reentry into field it once abandoned

  Nov. 26, 2019

• Novartis buys Medicines Co. in $9.7B bet on cholesterol drug

  Nov. 24, 2019

• 'I believe the drug works.' Biogen CMO defends decision to submit Alzheimer's drug to FDA

  Nov. 22, 2019

• AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron

  Nov. 21, 2019

• Takeda sees cell, gene therapy in its future. Is it too late?

  Nov. 20, 2019

• First look at CRISPR, Vertex gene-editing therapy hints at treatment potential

  Nov. 19, 2019

• Teva to restart production of cancer drug after shortages stressed treatment

  Nov. 14, 2019

• Sage's new drug starts slow, as Wall Street waits for depression data

  Nov. 13, 2019

• FDA documents appear to clear Amarin path to wider heart drug approval

  Nov. 12, 2019

• Regenxbio, stung by trial hold on gene therapy, sues FDA

  Nov. 11, 2019

• FDA approves first drug for anemia tied to rare blood disorder

  Nov. 8, 2019

• AnaptysBio shares collapse after 'worst case scenario' for key drug

  Nov. 8, 2019

• Trump administration sues Gilead over HIV drug patents

  Nov. 7, 2019

• Biogen broadens biosimilar bet to go after top-selling eye drugs

  Nov. 6, 2019

• Regeneron defends bid to challenge Merck in lung cancer

  Nov. 5, 2019

• China approves Alzheimer's drug, inviting fresh debate in field with few successes

  Nov. 4, 2019

• Stephen Hahn, top MD Anderson official, will be next FDA chief

  Nov. 1, 2019

• Roivant, Sumitomo alliance to target cystic fibrosis gene therapy

  Oct. 31, 2019

• FDA panel backs withdrawal of Amag drug to prevent preterm birth

  Oct. 30, 2019

• Strong sales buoy pharma even as risks grow

  Oct. 29, 2019

• Mirati keeps pace with Amgen in hunt for KRAS cancer drug

  Oct. 28, 2019

• Gilead CAR-T sales slow, renewing growth doubts

  Oct. 25, 2019

• J&J cuts profits to account for proposed opioid settlement

  Oct. 24, 2019

• 7 questions on Biogen's revival of a failed Alzheimer's drug

  Oct. 22, 2019

• Seattle Genetics stock hits record high on well-placed breast cancer bet

  Oct. 21, 2019

• Mirati data to test whether biotech can challenge Amgen in KRAS quest

  Oct. 18, 2019

• Lilly cancer drug pipeline hit by trial setback

  Oct. 16, 2019

• Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

  Oct. 15, 2019

• Revance CEO stepping down over 'misjudgment'

  Oct. 14, 2019

• Lilly's 1-drug migraine business gets support with new approval

  Oct. 11, 2019

• Gene therapy biotechs caught in manufacturing crunch

  Oct. 10, 2019

• Australian drugmaker's decade-long journey ends in FDA approval

  Oct. 9, 2019

• With new report, ICER puts itself at center of drug pricing storm

  Oct. 8, 2019

• Buttigieg targets pharma in aggressive plan to lower drug prices

  Oct. 7, 2019

• Arbutus stops early hepatitis B study on safety concerns

  Oct. 4, 2019

• J&J paying $20M to settle Ohio opioid suits

  Oct. 2, 2019

• Novartis, Microsoft ink 5-year AI alliance

  Oct. 2, 2019

• Sanofi's story needs to be 'better told,' new CEO says

  Oct. 1, 2019

• Seattle Genetics makes case it can be more than Adcetris

  Sept. 30, 2019

• Novartis, Lilly drugs set new survival bar in breast cancer

  Sept. 29, 2019

• Colon cancer proves tougher target for Amgen's KRAS drug

  Sept. 28, 2019

• Cancer immunotherapy boom showing no sign of slowdown

  Sept. 27, 2019

• FDA warning slowed immunotherapy use in bladder cancer

  Sept. 25, 2019

• Novartis to speed AveXis integration in wake of data manipulation

  Sept. 24, 2019

• States pull back curtain on drug prices, to uncertain effect

  Sept. 23, 2019

• With eye to competition, Biogen explores higher doses of Spinraza

  Sept. 20, 2019

• Novartis, shadowed by data scandal, renews case for Zolgensma

  Sept. 19, 2019

• In first, cancer drugs simultaneously approved in US, Canada, Australia

  Sept. 18, 2019

• Alexion's CFO steps down in surprise departure

  Sept. 18, 2019

• Ebola vaccine from Merck takes step toward US approval

  Sept. 17, 2019

• 5 questions ESMO cancer drug data might answer

  Sept. 16, 2019

• Novartis' strong MS results could pose challenge to Roche

  Sept. 13, 2019

• Moderna marks progress toward goal of coaxing medicine from body's cells

  Sept. 12, 2019

• Sanofi paying Lexicon $260M to exit diabetes alliance

  Sept. 11, 2019

• Biomarker data help Merck case for wide use of Keytruda combo

  Sept. 10, 2019

• After scandal, Novartis pledges faster action on data integrity

  Sept. 9, 2019

• Cancer drug data back up Lilly's Loxo buyout

  Sept. 9, 2019

• Amgen update shows promise, limits of KRAS cancer drug

  Sept. 8, 2019

• MD Anderson official emerges as top choice to run FDA, reports say

  Sept. 6, 2019

• With third pharma deal, IFM's unorthodox approach paying off

  Sept. 5, 2019

• Novartis secures NICE nod for Luxturna with discount offer

  Sept. 4, 2019

• UniQure stays a step ahead in hemophilia B

  Sept. 3, 2019

• Alexion shares slide on Amgen patent challenge to top-seller

  Aug. 30, 2019

• Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters

  Aug. 30, 2019

• Amgen patents on Repatha invalid, judge rules in reversal

  Aug. 28, 2019

• Purdue offering as much as $12 billion to settle opioid claims: report

  Aug. 28, 2019

• Oklahoma judge orders J&J pay $572M in landmark opioid case

  Aug. 26, 2019

• Lilly's case for Taltz helped by expanded approval

  Aug. 26, 2019

• Amgen buying Celgene's Otezla in $13B deal

  Aug. 26, 2019

• Moving quickly, GSK to advance myeloma drug on new data

  Aug. 23, 2019

• HHS to fund further manufacturing of Merck Ebola vaccine

  Aug. 22, 2019

• As supply shortages persist, ADMA relaunches immune globulin drug

  Aug. 22, 2019

• Trump administration not giving up on plan to require prices in TV drug ads

  Aug. 21, 2019

• AstraZeneca lung cancer miss is Merck's gain

  Aug. 21, 2019

• Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

  Aug. 19, 2019

• Celgene wins approval for drug key to Bristol buyout

  Aug. 16, 2019

• Novo faces shareholder suit over insulin sales disclosures

  Aug. 16, 2019

• Roche cancer drug the 3rd approved for pan-tumor use

  Aug. 15, 2019

• Study success strengthens case for Lynparza in ovarian cancer

  Aug. 14, 2019

• Novartis replaced AveXis chief scientist, R&D head amid Zolgensma uproar

  Aug. 14, 2019

• Lawmakers up pressure on Novartis in wake of data manipulation

  Aug. 13, 2019

• Amgen resurgent as court victory for top drug eases doubts

  Aug. 12, 2019

• In rebuke of Novartis, FDA making 'statement for the world'

  Aug. 9, 2019

• FDA decision on Amarin heart drug delayed as agency to hold expert review

  Aug. 8, 2019

• Medicare boosts CAR-T cancer therapies with expanded coverage

  Aug. 8, 2019

• Novartis CEO on defense as data scandal clouds gene therapy approval

  Aug. 7, 2019

• Novartis used manipulated data in winning Zolgensma approval, FDA says

  Aug. 6, 2019

• Novo buys North Carolina plant from Purdue

  Aug. 6, 2019

• In reversal, Mallinckrodt puts split plans on hold

  Aug. 6, 2019

• Roche trial win for Tecentriq leaves questions unanswered

  Aug. 5, 2019

• Congress is going after drug prices. Pharma CEOs aren't panicking, yet

  Aug. 2, 2019

• Akorn takes $74 million charge to settle shareholder lawsuit

  Aug. 1, 2019

• Sales gap grows between rival Merck, Bristol cancer therapies

  July 30, 2019

• Lilly cancer push boosted by survival benefit to key drug

  July 30, 2019

• Big pharma deals show industry's weak spots

  July 29, 2019

• Sanofi writes down hemophilia drug as competitive pressures rise

  July 29, 2019

• J&J advances MS drug candidate toward US, EU markets

  July 26, 2019

• Editas, Allergan launch first in vivo study of CRISPR-based medicine

  July 25, 2019

• Bristol-Myers hits snag in plan to catch Merck in lung cancer

  July 24, 2019

• In pivot, Sage turns focus to treatment-resistant depression

  July 24, 2019

• Acadia schizophrenia trial misses goal, setting back pipeline hopes

  July 23, 2019

• 5 questions going into this week's biopharma earnings

  July 22, 2019

• ViiV veteran science chief to step down

  July 19, 2019

• Catalent to help make Novartis' Zolgensma at Maryland site

  July 18, 2019

• Novartis gives first glimpse at Zolgensma launch

  July 18, 2019

• Inovio cuts staff, research to buy time

  July 17, 2019

• Novartis secures speedy review for sickle cell drug

  July 16, 2019

• Neon to advance cancer vaccine after early results suggest added benefit

  July 15, 2019

• Gilead forges closer ties with Galapagos in $5.1B deal

  July 14, 2019

• Lilly's Shaw to head Gilead's cancer push as new CEO of Kite

  July 11, 2019

• German court blocks sale of Sanofi, Regeneron cholesterol drug

  July 11, 2019

• White House pulls drug rebate rule to relief of payers

  July 11, 2019

• Amgen's KRAS success has other drugmakers eager to follow

  July 10, 2019

• Hunting better biomarkers, J&J taps Celsius to unpack role played by single cells

  July 9, 2019

• Pharma stocks slide as industry mulls Trump drug price action

  July 9, 2019

• Zolgensma set a new drug pricing bar. Insurers show some signs of pushback

  July 3, 2019

• Gilead firms up path to market for key arthritis drug

  July 2, 2019

• Bayer backs cell therapy startup with $215M in funding

  July 1, 2019

• Amgen bone drug application knocked back in Europe

  June 28, 2019

• Former FDA head Gottlieb joins Pfizer board

  June 27, 2019

• Catalent picks up Novavax facilities, 100 employees

  June 27, 2019

• Samsung Bioepis CEO urges patience as US biosimilar market lags

  June 26, 2019

• AbbVie buying Allergan in $63B deal for its post-Humira future

  June 25, 2019

• Roche wins speedy OK for lymphoma drug Polivy

  June 11, 2019

• Experimental drug delays Type 1 diabetes in research first

  June 10, 2019

• Vertex sets sights on DMD gene therapy, joining crowded field

  June 7, 2019

• Former GSK site to be redeveloped as WeWork-styled life sciences center

  June 6, 2019

• Opioid maker Insys to pay $225M to settle fraud charges

  June 6, 2019

• 3 takeaways from cancer's biggest conference

  June 5, 2019

• Bristol-Myers shuffles executive ranks for post-Celgene future

  June 5, 2019

• Biotech, pharma stocks climb higher after cancer meeting

  June 4, 2019

• Bluebird gene therapy approved in Europe in first for severe blood disorder

  June 3, 2019

• Blueprint keeps pressure on Lilly with RET-targeted cancer therapy

  June 3, 2019

• Early cancer drug data give Amgen hope it has 'cracked KRAS code'

  June 3, 2019

• At cancer conference, debate over speedy drug approvals in the spotlight

  June 3, 2019

• For some lung cancer patients, Keytruda provides lasting benefit

  June 1, 2019

• Novartis breast cancer drug shows survival benefit in younger women

  June 1, 2019

• Turning Point makes push to outdo Pfizer, Roche in targeted cancer therapy

  May 31, 2019

• Follow-up studies often lacking for cancer drugs approved early

  May 29, 2019

• Novartis gene therapy approved, but will come at cost of more than $2M

  May 24, 2019

• Nektar forms new biotech to sell under-review pain drug

  May 24, 2019

• Dynavax cuts staff in retreat from cancer research

  May 24, 2019

• Novartis looking earlier for deals as biotech valuations stay high

  May 23, 2019

• Verily lures major pharmas with promise of speedier clinical research

  May 21, 2019

• ICER seeks to make drug price research more accessible

  May 20, 2019

• Gilead CEO pressured on PrEP pricing at House hearing

  May 17, 2019

• FDA schedules Aimmune's peanut allergy drug for September expert review

  May 16, 2019

• Biotech in the spotlight at ASCO as pharma takes back seat

  May 16, 2019

• Vertex follows pharma lead in bet on protein degradation

  May 15, 2019

• Myovant reports a Phase 3 success, but Wall Street isn't cheered

  May 14, 2019

• Pharma, late to digital game, rushes to catch up

  May 13, 2019

• Catalent, hindered by Softgel weakness, sees stronger growth ahead

  May 9, 2019

• Nearing gene therapy launch, Bluebird cautions a slower start

  May 9, 2019

• Drugmakers will soon be required to disclose prices in TV ads

  May 8, 2019

• AstraZeneca blood cancer drug hits study goal early

  May 7, 2019

• 'Pathbreaking' Ionis trial offers way forward in Huntington's disease

  May 6, 2019

• Trelegy success gives GSK some respiratory respite

  May 3, 2019

• Renewable energy to power all Novo drug production by next year

  May 2, 2019

• Alnylam posts strong Onpattro sales as competition heats up

  May 2, 2019

• Longtime Gilead finance chief Robin Washington to step down next year

  May 1, 2019

• At gene therapy meeting, insurance execs grapple with expected cost

  April 30, 2019

• Keytruda powers Merck to another strong quarter

  April 30, 2019

• Praluent scores heart label, matching Amgen's rival Repatha

  April 29, 2019

• Cancer drugs lift AstraZeneca, aiding turnaround

  April 26, 2019

• Novartis chief defends cell, gene therapy push

  April 24, 2019

• In R&D, small biotechs hold their own against big pharma

  April 23, 2019

• Keytruda approved in kidney cancer, challenging Bristol-Myers

  April 22, 2019

• Roche's pharma business is booming, for now

  April 17, 2019

• With FDA decision near, Novartis bolsters SMA gene therapy case

  April 16, 2019

• J&J drugs sales outperform despite generic hit

  April 16, 2019

• Allergan wins support of influential advisory firms in shareholder fight

  April 15, 2019

• J&J wins FDA OK for first targeted therapy in bladder cancer

  April 12, 2019

• Bristol-Myers wins shareholder backing for Celgene buyout

  April 12, 2019

• Lonza's CEO on keeping up with microbiome, gene therapy boom

  April 11, 2019

• Unblinded: Hervé​ Hoppenot on solving Incyte's 'single asset syndrome'

  April 10, 2019

• Alcon spin-out marks step in Novartis plan to remake business

  April 9, 2019

• Coherus' Neulasta biosimilar surprises with strong early uptake

  April 8, 2019

• Pfizer wins expanded Ibrance approval using real world data

  April 5, 2019

• Amgen, Novartis clash in dispute over Aimovig partnership

  April 4, 2019

• AARP report offers window into generic drugmaker pain

  April 4, 2019

• Sangamo hemophilia A progress boosts shares

  April 2, 2019

• Despite research boom, few immunotherapy studies targeting pancreatic cancer

  April 1, 2019

• Early studies hint at some potential for CAR-T therapy in solid tumors

  March 31, 2019

• AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy

  March 29, 2019

• Gilead earns needed trial win as arthritis drug succeeds in 2 studies

  March 28, 2019

• Sarepta to seek speedy approval of third DMD drug

  March 28, 2019

• Novartis wins key US approval for multiple sclerosis drug Mayzent

  March 27, 2019

• A year after FDA refusal, Celgene resubmits ozanimod for review

  March 26, 2019

• Activist investor escalates pressure on Allergan

  March 25, 2019

• Aducanumab's failure puts pressure on field to look beyond amyloid

  March 22, 2019

• FDA's Gottlieb defends agency response to valsartan contamination

  March 21, 2019

• Soon to depart, Scott Gottlieb keeps focus on greater drug competition

  March 20, 2019

• Roche's Tecentriq secures another immunotherapy first

  March 19, 2019

• Gene therapy progress spurs competition in biotech buyouts

  March 19, 2019

• Heart benefits to AstraZeneca's Farxiga detailed in new findings

  March 18, 2019

• FDA's Gottlieb calls for greater adoption of new clinical trial tools

  March 15, 2019

• Celgene dodges Alvogen bid to overturn Revlimid patent

  March 14, 2019

• Amgen's top-selling Enbrel in balance as key court ruling nears

  March 13, 2019

• NCI Director Ned Sharpless to become acting FDA commissioner

  March 12, 2019

• Biogen sells biologics plant to Fujifilm in $890M deal

  March 12, 2019

• Roche wins first immunotherapy approval for triple-negative breast cancer

  March 8, 2019

• Mylan's Advair generic pressures GSK with strong launch

  March 8, 2019

• FDA walks back plan to alter generic names of already approved biologics

  March 7, 2019

• Allergan depression drug fails in setback for turnaround

  March 7, 2019

• FDA approves J&J's esketamine as faster-acting depression treatment

  March 6, 2019

• Gilead oncology chief departing to head up Glenmark spin-out

  March 5, 2019

• FDA Commissioner Scott Gottlieb resigning, to leave in one month

  March 5, 2019

• Celgene checks regulatory box for key drug in Bristol-Myers deal

  March 5, 2019

• Lilly to launch generic of its insulin Humalog, cutting list price in half

  March 4, 2019

• Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

  March 1, 2019

• Roche wins US approval of more convenient Herceptin

  March 1, 2019

• At Senate hearing, pharma shows split on biosimilars

  Feb. 27, 2019

• Gene therapy progress spurs Sarepta buy of Myonexus

  Feb. 27, 2019

• Pharma's day in Congress: 'A hearing not a show'

  Feb. 26, 2019

• In front of Congress, pharma execs blame 'broken' system

  Feb. 26, 2019

• Amgen wins jury verdict in PCSK9 court battle with Sanofi, Regeneron

  Feb. 25, 2019

• In gene editing milestone, first patient treated in Vertex, CRISPR Therapeutics study

  Feb. 25, 2019

• How lawmakers could pressure top pharma execs in Senate hearing

  Feb. 25, 2019

• Insulin drugmakers again come under Senate scrutiny

  Feb. 22, 2019

• In unusual step, FDA pushes back against reports on questionable generic drug quality

  Feb. 22, 2019

• FDA to accept drug plant inspections by Poland, Slovenia

  Feb. 21, 2019

• Sanofi handed payers nearly $12B in drug rebates last year

  Feb. 21, 2019

• Allergan rebuffs activist call to split CEO, chairman roles

  Feb. 20, 2019

• Intercept NASH drug succeeds in field's first positive Phase 3 trial

  Feb. 19, 2019

• Hunt for immunotherapy combinations turns up success in kidney cancer

  Feb. 16, 2019

• As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi

  Feb. 15, 2019

• Teva set to shed 11 manufacturing sites in 2019

  Feb. 14, 2019

• DBV sets sights on FDA resubmission for peanut allergy treatment

  Feb. 14, 2019

• Teva predicts bleak year ahead as generic, Copaxone sales drop

  Feb. 13, 2019

• J&J's esketamine wins backing of key advisory panel

  Feb. 12, 2019

• Merck kidney cancer data impresses, putting pressure on Bristol-Myers

  Feb. 12, 2019

• Celgene's Revlimid defenses withstand another challenge

  Feb. 12, 2019

• Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

  Feb. 11, 2019

• Sangamo setback pulls down gene editing biotech peers

  Feb. 8, 2019

• Sanofi turns R&D focus inward amid cuts to drug pipeline

  Feb. 7, 2019

• Pharma CEOs to testify in Senate drug pricing hearing

  Feb. 6, 2019

• Gilead investors hold their breath as trial readouts near

  Feb. 5, 2019

• 'Strategic fit' with Bristol-Myers kept Celgene from casting wider net in deal negotiations

  Feb. 1, 2019

• Trump administration proposal takes aim at drug rebates

  Jan. 31, 2019

• Lonza promotes biopharma head to CEO spot

  Jan. 31, 2019

• Pharma misses its prescription for growth

  Jan. 31, 2019

• Roche Alzheimer's setback puts Biogen in lonely spot

  Jan. 30, 2019

• Pfizer faces 2019 burdened by competitive challenges

  Jan. 29, 2019

• Amgen's migraine lead faces early test in CVS decision

  Jan. 28, 2019

• Lonza begins second-gen supply of Portola's Andexxa

  Jan. 24, 2019

• Opdivo questions hang over Bristol-Myers amid sales miss

  Jan. 24, 2019

• High-ranking Vertex exec fired over code of conduct violations

  Jan. 23, 2019

• Editas' CEO exit sparks investor fears

  Jan. 22, 2019

• J&J sales forecast disappoints as generic, pricing headwinds rise

  Jan. 22, 2019

• Aimmune drug application confusion leaves investors searching for answers

  Jan. 18, 2019

• 7 biopharma trends to watch in 2019

  Jan. 17, 2019

• Allergan, Mohawk tribe ask for Supreme Court review of scrutinized patent case

  Jan. 16, 2019

• FDA review of Aimmune drug put on hold due to government shutdown

  Jan. 14, 2019

• Hunting productivity, drugmakers pitch new 'pillars' of R&D

  Jan. 11, 2019

• The winners and losers from JPM 2019

  Jan. 11, 2019

• A biotech's M&A invitation and Editas' next CRISPR step

  Jan. 10, 2019

• Moderna's defense, biosimilar battles and other updates

  Jan. 9, 2019

• Shire deal done, Takeda turns to task of forging top pharma

  Jan. 9, 2019

• Novartis' cell therapy ambitions outpace early returns

  Jan. 7, 2019

• Sanofi zeroes in on bispecifics in reworked Regeneron deal

  Jan. 7, 2019

• Bristol-Myers' gamble on Celgene pipeline prospects

  Jan. 4, 2019

• Bristol-Myers to buy Celgene in industry-shaking $74B deal

  Jan. 3, 2019

• Drugmakers open new year with price increases on dozens of medicines

  Jan. 2, 2019

• Acorda wins FDA nod for Parkinson's drug

  Dec. 24, 2018

• Our 10 best stories of 2018

  Dec. 21, 2018

• Gene therapy could be cost effective in SMA, but not at $4M

  Dec. 21, 2018

• Novartis seeks to acquire French CAR-T contract manufacturer

  Dec. 20, 2018

• Pharma returns on R&D ebb to new low, Deloitte finds

  Dec. 20, 2018

• Trump drug ad proposal earns support from insurers, medical groups

  Dec. 19, 2018

• GSK, Pfizer to launch consumer joint venture in market-shifting partnership

  Dec. 19, 2018

• AstraZeneca's China push boosted by anemia drug OK

  Dec. 18, 2018

• AbbVie shows allure of pharma stock buybacks

  Dec. 14, 2018

• Mylan patent win for Lantus copy looks unlikely to speed market entry

  Dec. 13, 2018

• Kalé​o, facing criticism, launches generic overdose treatment at cut price

  Dec. 12, 2018

• Bausch bids $200M for Synergy gut drug, eyeing turnaround opportunity

  Dec. 12, 2018

• Roche wins key cancer drug approval, but taking on Merck remains a challenge

  Dec. 11, 2018

• Gilead names Roche veteran O'Day as CEO

  Dec. 10, 2018

• ASH successes set to lift Imbruvica in CLL

  Dec. 6, 2018

• In CAR-T, manufacturing a hurdle Novartis has yet to clear

  Dec. 6, 2018

• At ASH, bispecific cancer therapies make a mark

  Dec. 5, 2018

• ASH18: Bluebird's gene therapy progress shadowed by MDS case

  Dec. 4, 2018

• Pharma of the Year: Merck & Co.

  Dec. 3, 2018

• Innovation of the Year: RNA-targeting therapies

  Dec. 3, 2018

• Executive of the Year: Emma Walmsley, GlaxoSmithKline

  Dec. 3, 2018

• ASH18: CAR-T shows up in early CLL test

  Dec. 2, 2018

• ASH18: Cancer drug trials in need of modernization, NCI director says

  Dec. 1, 2018

• ASH18: Trial successes back Celgene belief in luspatercept

  Dec. 1, 2018

• Changing markets: A look at rheumatoid arthritis

  Nov. 30, 2018

• Bayer to cut 12,000 jobs in overhaul of business

  Nov. 29, 2018

• Alkermes' schizophrenia drug succeeds in needed trial win

  Nov. 29, 2018

• Outcry over gene-edited babies grows as Chinese researcher defends work

  Nov. 28, 2018

• Loxo cancer drug wins US approval in advance for targeted therapy

  Nov. 27, 2018

• Drugmakers vie to capture slice of rheumatoid arthritis market

  Nov. 26, 2018

• Gene-edited babies born in China, Chinese researcher claims

  Nov. 26, 2018

• Mylan taken to task for manufacturing failings at key plant

  Nov. 21, 2018

• Sage faces delayed decision on postpartum depression drug

  Nov. 20, 2018

• Pfizer tests Trump with plans to hike prices on 41 drugs

  Nov. 16, 2018

• At SITC, clear wins for immunotherapy combos remain elusive

  Nov. 12, 2018

• NASH drugs come into focus as field awaits late-stage data

  Nov. 9, 2018

• AstraZeneca at 'inflection point' in turnaround, predicts CEO

  Nov. 8, 2018

• 5 election takeaways for pharma

  Nov. 7, 2018

• Nektar lures Pfizer with promise of combo immunotherapy

  Nov. 6, 2018

• Humira biosimilar discounting 'aggressive' as competition enters in Europe

  Nov. 2, 2018

• Alkermes depression drug approval odds slim after negative FDA panel vote

  Nov. 2, 2018

• Gilead's stock wobbles on HIV pricing concerns

  Nov. 1, 2018

• Shingrix gives GSK a near-term boost

  Nov. 1, 2018

• Novartis wins US nod for Humira biosimilar, but focus now on Europe

  Oct. 31, 2018

• Come January, will pharma pricing pledges hold?

  Oct. 31, 2018

• Merck's Keytruda secures broader lung cancer approval

  Oct. 31, 2018

• Alkermes' depression drug set to test flexibility of FDA

  Oct. 29, 2018

• Pfizer, Novartis partner in hunt to find drugs for NASH

  Oct. 29, 2018

• Esperion clears final trial hurdle in bid to shake up cholesterol market

  Oct. 28, 2018

• Amgen, Regeneron appear most at risk from Trump's latest pricing plan

  Oct. 26, 2018

• Trump pitches new plan to bring US drug prices down

  Oct. 25, 2018

• Keytruda growth fuels Merck investment

  Oct. 25, 2018

• Biogen dips as BAN2401 data bring more questions than answers

  Oct. 25, 2018

• Amgen cuts US Repatha price 60% amid market pressure

  Oct. 24, 2018

• DTC's big issues: Trump, cancer drugs and the First Amendment

  Oct. 24, 2018

• Reimbursement lags cancer drug approvals, but some European countries wait longer

  Oct. 24, 2018

• Pfizer, Lilly avoid safety red flags in late-stage tanezumab trial

  Oct. 24, 2018

• Advair copy approval 'imminent,' Mylan says, but investors jittery

  Oct. 23, 2018

• Viagra no more: The changing face of drug ads on TV

  Oct. 22, 2018

• ESMO 2018: What you missed over the weekend

  Oct. 22, 2018

• Loxo's targeted therapy holds up to Roche challenge

  Oct. 20, 2018

• Benefit of Roche's Tecentriq looks limited in breast cancer

  Oct. 20, 2018

• Clovis aims at new market for cancer drug Rubraca

  Oct. 19, 2018

• Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan

  Oct. 18, 2018

• Humira biosimilars launch in Europe, testing AbbVie

  Oct. 17, 2018

• Biosimilars bite into Herceptin in Europe

  Oct. 17, 2018

• 5 questions on the Trump admin's bid to mandate prices in drug ads

  Oct. 16, 2018

• Confronting pharma, Trump admin seeks price disclosure in drug ads

  Oct. 15, 2018

• Under pressure, drugmakers give an inch on DTC drug ads

  Oct. 15, 2018

• Opdivo misses survival goal in small-cell lung cancer study

  Oct. 12, 2018

• Expansion gives Almac room to grow in North Carolina

  Oct. 11, 2018

• US tightens scrutiny of foreign investment into biotech sector

  Oct. 11, 2018

• Price increases on top drugs drove majority of recent growth, analysis finds

  Oct. 10, 2018

• Trevena shares sink on FDA concerns ahead of key panel meeting

  Oct. 9, 2018

• Loxo, Blueprint drive forward with RET-targeting cancer therapies

  Oct. 8, 2018

• FDA clears rare disease therapy from Akcea, Ionis

  Oct. 5, 2018

• Gilead reaches deal for Yescarta coverage in England

  Oct. 5, 2018

• Sarepta gene therapy for DMD takes another step forward

  Oct. 4, 2018

• Roche drug shows benefit in spinal muscular atrophy

  Oct. 3, 2018

• In reversal, GSK to restart limited payments to doctors

  Oct. 3, 2018

• Rare case of CAR-T resistance underscores manufacturing hurdles

  Oct. 2, 2018

• 10 biotechs set to shake up the industry's top ranks

  Oct. 1, 2018

• Pfizer's Bourla to succeed Read as CEO

  Oct. 1, 2018

• What you need to know about continuous manufacturing

  Oct. 1, 2018

• Regeneron wins early approval for cancer immunotherapy

  Sept. 29, 2018

• Alnylam puts its chips on speedy OK for rare disease drug

  Sept. 28, 2018

• Cancer drug approval expands Pfizer's targeted therapy ambition

  Sept. 28, 2018

• Lilly's migraine drug wins US approval, pressuring rivals Amgen, Teva

  Sept. 27, 2018

• Merck CEO to stay on through 2019

  Sept. 26, 2018

• AstraZeneca's Imfinzi shows its strength in Stage 3 lung cancer

  Sept. 25, 2018

• Tecentriq sets the bar in small-cell lung cancer

  Sept. 25, 2018

• Pharma's slow embrace of continuous manufacturing

  Sept. 24, 2018

• Foundation Med advances liquid biopsy ambition with new test

  Sept. 24, 2018

• Amicus expands into gene therapy with $100M deal

  Sept. 20, 2018

• AbbVie accused of 'far-reaching' kickback scheme for Humira

  Sept. 18, 2018

• Viking shares soar as NASH drug impresses

  Sept. 18, 2018

• Will Ajovy lead Teva's turnaround?

  Sept. 17, 2018

• Teva wins much-needed US approval of migraine drug

  Sept. 14, 2018

• Allergan's Bonti buy part of plan to double medical aesthetics business

  Sept. 14, 2018

• Sanofi looks to China in business restructure

  Sept. 13, 2018

• Boehringer bets on oncolytic viruses in ViraTherapeutics deal

  Sept. 13, 2018

• Gottlieb rebuffs pharma CEO who claimed price hikes were 'moral requirement'

  Sept. 12, 2018

• Bristol-Myers' psoriasis drug proves itself in mid-stage study

  Sept. 12, 2018

• Alcon to shift HQ to Switzerland after Novartis spinoff

  Sept. 11, 2018

• Appeals court upholds CRISPR patent ruling in win for Broad Institute

  Sept. 10, 2018

• FDA closes door to speedy OK for Amicus rare disease drug

  Sept. 10, 2018

• GSK's pitch for Nucala in COPD turned down by FDA

  Sept. 7, 2018

• Invokana gains heart labeling in Europe

  Sept. 7, 2018

• GSK eliminates 650 jobs amid R&D revamp

  Sept. 6, 2018

• Portola inches closer to large-scale Andexxa production

  Sept. 6, 2018

• BioMarin pumps $43M into Ireland drug plant

  Sept. 6, 2018

• FDA delays key Tecentriq decision by 3 months

  Sept. 6, 2018

• Sangamo pitches gene therapy progress, yet investors stay skeptical

  Sept. 5, 2018

• Chi-Med wins landmark cancer drug approval in China

  Sept. 5, 2018

• Mannkind stays afloat with United licensing deal

  Sept. 4, 2018

• Pfizer calls out pharma peers for 'scare tactics' on biosimilars

  Aug. 29, 2018

• UK's NICE judges Yescarta too pricey, dealing blow to Gilead

  Aug. 28, 2018

• FDA confronts its limits in push on drug pricing

  Aug. 27, 2018

• Pfizer's tafamidis cuts risk of death in rare disease study

  Aug. 27, 2018

• Esperion clears another milestone in bet on cholesterol pill

  Aug. 27, 2018

• Lawmakers push to require price disclosure in DTC drug ads

  Aug. 24, 2018

• Novartis' trial success revives PI3K potential in breast cancer

  Aug. 23, 2018

• AbbVie brings Argenx drug onboard amid immuno-oncology push

  Aug. 22, 2018

• HHS touts drug pricing 'wins,' but true tests still to come

  Aug. 21, 2018

• Aimovig launch bolsters hopes for blockbuster sales

  Aug. 20, 2018

• Amicus secures US approval for Fabry disease drug

  Aug. 10, 2018

• In first, FDA approves RNA interference drug from Alnylam

  Aug. 10, 2018

• CVS rejects pharma claim that rebates push up drug prices

  Aug. 9, 2018

• AstraZeneca settles Texas suits claiming it mismarketed Crestor, Seroquel

  Aug. 8, 2018

• Mylan to explore its options as North American business struggles

  Aug. 8, 2018

• Express Scripts drops Mavyret from 2019 formulary in blow to AbbVie

  Aug. 7, 2018

• Spark sheds $1B in value on hemophilia gene therapy data

  Aug. 7, 2018

• Regeneron expands immuno-oncology push with Bluebird pact

  Aug. 6, 2018

• Drugs make up more US health spending than thought, report suggests

  Aug. 3, 2018

• AbbVie surprised investors with its hepatitis C success. Will it last?

  Aug. 2, 2018

• Latest PRV sale further evidence of sliding value

  Aug. 2, 2018

• Gilead spotlights Truvada ads as preventive use grows

  Aug. 1, 2018

• Pfizer CEO sees drug rebates 'going away' in US

  July 31, 2018

• RedHill drug for Crohn's clears first Phase 3 hurdle

  July 30, 2018

• AbbVie faith in Humira, future growth remains ironclad

  July 27, 2018

• Sales of Roche new drugs are surging. Will that be enough?

  July 26, 2018

• Positive Alzheimer's results from Biogen, Eisai spark 'cautious optimism'

  July 25, 2018

• GSK secures US approval of new malaria drug

  July 25, 2018

• Two-drug HIV regimen from GSK bolstered by Phase 3 data

  July 24, 2018

• Seeking to adopt AI, drugmakers search for right mix of talent

  July 23, 2018

• Sangamo to buy TxCell, cell therapy tech in $84M deal

  July 23, 2018

• 7 companies to watch during Q2 earnings

  July 19, 2018

• Novartis hits CAR-T manufacturing snag as Kymriah sales disappoint

  July 19, 2018

• Tecentriq misses another chance to catch Keytruda

  July 19, 2018

• Drug lobby aims to shake up how medicines are paid for

  July 18, 2018

• Novartis points to price hike pause, potentially dodging Pfizer fate

  July 18, 2018

• Roche experimental flu drug clears second Phase 3

  July 17, 2018

• Cassiopea prospects fill in as hair loss drug shows promise

  July 16, 2018

• Novartis' contacts with Trump lawyer broader than company let on, US senators charge

  July 13, 2018

• Novartis partners with French CDMO to bolster CAR-T supply

  July 12, 2018

• Dermavant finds 'cornerstone' drug in GSK's pipeline

  July 12, 2018

• Pfizer price hikes on pause after Trump pressure

  July 11, 2018

• Aquinox cuts staff by 50% in wake of late-stage miss

  July 10, 2018

• CTI cancer drug faces clouded future after study failure

  July 9, 2018

• Biogen Alzheimer's drug shows unexpected signs of promise

  July 6, 2018

• Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

  July 5, 2018

• Catalent expands with $133M deal for Juniper

  July 3, 2018

• Sanofi expands China presence with new R&D hub

  July 2, 2018

• Tecentriq extends streak with win in breast cancer trial

  July 2, 2018

• Galapagos posts 'underwhelming' cystic fibrosis results, boosting Vertex

  June 29, 2018

• Biogen pays $700M to up stake in Samsung Bioepis

  June 29, 2018

• Akebia, Keryx to merge, creating $1B kidney disease company

  June 28, 2018

• Gottlieb calls out Perrigo for missed postmarket study deadline

  June 27, 2018

• Global Blood bets sickle cell drug success will convince FDA

  June 27, 2018

• FDA to pub surrogate endpoints used in cancer drug approvals

  June 26, 2018

• Jardiance shows potential in type 1 diabetes, clearing Phase 3 tests

  June 26, 2018

• Immunotherapy advances spur new look at cancer vaccines

  June 25, 2018

• Roche aims for first-mover edge in small cell lung cancer

  June 25, 2018

• Novo's case for oral semaglutide bolstered by Phase 3 trial wins

  June 21, 2018

• Purdue Pharma lays off 350, cutting remainder of sales force

  June 20, 2018

• Anika shares slump on Phase 3 miss

  June 20, 2018

• Roche buys out Foundation Med in $2.4B bet on targeted cancer treatment

  June 19, 2018

• Solid finds its footing as FDA lifts trial hold

  June 18, 2018

• Valeant hit with CRL for key dermatology drug

  June 18, 2018

• Bluebird's changes to LentiGlobin begin to pay off

  June 15, 2018

• Recipharm to pay $60M for Sanofi manufacturing plant

  June 14, 2018

• Sage licenses out depression drug in Asia, adding to cash warchest

  June 14, 2018

• Biosimilars could still pack revenue-busting punch, analyst suggests

  June 13, 2018

• FDA permits more expansive communication between drugmakers, payers

  June 13, 2018

• Sun Pharma gets reprieve as FDA clears key Halol plant

  June 12, 2018

• Allergan notches another CGRP success, but faces changing migraine market

  June 11, 2018

• AbbVie, Roche win key US approval for blood cancer drug

  June 11, 2018

• Sanofi partners with Translate Bio on mRNA vaccines

  June 11, 2018

• Novartis won't face Swiss criminal probe over payments to Trump lawyer

  June 7, 2018

• ASCO18: 3 unanswered questions from oncology's largest conference

  June 6, 2018

• ASCO18: Who were the big winners and losers?

  June 6, 2018

• ASCO18: Bristol-Myers fights for its place in first-line lung cancer

  June 5, 2018

• ASCO18: Celgene makes its case as CAR-T rival in lymphoma

  June 3, 2018

• ASCO18: Merck raises the bar in lung cancer with Keytruda data

  June 3, 2018

• ASCO18: Bristol-Myers, Nektar forge ahead with Phase 3 tests for cancer combo

  June 2, 2018

• ASCO18: Positive readout marks step forward for Bluebird's CAR-T

  June 1, 2018

• Gilead's filgotinib clears mid-stage test in arthritis

  May 31, 2018

• PhRMA criticizes ICER in latest skirmish over valuing drugs

  May 31, 2018

• Allergan to sell off women's health, anti-infective businesses

  May 30, 2018

• AstraZeneca won't submit lung drug for COPD after 2nd study miss

  May 30, 2018

• Tecentriq trial wins boost Roche bid to compete with Merck

  May 29, 2018

• AstraZeneca's Imfinzi delivers survival benefit in Stage 3 lung cancer

  May 25, 2018

• Cancer drug spending climbs, with top winners earning lion's share

  May 24, 2018

• Momentum grows for hemophilia gene therapies

  May 22, 2018

• Regeneron's Aris Baras on probing the genome to find drugs for NASH

  May 21, 2018

• Pharma turn to NASH unlikely to mirror meteoric rise of hep C

  May 21, 2018

• FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

  May 21, 2018

• Celgene, J&J top complaint list to FDA for blocking generics

  May 18, 2018

• 5 takeaways from the first look at cancer's biggest conference

  May 17, 2018

• To shame drugmakers, CMS publicizes price hikes

  May 16, 2018

• Top Novartis lawyer to exit over deal with Trump insider

  May 16, 2018

• Gilead finds new home in Europe for CAR-T manufacturing

  May 15, 2018

• Bluebird widens hunt for TCR therapies in revised Medigene deal

  May 14, 2018

• AstraZeneca lung drug comes up short in COPD

  May 11, 2018

• Tecentriq stumbles in Phase 3 colon cancer study

  May 10, 2018

• Walmart to limit opioid prescriptions to 7-day supply

  May 9, 2018

• Novartis paid $1.2M to firm linked to Trump attorney

  May 9, 2018

• Takeda secures Shire takeover with $62B deal

  May 8, 2018

• J&J's ketamine-based antidepressant sees mixed results in Phase 3

  May 7, 2018

• Merck bets Moderna's mRNA tech can unlock KRAS puzzle

  May 5, 2018

• FDA approves Andexxa in major boost to Portola

  May 4, 2018

• Fremanezumab approval by mid-June unlikely, Teva says

  May 3, 2018

• Regeneron, Sanofi drop PCSK9 price in deal with Express Scripts

  May 2, 2018

• IDO drug development scaled back in wake of Incyte trial miss

  May 2, 2018

• Merck, riding clinical success, eyes cancer immunotherapy lead

  May 1, 2018

• Q1 earnings preview: Novo, Celgene still to come

  May 1, 2018

• Saunders: All options remain on the table for Allergan

  April 30, 2018

• Opdivo sales rise again, but analysts question what's next

  April 26, 2018

• Ocrevus fuels fast start to year for Roche

  April 26, 2018

• Biogen to increase stake in biosimilar developer Samsung Bioepis

  April 25, 2018

• GSK new drug success eclipsed by currency, Advair slump

  April 25, 2018

• Immunotherapies, biosimilars to dominate next week of earnings

  April 24, 2018

• Setback for AstraZeneca cancer combo raises MYSTIC stakes

  April 24, 2018

• Lilly raises sales forecasts as diabetes drugs outperform

  April 24, 2018

• As India, China drug industries mature, FDA scrutiny an overhang

  April 23, 2018

• Top challenges facing drug supply chains

  April 23, 2018

• Pfizer's Herceptin copy hits FDA roadblock

  April 23, 2018

• Biogen, facing questions, turns again to Ionis in $1B research deal

  April 20, 2018

• Astellas sells Agensys facilities to Gilead

  April 19, 2018

• Cosentyx jitters weigh on Novartis

  April 19, 2018

• Pushing 'value,' Harvard Pilgrim tests outcomes deals

  April 18, 2018

• DEA seeks to more strictly manage opioid manufacturing

  April 18, 2018

• Sanofi nears deal to sell EU generics unit for $2.4B

  April 17, 2018

• Two years after cancer setback, Bristol-Myers' new biomarker bet pays off

  April 16, 2018

• I/O combos inch forward in pharma's lung cancer quest

  April 16, 2018

• Q1 kicks off with J&J, Novartis, Glaxo results

  April 13, 2018

• Lonza makes gene therapy ambitions clear with Texas plant

  April 12, 2018

• GSK offloads gene therapy drugs to UK's Orchard

  April 12, 2018

• CVS hands pharmacists tool to compare drug prices

  April 11, 2018

• Pfizer's Inlyta misses mark in Phase 3 kidney cancer study

  April 11, 2018

• With study success, AbbVie's arthritis hopeful looks to be a safer bet

  April 9, 2018

• Novartis buys AveXis for $8.7B, broadening gene therapy bet

  April 9, 2018

• AbbVie staves off another biosimilar challenge to Humira

  April 6, 2018

• Incyte cancer study fails, setting back drug combo hopes

  April 6, 2018

• Corning to build NC facility in pharma packaging expansion

  April 5, 2018

• Boehringer joins checkpoint inhibitor race with OSE deal

  April 5, 2018

• Alnylam taps Agilent for commercial API supply

  April 4, 2018

• Amgen's money-back offer on Repatha isn't all that meaningful, researchers find

  April 4, 2018

• Proposed China tariffs target dozens of medical products

  April 4, 2018

• Rigel's fostamatinib falls short in Phase 2

  April 3, 2018

• Pfizer surprises ATTR rivals with tafamidis success

  April 2, 2018

• Eisai partners with Nichi-Iko in generics pact

  March 29, 2018

• Indivior inks deal for preclinical addiction treatment candidate

  March 29, 2018

• PhRMA goes after drug 'middlemen' in new ad attack

  March 28, 2018

• Roche reports deaths of patients taking Hemlibra

  March 28, 2018

• GSK buys Novartis stake in consumer business for $13B

  March 27, 2018

• Lilly's bet on pain stands out amid bare pharma pipeline

  March 26, 2018

• Roche's momentum grows as Tecentriq combo delivers survival benefit

  March 26, 2018

• GSK drops bid to acquire Pfizer's consumer business

  March 23, 2018

• Novartis readies MS drug for speedy US filing

  March 22, 2018

• FDA warns Indian drugmaker over open-air API production

  March 22, 2018

• Regeneron, Alnylam partner to turn discovery into new drugs for NASH

  March 22, 2018

• Seattle Genetics secures key label expansion for Adcetris

  March 21, 2018

• Tecentriq combo success boosts Roche in lung cancer

  March 20, 2018

• Heron's non-opioid pain drug succeeds in Phase 3, lifting shares

  March 19, 2018

• Ionis taps majority-owned Akcea to launch inotersen

  March 16, 2018

• Novartis splits operations unit as part of leadership reshuffle

  March 15, 2018

• SEC charges against Theranos, Holmes dispel last shreds of unicorn myth

  March 15, 2018

• Federal panel calls for 'urgent action' on cancer drug prices

  March 14, 2018

• Incyte study could bring lessons for cancer immunotherapy

  March 14, 2018

• Teva hands back rights to preclinical CGRP blocker

  March 13, 2018

• AstraZeneca pushes back readout of key lung cancer study

  March 12, 2018

• Regeneron-Sanofi cholesterol drug cuts heart risk in major study

  March 10, 2018

• Despite crowded I/O field, pharma, VCs still eager to invest

  March 9, 2018

• FDA recognizes GMP inspections by 4 more EU states

  March 8, 2018

• Merck partners with Eisai in sweeping bet on Keytruda combo

  March 8, 2018

• UnitedHealthcare to use rebates to lower drug costs for patients

  March 6, 2018

• Santhera shares slide as Raxone fails in MS study

  March 5, 2018

• Dermira acne drug misses the mark, surprising investors

  March 5, 2018

• Roche, Ionis showcase potential of Huntington's disease drug

  March 2, 2018

• Regeneron links rise in Eylea safety reports to syringes

  March 1, 2018

• Mylan partners with Revance to develop a Botox biosimilar

  March 1, 2018

• Benzo overprescribing risk may be overlooked amid opioid crisis

  Feb. 28, 2018

• AstraZeneca spins out new biotech, shedding autoimmune drugs

  Feb. 28, 2018

• Lilly wins broader Verzenio approval, drawing even with rivals

  Feb. 27, 2018

• Messy Phase 2 data for Arca's heart drug leave investors unimpressed

  Feb. 26, 2018

• Cancer and the microbiome: What's old is new again

  Feb. 26, 2018

• Patent board ruling undermines Allergan effort to defend Restasis patents

  Feb. 26, 2018

• Bellicum outlines path to restart US studies of cell therapy

  Feb. 23, 2018

• CAR-T growing up with big pharma's big bet

  Feb. 20, 2018

• Charles River boosts CRO chops with $800M deal for MPI

  Feb. 15, 2018

• Biogen shares fall after unexpected 'variability' in Alzheimer's studies

  Feb. 15, 2018

• Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug

  Feb. 14, 2018

• Teva's Copaxone sales hit hastened with OK of Novartis copy

  Feb. 13, 2018

• Maker of Oxycontin to halt opioid promotion to doctors

  Feb. 12, 2018

• Boehringer ends Alzheimer's research for PDE9 blocker

  Feb. 9, 2018

• FDA warning letter details violations at Celltrion plant

  Feb. 8, 2018

• Citing lower tax rate, Amgen plans new biomanufacturing plant

  Feb. 8, 2018

• FDA knocks back Novartis' Advair copy

  Feb. 8, 2018

• Express Scripts: Plan drug spending rose at slowest rate in 24 years

  Feb. 7, 2018

• Mixed results muddy Sanofi's plans for 2018 growth

  Feb. 7, 2018

• Gilead forecasts steep slide in 2018 hepatitis C revenues

  Feb. 6, 2018

• Strong data lift profile of J&J's cancer drug apalutamide

  Feb. 5, 2018

• Biopharma in charts: Key takeaways from Q4 earnings

  Feb. 5, 2018

• Keytruda boosts Merck, yet 2018 will be crucial year

  Feb. 2, 2018

• Celltrion biosimilars plant hit with FDA warning letter

  Feb. 1, 2018

• Pharma tees up US capital spending, yet details remain vague

  Feb. 1, 2018

• FDA adds black box warning to Intercept's Ocaliva

  Feb. 1, 2018

• Aegerion sentenced for mismarketing of cholesterol drug

  Jan. 31, 2018

• Boosted by tax reform, Lilly looking for ways to spend $9B

  Jan. 31, 2018

• How Bristol-Myers and Pfizer are using real-world data to unseat warfarin

  Jan. 29, 2018

• 5 Drivers spurring use of real-world evidence

  Jan. 29, 2018

• Aradigm stung by FDA rejection of inhaled antibiotic

  Jan. 29, 2018

• AbbVie shares boom on rosy outlook

  Jan. 26, 2018

• Chinese drugmakers tap GE tech, seeing biologic boom ahead

  Jan. 25, 2018

• Spark deals Novartis ex-US rights to gene therapy for $105M

  Jan. 25, 2018

• US in 'desperate need' of biosimilars: Novartis' Narasimhan

  Jan. 24, 2018

• Novartis pulls Arzerra outside US markets amid rising CLL competition

  Jan. 24, 2018

• Novartis predicts growth pick-up on back of Cosentyx, Entresto

  Jan. 24, 2018

• Astellas, Vical's CMV vaccine comes up short in Phase 3

  Jan. 23, 2018

• Celgene buys Juno for $9B, deepening bet on CAR-T

  Jan. 22, 2018

• FDA to speed public notification of product recalls

  Jan. 19, 2018

• Ipca Labs buys North Carolina manufacturer for $9.7M

  Jan. 18, 2018

• With eye to Brexit, Almac to invest $42M in Ireland site

  Jan. 18, 2018

• Patent setback could sting J&J prostate cancer franchise

  Jan. 18, 2018

• Exelixis details Phase 3 cabozantinib results

  Jan. 17, 2018

• Price for Spark gene therapy too high, ICER says

  Jan. 16, 2018

• BioPharma Dive's 3 predictions for 2018 and beyond

  Jan. 12, 2018

• Closing JPM18: Winners and losers, brighter days for neuroscience

  Jan. 11, 2018

• JPM18 Day 3: Valeant and Acorda make plans, promises of M&A

  Jan. 10, 2018

• Price competition to hit oncology next: BioPharma Dive's 2018 predictions

  Jan. 10, 2018

• JPM18: Bluebird set to file 3 drugs for approval by 2019

  Jan. 9, 2018

• JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T

  Jan. 9, 2018

• JPM18 Day 1: Celgene bullish, Alnylam tempers hopes, Axovant shocks

  Jan. 8, 2018

• Celgene aims to quell growth worries with $7B Impact deal

  Jan. 7, 2018

• Pfizer pulls back from neuroscience, ending research

  Jan. 7, 2018

• FDA rejects Allergan's latest bid to block Restasis copies

  Jan. 5, 2018

• FDA aims to strengthen oversight of compounded drug manufacturing

  Jan. 4, 2018

• MacroGenics finds new pharma partner in Roche

  Jan. 4, 2018

• Drug approvals surged in 2017. What does that mean for pharma?

  Jan. 3, 2018

• Allergan to cut 1,000 jobs as generic competition threatens

  Jan. 3, 2018

• Pfizer teams up with Sangamo to develop ALS gene therapy

  Jan. 3, 2018

• J&J builds case for ketamine-based depression drug

  Jan. 2, 2018

• Mallinckrodt builds pipeline through $1.2B Sucampo deal

  Dec. 26, 2017

• J&J enters CAR-T field with $350M Legend deal

  Dec. 22, 2017

• Biopharma trends to watch in 2018

  Dec. 22, 2017

• Kymriah, Yescarta could be cost-effective, ICER finds

  Dec. 21, 2017

• Juno inks CAR-T supply deal with Thermo Fisher

  Dec. 21, 2017

• Galera scores trial win for cancer side effect treatment

  Dec. 20, 2017

• FDA approves Spark blindness drug in gene therapy first

  Dec. 19, 2017

• Aerie eyes glaucoma market after early FDA win

  Dec. 19, 2017

• Novartis buys regulatory fast pass for $130M

  Dec. 18, 2017

• Trial miss sets back Merck's Keytruda plans in stomach cancer

  Dec. 15, 2017

• EMA signs off on Samsung BioLogics manufacturing plant

  Dec. 14, 2017

• FDA warns Korean OTC manufacturer for GMP violations

  Dec. 14, 2017

• Regeneron's play for a stake in the I/O market boosted by study success

  Dec. 14, 2017

• ASH 2017: What you missed

  Dec. 13, 2017

• ASH17: J&J's Darzalex delivers combo win

  Dec. 12, 2017

• ASH17: Spark gene therapy falls behind BioMarin in hemophilia

  Dec. 11, 2017

• Shire CEO: Hemophilia will remain a core business

  Dec. 10, 2017

• ASH17: Benefit of Gilead's CAR-T remains durable over longer term

  Dec. 10, 2017

• ASH17: Seattle Genetics sees market opportunity in cancer combo success

  Dec. 10, 2017

• ASH17: bluebird bio makes strides in CAR-T, gene therapy

  Dec. 9, 2017

• ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

  Dec. 9, 2017

• Gilead deepens CAR-T push with deal for Cell Design

  Dec. 7, 2017

• Chasing leaders, Juno rides CAR-T momentum into ASH

  Dec. 7, 2017

• Wuxi preps for biologics manufacturing surge in China

  Dec. 7, 2017

• Roche's Tecentriq combo cuts risk of lung cancer progression

  Dec. 7, 2017

• Biogen inks outcomes-based contract for MS meds

  Dec. 6, 2017

• FDA cautiously lifts holds on combo studies of checkpoint inhibitors

  Dec. 6, 2017

• Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit

  Dec. 4, 2017

• 7 Biopharmas to watch at ASH 2017

  Dec. 4, 2017

• Mylan wins first US approval of Herceptin biosimilar

  Dec. 4, 2017

• Deal of the Year: Gilead Buys Kite Pharma

  Dec. 4, 2017

• Most Impressive Drug Launch: Roche's Ocrevus

  Dec. 4, 2017

• The BioPharma Dive Awards for 2017

  Dec. 4, 2017

• Bayer unblinds cancer drug study early to investigate patient deaths

  Dec. 1, 2017

• Corning adds 185 jobs to support pharma packaging production

  Nov. 30, 2017

• Sanofi to propose limits on use of dengue vaccine after safety signal

  Nov. 30, 2017

• FDA knocks generic maker for misbranding sleep aid

  Nov. 29, 2017

• Biopharma in charts: New drugs and the search for growth

  Nov. 28, 2017

• Pfizer, Merck KGaA's Bavencio falls short in gastric cancer study

  Nov. 28, 2017

• AstraZeneca launches JV, furthering play for China market

  Nov. 27, 2017

• Teva restructures to stabilize struggling business

  Nov. 27, 2017

• J&J eyes broader market for blood cancer med Darzalex

  Nov. 22, 2017

• GSK boosted by US approval of two-drug HIV pill

  Nov. 22, 2017

• Cytokinetics to discontinue ALS drug after Phase 3 miss

  Nov. 21, 2017

• Roche lung cancer results boost Tecentriq versus I/O rivals

  Nov. 20, 2017

• Proposed Medicare policy could shift drug rebates to consumers

  Nov. 17, 2017

• Recipharm to shutter two plants, cutting 225 jobs

  Nov. 16, 2017

• Avista doubles API manufacturing capacity at CO facility

  Nov. 16, 2017

• Quotient Sciences buys UK CDMO in third acquisition of year

  Nov. 16, 2017

• Janssen picks up second GI drug from Ionis

  Nov. 16, 2017

• Novartis sets Cosentyx hopes higher

  Nov. 15, 2017

• AstraZeneca wins US approval for asthma biologic

  Nov. 15, 2017

• Loxo parlays cancer drug success into $1.5B deal with Bayer

  Nov. 14, 2017

• Novartis turns to startup to boost gene editing efforts

  Nov. 13, 2017

• Zymeworks adds 6th pharma partner with J&J deal

  Nov. 13, 2017

• Juno analysis of shuttered study offers clues for CAR-T

  Nov. 10, 2017

• Sage shares boom on success of postpartum depression drug

  Nov. 9, 2017

• 'Hard' Brexit risks disrupting supply of thousands of drugs

  Nov. 8, 2017

• Roche to shift packaging operations, trimming 235 jobs

  Nov. 8, 2017

• Spark gene therapy for blindness could come at steep cost

  Nov. 8, 2017

• Regeneron boosted by Eylea strength

  Nov. 8, 2017

• FDA lifts clinical hold on Cellectis CAR-T

  Nov. 7, 2017

• FDA agrees to review TherapeuticsMD drug, dropping safety demands

  Nov. 6, 2017

• One-two punch hits Teva, sparking worries about debt

  Nov. 3, 2017

• FDA to recognize GMP inspections by 8 EU drug regulators

  Nov. 2, 2017

• Diabetes drags on Sanofi, even as Dupixent shines

  Nov. 2, 2017

• ICER looks to expand watchdog role with new funding

  Nov. 1, 2017

• AstraZeneca secures US approval for 'cornerstone' cancer drug

  Nov. 1, 2017

• Bluebird marks progress on Lentiglobin gene therapy

  Nov. 1, 2017

• AstraZeneca looks to build edge in early-stage lung cancer

  Oct. 31, 2017

• Pharma's betting big on China, but R&D boom still to come

  Oct. 30, 2017

• Novartis bolsters oncology with $3.9B Advanced Accelerator buy

  Oct. 30, 2017

• Merck sales slip, even as Keytruda gains ground

  Oct. 27, 2017

• What to expect from the rest of pharma's earnings

  Oct. 26, 2017

• Gilead warns hep C sales could fall further

  Oct. 26, 2017

• Drug production in Puerto Rico still disrupted, FDA says

  Oct. 26, 2017

• Lilly to spend $72M on upgrading insulin production

  Oct. 26, 2017

• Vertex grows CF franchise as combos move forward

  Oct. 26, 2017

• With Advair copies looming, GSK keeps focus on new drugs

  Oct. 25, 2017

• Eyes on Alcon as Novartis notches modest growth

  Oct. 24, 2017

• Vaccine approval buoys GSK new drug push

  Oct. 23, 2017

• What's next for biopharma Q3 earnings

  Oct. 20, 2017

• Gritstone taps Arbutus' LNP tech for RNA-based therapies

  Oct. 19, 2017

• J&J says Puerto Rico plants returning to full operations

  Oct. 19, 2017

• Gilead wins US approval for CAR-T cancer therapy

  Oct. 18, 2017

• Despite increased spending, orphan drugs still small piece of US medicines market

  Oct. 18, 2017

• In Congressional spotlight, drug industry groups blame each other

  Oct. 18, 2017

• Amneal, Impax combine amid generics crunch

  Oct. 17, 2017

• Federal judge invalidates Restasis patents in blow to Allergan

  Oct. 16, 2017

• Exelixis continues to gain momentum with positive data

  Oct. 16, 2017

• What Q3 earnings will look like for 5 pharma giants

  Oct. 13, 2017

• Spark's gene therapy for blindness takes major step toward approval

  Oct. 12, 2017

• Pfizer sells off Colorado facility to CordenPharma

  Oct. 12, 2017

• Sanofi commits €170M to expand flu vaccines production

  Oct. 12, 2017

• Long rundowns of side effects can make drugs seem less risky, study finds

  Oct. 11, 2017

• Lupin expands US presence with $150M Symbiomix deal

  Oct. 11, 2017

• Lilly's plans for abemaciclib dented by lung trial miss

  Oct. 10, 2017

• Flexion secures US approval for osteoarthritis drug

  Oct. 9, 2017

• Strong data for Pompe therapy boosts Amicus

  Oct. 3, 2017

• Rigel blood drug hits mark in mid-stage study

  Oct. 3, 2017

• Express Scripts: Specialty meds driving up US drug spend

  Oct. 2, 2017

• Arbutus boosted by $116M investment from Roivant

  Oct. 2, 2017

• Zogenix looks to filing after epilepsy trial success

  Sept. 29, 2017

• A drug 15 years in the making: Alnylam's quest to prove RNAi

  Sept. 29, 2017

• Abeona taps Brammer Bio for gene therapy manufacturing support

  Sept. 28, 2017

• AbbVie to keep limits on price hikes next year, denying backtrack

  Sept. 27, 2017

• Axovant's closely watched Alzheimer's drug fails late-stage trial

  Sept. 26, 2017

• Without power, Puerto Rico's drug manufacturing left battered by Maria

  Sept. 25, 2017

• Premium price for Novartis' CAR-T sparks pushback from top PBM

  Sept. 25, 2017

• Versartis crashes after Phase 3 miss

  Sept. 22, 2017

• Brammer Bio doubles manufacturing capacity at Florida site

  Sept. 21, 2017

• Provention builds pipeline with Janssen licensing deal

  Sept. 21, 2017

• Alnylam soars on trial win for RNAi drug

  Sept. 20, 2017

• Bayer ends sales of Essure implant outside of US

  Sept. 19, 2017

• GSK's respiratory business boosted by lung drug approval

  Sept. 19, 2017

• AbbVie, Roche to seek broader market for leukemia drug after trial success

  Sept. 18, 2017

• Smaller sales forces get the job done in rare disease

  Sept. 18, 2017

• Nabriva shares leap higher on antibiotic trial success

  Sept. 18, 2017

• Samsung Bioepis first to secure EMA backing for Herceptin biosimilar

  Sept. 15, 2017

• Amgen, Allergan win first approval of cancer biosimilar in US

  Sept. 14, 2017

• FDA calls for industry input on continuous manufacturing guidelines

  Sept. 14, 2017

• Pfizer, Astellas eye wider market for prostate cancer drug

  Sept. 14, 2017

• Amicus drops wound drug after trial miss

  Sept. 13, 2017

• ICER analysis latest salvo in debate over Repatha price

  Sept. 12, 2017

• Sage stock sinks after epilepsy drug fails to beat placebo

  Sept. 12, 2017

• Blockbuster hopeful Dupixent succeeds in asthma study

  Sept. 11, 2017

• ESMO: New momentum for AstraZeneca as lung cancer studies impress

  Sept. 11, 2017

• ESMO: Lilly breast cancer drug keeps pace with Pfizer, Novartis rivals

  Sept. 9, 2017

• ESMO: Foundation biomarker test could help boost immunotherapy

  Sept. 8, 2017

• Opdivo combo shows early survival benefit in kidney cancer

  Sept. 7, 2017

• Cell therapy emergence opens up new markets for shippers, logistic companies

  Sept. 7, 2017

• AstraZeneca sees first-in-class potential for asthma biologic

  Sept. 7, 2017

• FDA warns drugmaker over misleading marketing of opioid

  Sept. 6, 2017

• Verastem bet on blood cancer drug pays off with trial success

  Sept. 6, 2017

• Industry Pulse: 10 charts on M&A, I/O and biosimilar threats

  Sept. 1, 2017

• Janssen drops MacroGenics cancer candidate over safety concerns

  Sept. 1, 2017

• Landmark approval won, Novartis' next test is scaling CAR-T manufacturing

  Aug. 31, 2017

• Incyte, Merck build case for skin cancer combo

  Aug. 31, 2017

• In historic first, FDA approves Novartis CAR-T therapy

  Aug. 30, 2017

• Lilly speeds up timeline for refiling of baricitinib

  Aug. 30, 2017

• AstraZeneca strikes $400M deal with Takeda for Parkinson's drug

  Aug. 29, 2017

• Bristol-Myers, Pfizer continue to build case for Eliquis

  Aug. 28, 2017

• Novartis rare disease drug opens up new way to treat heart disease

  Aug. 27, 2017

• Regenxbio picks up Dimension in $86M stock deal

  Aug. 25, 2017

• Samsung Bioepis locks down EU approval for Humira biosimilar

  Aug. 24, 2017

• FDA warns compounding pharmacy of wood contamination

  Aug. 24, 2017

• Roche lines up February decision date for hemophilia prospect

  Aug. 24, 2017

• Pfizer secures patent in India for pneumonia vaccine

  Aug. 23, 2017

• In cost debate, Amgen stands by Repatha's value

  Aug. 23, 2017

• PCSK9 inhibitors still too pricey, study finds

  Aug. 22, 2017

• Ironwood wins FDA approval for combo gout drug

  Aug. 21, 2017

• Samsung Bioepis partners with Takeda to break into novel biologics

  Aug. 21, 2017

• Expanded label boosts AstraZeneca and Merck's Lynparza

  Aug. 18, 2017

• House Democrats to probe 'skyrocketing' prices for MS meds

  Aug. 17, 2017

• Valeant says FDA to reclassify troubled Tampa plant

  Aug. 17, 2017

• CEOs break with Trump amid disintegration of business councils

  Aug. 17, 2017

• Bristol-Myers' Opdivo comes up short in kidney cancer study

  Aug. 16, 2017

• Amid CEO exits, J&J chief to stay on Trump manufacturing council

  Aug. 15, 2017

• Mundipharma picks up chemo prodrug in $250M deal

  Aug. 15, 2017

• As federal efforts slow, states take up drug pricing pushback

  Aug. 14, 2017

• Merck CEO resigns from Trump's manufacturing council

  Aug. 14, 2017

• PharmaTech liquid drugs possibly contaminated, FDA says

  Aug. 10, 2017

• Manufacturing issues threaten delay for Aerie eye drug

  Aug. 10, 2017

• Alnylam review turns up no clear answers on revusiran deaths

  Aug. 10, 2017

• Mylan cuts sales forecast as pricing pressure grows

  Aug. 9, 2017

• Roche sells off dermatitis drug to Dermira

  Aug. 8, 2017

• Lilly's turn to pain gathers momentum

  Aug. 7, 2017

• Payer coverage boosts Radius' Tymlos

  Aug. 4, 2017

• J&J set back by negative panel vote for sirukumab

  Aug. 3, 2017

• Cytokinetics inches forward with heart failure program

  Aug. 2, 2017

• Vertex wins new Kalydeco approval, ups sales forecast

  Aug. 1, 2017

• Express Scripts shuts out 64 branded drugs from 2018 formulary

  July 31, 2017

• Unfazed by competition, Allergan sees room at CGRP table

  July 28, 2017

• AbbVie confident in strategy as Humira mints money

  July 28, 2017

• GSK looks to exit rare diseases

  July 27, 2017

• Novartis taps Cryoport for CAR-T logistics support

  July 27, 2017

• Corning invests $500M to build better glass packaging for pharma

  July 27, 2017

• MYSTIC flop a major blow to AstraZeneca's I/O hopes

  July 27, 2017

• Merck undercuts Pfizer on Remicade biosimilar price

  July 26, 2017

• GSK overhauls R&D, axes 30 programs to regain edge

  July 26, 2017

• Lilly maps out new approach to cancer R&D

  July 25, 2017

• Nektar secures $400M deal with Lilly for Phase 1 drug

  July 24, 2017

• 5 trends shaping Alzheimer's drug development

  July 17, 2017

• Amid supply shortage, FDA clears import of in-demand drug

  July 13, 2017

• Lilly extends patent runway for Cialis

  July 13, 2017

• FDA panel unanimously backs approval of Novartis CAR-T

  July 12, 2017

• FDA changes tune on Amicus Fabry disease drug

  July 11, 2017

• Safety issues for Novartis CAR-T therapy main focus of FDA

  July 10, 2017

• Generic drug association sues to stop state price-gouging law

  July 7, 2017

• Novo Nordisk recalls six batches of insulin cartridge holders

  July 6, 2017

• 3 Keytruda studies put on clinical hold after deaths

  July 6, 2017

• Industry paid $8.2B to docs, hospitals last year

  July 5, 2017

• Daiichi Sankyo pulls plug on Coherus biosimilar

  July 5, 2017

• A head above the rest? Drugmakers face off in migraine market

  June 30, 2017

• Patheon maps out $45M investment in services network

  June 29, 2017

• Chemicals giant BASF builds out ibuprofen API production

  June 29, 2017

• Exelixis clears debt, turning eye to future growth

  June 29, 2017

• SEC charges ex-Ariad employees with insider trading

  June 28, 2017

• Alder scores CGRP win but investors not impressed

  June 27, 2017

• Alnylam lines up Phase 3 for another RNAi drug

  June 26, 2017

• Seattle Genetics' Adcetris succeeds in study but shares slide

  June 26, 2017

• CHMP decisions: Novartis locks up backing for Kisqali

  June 23, 2017

• Mylan board weathers shareholder challenge

  June 23, 2017

• FDA surprises with rejection of Pfizer's Epogen biosimilar

  June 23, 2017

• Takeda set to open new German manufacturing facilities

  June 22, 2017

• FDA targets regulatory 'gaming' to boost generic competition

  June 21, 2017

• Report: Biopharma dealmaking set to level off

  June 21, 2017

• FDA approves new antibiotic for skin infections

  June 20, 2017

• Clovis soars on strong results for PARP inhibitor

  June 19, 2017

• BioMarin secures FDA approval for Ireland production facility

  June 15, 2017

• Sanofi continues biologics push, building on recent approvals

  June 15, 2017

• Novartis, Verily back new $300M fund for European biotechs

  June 15, 2017

• Rebates not to blame for rising drug costs, says PBM trade group

  June 14, 2017

• How Merck hopes to win in I/O combos: Q&A with Roy Baynes

  June 14, 2017

• Supreme Court ruling gives biosimilar makers a boost

  June 13, 2017

• Gene therapy by the numbers

  June 12, 2017

• ADA: Merck, Pfizer notch success, but late with SGLT-2 data

  June 12, 2017

• Novartis' CAR-T stacks up to Kite in lymphoma

  June 7, 2017

• ASCO17: CAR-Ts steal the show

  June 6, 2017

• ASCO17: Juno marks progress with second-gen CAR-T

  June 5, 2017

• ASCO 2017: What you missed

  June 5, 2017

• ASCO17: Roche's Perjeta cuts risk in Aphinity, but is it enough?

  June 5, 2017

• ASCO17: Roche's Alecensa bests Xalkori in lung study

  June 5, 2017

• ASCO17: AstraZeneca's Lynparza stays step ahead of PARP rivals

  June 4, 2017

• ASCO17: Incyte pads its IDO numbers

  June 3, 2017

• ASCO17: Loxo shows promise of biomarker approach to cancer

  June 3, 2017

• FDA cites Braun Medical for repeat GMP violations

  June 1, 2017

• Chiltern acquires Japanese CRO in Asia expansion bid

  June 1, 2017

• US may have overpaid $1.3B for Mylan's EpiPen, HHS watchdog says

  June 1, 2017

• Drug rebates may shift costs to Medicare, study finds

  May 31, 2017

• AstraZeneca taps outcomes deals to boost CV, diabetes meds

  May 31, 2017

• Gilead tees up filing for HIV triple combo after Phase 3 wins

  May 30, 2017

• Industry Pulse: R&D spending in charts

  May 30, 2017

• Industry Pulse: Aging blockbusters tax bottom lines

  May 26, 2017

• Problems at Sun Pharma plant trip up drug approval

  May 25, 2017

• J&J settles OTC manufacturing issue for $33M

  May 25, 2017

• Aerie shares rise on trial success for eye drug

  May 25, 2017

• Under new CEO, Alexion continues overhaul of leadership

  May 24, 2017

• Trial success buoys AstraZeneca's hopes for asthma biologic

  May 23, 2017

• Overcoming delay, Sanofi, Regeneron win US approval for RA drug

  May 23, 2017

• Celgene MS drug succeeds in second Phase 3 study

  May 22, 2017

• Safety signal derails expected approval of Amgen bone drug

  May 22, 2017

• Thermo Fisher to buy Patheon in $7.2B deal, accelerating CDMO consolidation

  May 18, 2017

• 7 Areas to watch from the ASCO abstracts

  May 18, 2017

• FDA warns of higher amputation risk for J&J's Invokana

  May 17, 2017

• Coherus wins Humira patent ruling, chipping away at AbbVie's defenses

  May 17, 2017

• Taking office, Gottlieb keeps drug pricing front and center

  May 16, 2017

• EU investigating generic drugmaker over cancer drug price hikes

  May 15, 2017

• Can value-based deals work if patients don't take the drug?

  May 15, 2017

• AstraZeneca rises after positive lung cancer results for key drug

  May 12, 2017

• Indian drugmaker stages worker strike to avoid FDA inspection

  May 11, 2017

• Second Advair copy rejected, giving GSK short-term respite

  May 11, 2017

• Merck bolsters I/O edge with Keytruda combo approval

  May 11, 2017

• Senate confirms Scott Gottlieb as FDA chief

  May 10, 2017

• PhRMA ousts 22 drugmakers from ranks in membership change

  May 10, 2017

• Valeant pitches a turnaround but new roadblocks complicate story

  May 9, 2017

• Kite discloses patient death in CAR-T trial, sparking safety worries

  May 8, 2017

• Pfizer making progress on Hospira manufacturing issues, execs say

  May 4, 2017

• BIO accuses insurer report of shifting blame on drug prices

  May 4, 2017

• Weak Xtandi sales spur questions on Pfizer's $14B Medivation takeover

  May 3, 2017

• Pieris teams up with AstraZeneca on respiratory drug development

  May 3, 2017

• Amgen inks first money-back guarantee for Repatha

  May 2, 2017

• Merck sees Keytruda gains, offsetting generic hits to sales

  May 2, 2017

• Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan

  May 1, 2017

• Radius targets quick ramp up for newly approved osteoporosis drug

  April 30, 2017

• Diabetes decline hangs over Sanofi's growth in specialty care, immunology

  April 28, 2017

• Sun Pharma tripped up by Form 483 at Dadra unit

  April 27, 2017

• Daiichi Sankyo to invest $135M in ADC manufacturing expansion

  April 27, 2017

• Amid sales growth, Roche plans defense from biosimilar threats

  April 27, 2017

• Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

  April 26, 2017

• Medicines Co. charts ambitious late-stage tests for heart drug

  April 26, 2017

• FDA busts 14 companies for selling bogus cancer cures

  April 25, 2017

• Lilly gets lift from new drugs, but baricitinib setback hangs over revenue growth

  April 25, 2017

• Cancer immunotherapy works, but how to find which patients will benefit?

  April 25, 2017

• Biogen, BioMarin secure orphan drug endorsements in Europe

  April 24, 2017

• Q1 Earnings Preview: Novartis, Lilly, Biogen, GSK, Amgen

  April 24, 2017

• Biopharma opening up to new ways of partnering on R&D

  April 20, 2017

• Theranos pays $4.65M to refund cost of blood tests in Arizona

  April 19, 2017

• Former Dendreon CEO debuts new public company in reverse merger

  April 19, 2017

• Pharma bellwether J&J not worried about drug pricing for specialty meds

  April 18, 2017

• Bristol-Myers taps Danish biotech in NASH biomarker deal

  April 17, 2017

• GE acquires British cold chain specialist, deepening cell therapy push

  April 13, 2017

• FDA warns Teva over violations at China plant

  April 13, 2017

• University of California appeals patent setback, extending CRISPR fight

  April 13, 2017

• Biotech calls on 'Poop Troop' to drive constipation awareness

  April 12, 2017

• SV Health secures $400M for new life sciences venture fund

  April 12, 2017

• Cancer combos key to AstraZeneca success, but rivals have long lead

  April 11, 2017

• In familiar routine, ICER finds rheumatoid arthritis drugs overpriced

  April 10, 2017

• 5 trends shaping rare disease drug development

  April 10, 2017

• FDA shoots down Merck's bid to expand Januvia label

  April 7, 2017

• Indoco Remedies handed FDA warning letter

  April 6, 2017

• PhRMA takes shot at payers in drug pricing war

  April 6, 2017

• Scott Gottlieb commits to defend FDA's 'gold standard' for drug reviews

  April 5, 2017

• AACR recap: IDOs under the microscope

  April 5, 2017

• AACR: NewLink's IDO data shows promise, but is it enough?

  April 4, 2017

• AACR: Incyte hedges bet on combo strategy

  April 3, 2017

• AACR: Busy start for Bristol-Myers Squibb's Opdivo

  April 3, 2017

• CAR-T race heats up as Kite, Novartis complete filings to FDA

  April 2, 2017

• Warp Drive Bio teams up with GSK, taking aim at 'undruggable' targets

  March 30, 2017

• Agenus trims staff, narrows focus in restructuring

  March 30, 2017

• Drug prices continue to climb, but who's to blame?

  March 30, 2017

• GSK breathes sigh of relief as Mylan Advair copy rejected

  March 29, 2017

• Vertex boosted by strong trial data for next-gen CF drug

  March 29, 2017

• AACR preview: IDO1, CDK 4/6 and cancer combos

  March 29, 2017

• In twisting patent fight, CRISPR Therapeutics scores win in Europe

  March 28, 2017

• Alexion taps ex-Baxalta chief as new CEO

  March 27, 2017

• Lilly touts $850M manufacturing investment as CEO stumps for tax reform

  March 24, 2017

• Control over production data still tripping up foreign drug manufacturers with FDA

  March 23, 2017

• Valeant hopes for August approval of eye drug

  March 23, 2017

• J&J, GSK pull ads from YouTube amid display concerns

  March 23, 2017

• Biogen staves off patent challenge to blockbuster MS drug

  March 22, 2017

• Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

  March 20, 2017

• Phase 3 win moves Lilly's breast cancer drug closer to market

  March 20, 2017

• Real world study shows cardiovascular benefit to SGLT2 drugs

  March 20, 2017

• Medicines Co. hits mark in ORION, plans PCSK9 Phase 3

  March 17, 2017

• Amgen's Repatha shows CV benefit, but falls short of expectations

  March 17, 2017

• FDA warns two manufacturers from China, India for GMP lapses

  March 16, 2017

• Takeda teams up with venture firm on drug discovery unit

  March 16, 2017

• Under fire, Marathon offloads Duchenne drug to PTC for $140M

  March 16, 2017

• AstraZeneca staves off Tesaro threat to PARP crown

  March 14, 2017

• Allergan taps CRISPR biotech Editas in eye care deal

  March 14, 2017

• Novartis locks up Kisqali approval, eyes Pfizer's lead

  March 13, 2017

• Mylan clears way for biosimilar Herceptin launch in US

  March 13, 2017

• Trump taps Scott Gottlieb to head FDA

  March 10, 2017

• Radius shares slide after FDA delays decision on bone drug

  March 10, 2017

• Nicox resubmits eye drug to FDA after manufacturing setback

  March 9, 2017

• Indian drugmaker slammed for repeated GMP failures

  March 9, 2017

• Trump 'enthusiastic' about drug price negotiation, lawmakers say

  March 9, 2017

• Despite hype, still much to uncover about immunotherapy

  March 8, 2017

• MS drugs too expensive, ICER says

  March 7, 2017

• Pressure builds on Marathon over orphan drug price

  March 7, 2017

• Changes to MYSTIC could set AstraZeneca up for success

  March 6, 2017

• Vertex fine tunes CF portfolio with Concert deal

  March 6, 2017

• Industry Pulse: Who's spending on R&D?

  Feb. 28, 2017

• Merck writes off $2.9B as new hep C reality blooms

  Feb. 24, 2017

• Pharma CEOs sign on to letter urging tax reform

  Feb. 23, 2017

• Safety concerns reemerge for Roche hemophilia drug

  Feb. 23, 2017

• Harvard Pilgrim bets on value-based drug payments with new deals

  Feb. 22, 2017

• Gilead snaps up Sarepta's priority review voucher for $125M

  Feb. 21, 2017

• FDA warns another Japanese drug manufacturer over GMP flaws

  Feb. 16, 2017

• Are commercial prospects limited for Valeant's Siliq?

  Feb. 16, 2017

• Broad Institute notches win in CRISPR patent battle

  Feb. 15, 2017

• Merck scraps late-stage study of Alzheimer's candidate

  Feb. 15, 2017

• Marathon presses pause on Emflaza launch after pricing pushback

  Feb. 13, 2017

• 5 trends being impacted by biomarkers

  Feb. 13, 2017

• Liquid biopsies: The next frontier in cancer?

  Feb. 13, 2017

• Sanofi confident in case to overturn Praluent ban

  Feb. 10, 2017

• Regeneron, Sanofi win reprieve from court ban on Praluent

  Feb. 9, 2017

• Sanofi pins hopes on immunology as Lantus sales fade

  Feb. 8, 2017

• Teva CEO out, board chairman steps in as interim chief

  Feb. 6, 2017

• Innate's cancer immunotherapy falls short in Phase 2

  Feb. 6, 2017

• FDA warns Italian drug manufacturer for quality lapses

  Feb. 2, 2017

• Trump pushes pharma to boost drug production in US

  Feb. 2, 2017

• Pfizer counts on Ibrance as Prevnar sales slip

  Jan. 31, 2017

• Pfizer's Read sees positives for industry under Trump

  Jan. 31, 2017

• Insulin drugmakers sued for inflating prices

  Jan. 31, 2017

• Merck ups pricing transparency amid industry ad blitz

  Jan. 30, 2017

• Earnings Preview: Merck set to solidify I/O lead, Sanofi still looking for deals and more

  Jan. 26, 2017

• Intrexon picks up struggling GenVec to build delivery tech

  Jan. 26, 2017

• On the defensive, Bristol faces down I/O competition

  Jan. 26, 2017

• J&J seals $30B deal for Actelion

  Jan. 26, 2017

• Novartis aims to gain ground on I/O leaders

  Jan. 25, 2017

• As Trump moves to repeal, J&J says preserve some of ACA

  Jan. 25, 2017

• Anthem limits coverage for Biogen's new SMA drug

  Jan. 24, 2017

• J&J earnings disappoint, with no word on Actelion deal

  Jan. 24, 2017

• Endo reaches deal with FTC over pay-for-delay allegations

  Jan. 23, 2017

• 7 companies to know in the emerging biosimilars field

  Jan. 23, 2017

• Actelion misses goal in study, but takeover talks likely unaffected

  Jan. 23, 2017

• Biosimilars: What's in a name?

  Jan. 23, 2017

• Bristol-Myers nixes hopes of early filing for Opdivo combo

  Jan. 20, 2017

• Earnings preview: 7 biopharmas to watch

  Jan. 19, 2017

• FDA details thinking on off-label communications

  Jan. 19, 2017

• Chinese API supplier lands in hot water with FDA

  Jan. 18, 2017

• Cellceutix fires back against short-seller accusations

  Jan. 18, 2017

• FDA spells out expectations on biosimilar interchangeability

  Jan. 18, 2017

• Why Jay Bradner thinks Novartis can recharge drug discovery

  Jan. 17, 2017

• Supreme Court to review key biosimilar dispute

  Jan. 17, 2017

• FDA issues long-awaited guidance on biosimilar naming

  Jan. 12, 2017

• Kite confident as CAR-T readout nears

  Jan. 12, 2017

• NCI launches new cancer drug formulary to speed combo trials

  Jan. 11, 2017

• JPM: Day 2 round-up

  Jan. 11, 2017

• JPM: Valeant sells off Dendreon, skincare brands for $2.1B

  Jan. 10, 2017

• JPM: Vertex stakes out cautious 2017 forecasts

  Jan. 9, 2017

• JPM: Ipsen snatches up Merrimack's Onivyde for $575M

  Jan. 8, 2017

• Judge hands Amgen major patent victory over PCSK9 rivals

  Jan. 6, 2017

• FDA to drugmakers: Don't let manufacturing lead to rejection

  Jan. 5, 2017

• Alexion faults tone at top, management pressure in Soliris investigation

  Jan. 5, 2017

• Amgen notches another win in patent dispute with Sanofi, Regeneron

  Jan. 4, 2017

• Tiny Rana makes a play for mRNA with Shire deal

  Jan. 4, 2017

• Gates Foundation invests $50M in Intarcia for anti-HIV work

  Jan. 3, 2017

• Threat grows for biologics makers as biosimilars take root

  Dec. 29, 2016

• As R&D returns take a hit, some pharmas are ramping up spending

  Dec. 24, 2016

• Teva pays up $520M to settle bribery charges

  Dec. 22, 2016

• Vitality secures approvals for cannabinoid facility

  Dec. 22, 2016

• A rough year for biotech IPOs

  Dec. 22, 2016

• FDA warns drugmakers on misleading marketing

  Dec. 21, 2016

• Incyte puts up $200M in bispecifics deal with Merus

  Dec. 21, 2016

• Allergan picks up regenerative med company for $2.9B

  Dec. 20, 2016

• Conatus soars on Novartis deal

  Dec. 20, 2016

• Editas locks down rights to add-on CRISPR tech

  Dec. 19, 2016

• Nasdaq shuffles biotech index ranks, highlighting 2016 hits, misses

  Dec. 19, 2016

• Ophthotech shrinks staff in wake of Fovista setback

  Dec. 16, 2016

• CRISPR biotechs band together in IP pact

  Dec. 16, 2016

• 20 states sue 6 generic drugmakers over price fixing

  Dec. 15, 2016

• Biogen cuts jobs in MA manufacturing slimdown

  Dec. 15, 2016

• First charges come in generic price-fixing probe

  Dec. 14, 2016

• Sanofi, Celgene flagged for misleading DTC ads

  Dec. 14, 2016

• Bristol-Myers plans R&D overhaul, site shutdowns

  Dec. 13, 2016

• Cempra makes CEO change ahead of FDA decision

  Dec. 13, 2016

• Armed with IPO cash, CRISPR biotechs grow gene-editing tech

  Dec. 12, 2016

• Alexion CEO, CFO out amid Soliris investigation

  Dec. 12, 2016

• Purdue lands rights to psoriasis drug in diversification deal

  Dec. 12, 2016

• Biogen boosted by early Alzheimer's data

  Dec. 9, 2016

• Former pharma execs arrested in bribery scheme

  Dec. 8, 2016

• Sun Pharma faces new worries at key Halol plant

  Dec. 8, 2016

• 'Cures' clears Senate in 94-5 vote

  Dec. 8, 2016

• Pfizer hit with record fine in UK for drug price hike

  Dec. 7, 2016

• AbbVie breast cancer drug falls short in Phase 2

  Dec. 7, 2016

• Sage locks in regulatory path for postpartum depression drug

  Dec. 6, 2016

• Kite begins march to market

  Dec. 6, 2016

• Juno turns to JCAR017 amid Rocket setback

  Dec. 5, 2016

• Alnylam scores ASH win in hemophilia

  Dec. 5, 2016

• Novartis forges ahead with lead CAR-T

  Dec. 5, 2016

• Eli Lilly, Boehringer secure CV label for Jardiance

  Dec. 2, 2016

• House passes 'Cures' in overwhelming vote

  Dec. 1, 2016

• Alnylam touts hemophilia drug's edge over Roche rival

  Nov. 30, 2016

• Arrowhead nixes clinical pipeline, trims staff

  Nov. 30, 2016

• ASH preview: CAR-Ts, mixed results and pipeline progress

  Nov. 30, 2016

• Recro Pharma notches second Phase 3 win for pain drug

  Nov. 28, 2016

• Juno halts CAR-T trial after new patient deaths

  Nov. 23, 2016

• AstraZeneca restarts halted durvalumab trials

  Nov. 22, 2016

• Halozyme falls after AbbVie nixes partnered program

  Nov. 21, 2016

• Ex-Valeant exec arrested in Philidor kickback scheme

  Nov. 17, 2016

• Ex-FDA official settles insider trading charges

  Nov. 16, 2016

• Boxed warning added to label of Bayer's Essure

  Nov. 16, 2016

• Data in hand, The Medicines Co. speeds PCSK9 plans

  Nov. 15, 2016

• Costs for many Medicare drugs continue steady rise

  Nov. 15, 2016

• Dynavax drops on FDA rejection of hep B vaccine

  Nov. 14, 2016

• CHMP decision round-up; PTC wins reprieve

  Nov. 11, 2016

• Valeant hit with another FDA warning letter

  Nov. 10, 2016

• As rival surges forward, Juno touts CAR-T pipeline

  Nov. 10, 2016

• FDA invites pharma input in off-label debate

  Nov. 9, 2016

• The Medicines Co. abandons heart drug, focus all on PCSK9si

  Nov. 8, 2016

• Biogen eyes quick launch for SMA drug

  Nov. 7, 2016

• 5 trends turning biotech toward incubators

  Nov. 7, 2016

• Advice to an emerging biotech

  Nov. 7, 2016

• Key people to know in early drug development

  Nov. 7, 2016

• Portola broadens AndexXa partnership with Daiichi

  Nov. 3, 2016

• Doctors willing to prescribe biosimilars, survey shows

  Nov. 2, 2016

• What would a Salix sale do for Valeant?

  Nov. 2, 2016

• Shire confident in hemophilia despite looming pricing challenge

  Nov. 1, 2016

• Amid pricing scrutiny, Amgen CEO predicts more value-based contracts

  Oct. 31, 2016

• Third Rock Ventures secures $616M in new biotech fund

  Oct. 31, 2016

• Czech drugmaker hit with FDA warning letter

  Oct. 27, 2016

• Continuing M&A spree, Allergan picks up Motus for $200M

  Oct. 27, 2016

• The Medicines Co. moves cholesterol drug forward as sales fall

  Oct. 26, 2016

• Humana to cover Sarepta's DMD drug with caveats

  Oct. 26, 2016

• Lilly says complete Sola failure unlikely

  Oct. 25, 2016

• Merck cements advantage in I/O with first-line approval

  Oct. 24, 2016

• Aduro hit with partial hold, sending shares spiraling

  Oct. 24, 2016

• Alkermes surges on antidepressant success

  Oct. 21, 2016

• Dimension beefs up AAV manufacturing

  Oct. 20, 2016

• Single placebo response derails Rigel study

  Oct. 20, 2016

• Merck lays groundwork for biosimilar push

  Oct. 19, 2016

• CAR-T ready for flight, says Kite

  Oct. 19, 2016

• Earnings guide: A preview of 9 big pharmas in Q3

  Oct. 18, 2016

• Medicines Co. scores positive results for PCSK9 drug

  Oct. 18, 2016

• FDA snubs PTC appeal for Duchenne drug

  Oct. 17, 2016

• Bluebird touts upgrades to gene therapy

  Oct. 16, 2016

• Insulin makers become casualties of pricing war

  Oct. 13, 2016

• AstraZeneca halts asthma study in blow to Synairgen

  Oct. 12, 2016

• Merck inks pay-for-performance deal to boost diabetes drugs

  Oct. 11, 2016

• Takeda broadens oncology pipeline with Crescendo deal

  Oct. 10, 2016

• Downfall of a unicorn: How Theranos fell apart

  Oct. 10, 2016

• Major US insurer snubs Sarepta's Duchenne drug

  Oct. 9, 2016

• Theranos shuts down labs, lays off 340

  Oct. 6, 2016

• Novartis shakes up R&D, closing down two biologics units

  Oct. 5, 2016

• Sarepta steps up DMD dealmaking

  Oct. 4, 2016

• Biosimilars emerge in US, but what to call them?

  Oct. 3, 2016

• AstraZeneca furthers sell-off strategy with new deal

  Oct. 3, 2016

• Regeneron slips on trial setback for Eylea combo

  Sept. 30, 2016

• FDA cites Chinese manufacturers for GMP lapses

  Sept. 29, 2016

• Novartis, Amgen score Phase 3 win for migraine drug

  Sept. 29, 2016

• Will staff cuts help Novo stay competitive?

  Sept. 29, 2016

• Boehringer gets option to buy in I/O deal

  Sept. 28, 2016

• Kite bolsters lead with positive CAR-T data

  Sept. 27, 2016

• Pfizer nixes split plans, opts to remain one company

  Sept. 26, 2016

• Indivior stumbles as US states file antitrust suit

  Sept. 23, 2016

• FDA approval in hand, Sarepta plans for future studies

  Sept. 22, 2016

• Moderna lifts curtain on manufacturing plant plans

  Sept. 22, 2016

• Gilead shutters study for anti-MMP9 drug

  Sept. 22, 2016

• Allergan pays steep premium for Tobira and NASH drugs

  Sept. 20, 2016

• Drama at FDA: 5 things to know about the Sarepta approval

  Sept. 19, 2016

• Sarepta skyrockets as FDA approves DMD drug

  Sept. 19, 2016

• Valeant: rebates on heart drugs are coming

  Sept. 19, 2016

• Novavax short on options after vaccine fails trial

  Sept. 16, 2016

• Eisai ramps up precision med efforts with new unit

  Sept. 15, 2016

• Lonza builds out gene therapy offerings

  Sept. 15, 2016

• Novo pulls 71,000 kits of glucagon med from US market

  Sept. 15, 2016

• AcelRx stock jumps after trial success

  Sept. 15, 2016

• UN group urges 'de-linkage' of R&D costs from drug prices

  Sept. 14, 2016

• BIO blames insurers in pushback on drug pricing

  Sept. 14, 2016

• Roche bolsters evidence for MS drug Ocrevus

  Sept. 14, 2016

• Irish startup secures $17M Series A

  Sept. 13, 2016

• Generic drugmaker under federal pricing probe

  Sept. 12, 2016

• Aveo halts study of lung cancer drug

  Sept. 12, 2016

• Horizon adds rare disease drugs in $800M Raptor deal

  Sept. 12, 2016

• CRISPR closes in on $90M IPO

  Sept. 12, 2016

• J&J pushes forward with hep C triple-combo

  Sept. 9, 2016

• Allergan highlights new drug potential

  Sept. 9, 2016

• Fresh off new funding, Moderna plans new manufacturing plant

  Sept. 8, 2016

• FDA renews ban on Indian drugmaker after fresh violations

  Sept. 8, 2016

• Bluebird proceeds with late-stage trial after key improvement

  Sept. 8, 2016

• Gilead comments on split rumors

  Sept. 8, 2016

• Tonix shelves fibromyalgia plans after Phase 3 miss

  Sept. 7, 2016

• Karyopharm tees up filing for multiple myeloma drug

  Sept. 7, 2016

• Jazz subsidiary warned over misbranding of cancer drug

  Sept. 6, 2016

• Allergan CEO disavows 'predatory pricing'

  Sept. 6, 2016

• Flush from Pfizer deal, Medivation execs set to cash in

  Sept. 6, 2016

• Momenta pulls the plug on pancreatic cancer drug

  Sept. 2, 2016

• Sunovion snaps up Cynapsus in $624M deal

  Sept. 1, 2016

• In wake of generics deal, Teva to close New York plant

  Sept. 1, 2016

• Theranos stumbles in efforts to sell Zika test: report

  Sept. 1, 2016

• Gilead hit with patent suit over hepatitis C drugs

  Sept. 1, 2016

• Roche's Tecentriq ready to compete in lung cancer

  Sept. 1, 2016

• Weighing in on EpiPen, PhRMA calls for reforms at FDA

  Aug. 31, 2016

• Novartis breaks up CAR-T unit in major shift

  Aug. 31, 2016

• Novartis wins US approval for biosimilar Enbrel

  Aug. 30, 2016

• Looking past FDA snub, Portola touts new Andexxa data

  Aug. 30, 2016

• Trial failure dashes Vectura's hopes for wider use of asthma drug

  Aug. 30, 2016

• Stada elects new chairman after activist pressure

  Aug. 30, 2016

• Moderna reels in $450M in new funding

  Aug. 29, 2016

• Biosim threat stiffens for Roche's Herceptin

  Aug. 28, 2016

• Mallinckrodt sharpens specialty pharma focus

  Aug. 26, 2016

• Theranos planning appeal of federal penalties

  Aug. 26, 2016

• Sagent recalls injectable antibiotic

  Aug. 25, 2016

• Denali secures $130M in new funding, reveals R&D plans

  Aug. 25, 2016

• FDA unexpectedly snubs Amgen drug

  Aug. 25, 2016

• Pfizer continues dealmaking with antibiotics buy

  Aug. 24, 2016

• With PDUFA date for rucaparib set, Clovis eyes rebound

  Aug. 24, 2016

• MI Labs to biotechs: Call us home

  Aug. 16, 2016

• OncoGenex scrambles after trial fail

  Aug. 16, 2016

• Aurinia succeeds, but safety concerns loom

  Aug. 16, 2016

• Veteran CEO of German drugmaker Stada resigns

  Aug. 15, 2016

• Chinese regulators advance overhaul of drug manufacturing

  Aug. 15, 2016

• AcelRx meets goal in Phase 3, but stock slips

  Aug. 15, 2016

• Gilead can recoup legal fees from Merck, judge says

  Aug. 15, 2016

• Drug pricing studies anger industry, ICER pushes back

  Aug. 12, 2016

• Valeant tumbles on report of fraud investigation

  Aug. 11, 2016

• NIH shuts down facility used to produce drugs for clinical trials

  Aug. 10, 2016

• Pfizer temporarily shutters Indian facility after inspections

  Aug. 9, 2016

• Seizing CAR-T lead, Kite readies commercial-scale manufacturing

  Aug. 9, 2016

• Editas continues to expand CRISPR capabilities with new deal

  Aug. 9, 2016

• Kite steps up plans for leading CAR-T, putting pressure on Juno

  Aug. 8, 2016

• Novo Nordisk sees pricing challenges 'intensifying'

  Aug. 8, 2016

• Despite trial restart, Juno pushes back launch timeline for CAR-T therapy

  Aug. 5, 2016

• Bristol-Myers' Opdivo fails key lung cancer study, stocks ricochet

  Aug. 5, 2016

• Pfizer cuts 151 jobs at New York plant

  Aug. 4, 2016

• Chinese drug manufacturer lies to FDA, promptly gets banned

  Aug. 4, 2016

• Gilead: 'We stand behind the pricing of our therapies'

  Aug. 4, 2016

• Takeover rumors juice Biogen stock, but fade fast

  Aug. 3, 2016

• Amgen secures rights to cancer immunotherapy from biotech Advaxis

  Aug. 2, 2016

• Theranos founder Holmes touts new tech despite unanswered questions

  Aug. 2, 2016

• Biogen snaps up rights to neuromuscular disease drug after trial success

  Aug. 1, 2016

• GSK, Verily launch $715 million bet on bioelectronic medicines

  Aug. 1, 2016

• Higher Humira sales lift AbbVie in Q2

  July 29, 2016

• Merck's Keytruda continues gains, driving Q2 revenues higher

  July 29, 2016

• Bristol-Myers revenues climb on strong Opdivo performance

  July 28, 2016

• Amgen boosts sales forecast as Q2 profits jump

  July 27, 2016

• US regulators clear Teva, Allergan generics deal

  July 27, 2016

• TauRx Alzheimer's drug flunks late-stage study

  July 27, 2016

• Lilly CEO John Lechleiter to retire by year-end

  July 27, 2016

• Health plans slow to adopt new drug value assessments: survey

  July 26, 2016

• Lilly blames stiff competition for lower US sales of lung cancer drugs

  July 26, 2016

• Gilead trims guidance as Hepatitis C drug sales slip

  July 25, 2016

• Alzheon readies Phase 3 study of Alzheimer's drug

  July 25, 2016

• AbbVie partners with Bristol-Myers in combo study of cancer drugs

  July 25, 2016

• Fresh off Relistor win, Valeant hits FDA roadblock for eye drug

  July 22, 2016

• Chinese team to test CRISPR in humans, jumping ahead of planned US study

  July 22, 2016

• Swiss group Galencia buys US biotech Relypsa for $1.5 billion

  July 21, 2016

• Biogen CEO George Scangos to step down

  July 21, 2016

• Roche sales buoyed by cancer drugs

  July 21, 2016

• Federal court thwarts AstraZeneca efforts to block Crestor copies

  July 20, 2016

• Valeant wins backing of FDA panel for psoriasis drug

  July 20, 2016

• Bristol-Myers settles for $30 million over California kickback claims

  July 19, 2016

• Ziopharm says patient death unrelated to gene therapy

  July 19, 2016

• Novartis doubles down on new drugs as sales slump for top cancer med

  July 19, 2016

• FDA: Flood of orphan drug applications slowing review process

  July 19, 2016

• Roche blood cancer drug falls short in late-stage study

  July 18, 2016

• With new additions, PhRMA opens door to generics drugmaker Teva

  July 15, 2016

• FDA staff raises safety concerns for Valeant psoriasis drug

  July 15, 2016

• Why Allergan thinks an 'open science' approach can help it develop new antibiotics

  July 14, 2016

• Amgen partners with Daiichi to market biosimilars in Japan

  July 14, 2016

• Large Valeant investor sold off remaining stake last quarter

  July 13, 2016

• Juno restarts suspended CAR-T trial after FDA lifts clinical hold

  July 12, 2016

• Merck trims research jobs at three sites, shifts drug discovery focus

  July 12, 2016

• Sage soars after small study of postpartum depression drug shows benefit

  July 12, 2016

• Cancer drug could benefit Parkinson's patients, study shows

  July 11, 2016

• Facing major penalties, Theranos could be forced to change business

  July 11, 2016

• FDA staff backs Amgen biosim of AbbVie's Humira

  July 8, 2016

• Theranos founder banned from blood-testing business

  July 8, 2016

• Juno CAR-T trial halted by FDA after three patient deaths

  July 7, 2016

• AbbVie bet on Ablynx gets boost after arthritis drug shows promise

  July 7, 2016

• Pfizer pledges to disclose risks of opioid addiction

  July 6, 2016

• Federal appeals court reaffirms biosimilar launch rules

  July 5, 2016

• Medivation enters takeover talks with Sanofi after rejecting new bid

  July 5, 2016

• UK cost agency knocks back Bristol-Myers' Opdivo in kidney cancer

  July 5, 2016

• Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential

  July 5, 2016

• AstraZeneca sells off dermatology drug rights to LEO Pharma

  July 1, 2016

• Major trade group slams 'misleading' analysis of drug prices

  June 30, 2016

• Tesaro soars after ovarian cancer drug meets Phase 3 goal

  June 29, 2016

• In narrow vote, FDA panel supports heart benefit claim for Lilly diabetes drug

  June 29, 2016

• VA teams up with IBM's supercomputer Watson to expand precision medicine

  June 28, 2016

• Harvard Pilgrim inks pay-for-performance deals with Novartis, Eli Lilly

  June 28, 2016

• Gilead wins FDA nod for pan-genotypic Hep C drug

  June 28, 2016

• Pfizer to open first Asia biotech center in China

  June 28, 2016

• Novartis jumps into bi-specific antibody space with $150 million Xencor deal

  June 28, 2016

• FDA halts testing of Regulus' Hep C drug, sending shares into tailspin

  June 27, 2016

• GW Pharma shares jump on Phase 3 data for cannabis-based drug

  June 27, 2016

• Sanofi, Boehringer trade business units in $25 billion swap

  June 27, 2016

• Teva seals deal to market copy of AstraZeneca diabetes drug

  June 24, 2016

• Brexit vote creates new uncertainty for UK, EU pharma industry

  June 24, 2016

• Epizyme partners with Roche to test cancer drug combo

  June 23, 2016

• Pfizer plans to close Colorado production facility

  June 23, 2016

• AstraZeneca writes off $80 million after US authorities say nasal flu vaccine ineffective

  June 23, 2016

• First human study of CRISPR approved by federal panel

  June 22, 2016

• Startup biotech Homology Med aims to 'leapfrog' CRISPR competitors

  June 21, 2016

• Teva, Allergan continue to shed assets with $586 million sale to Impax

  June 21, 2016

• Takeda begins field testing norovirus vaccine

  June 21, 2016

• NIH turns down request to override cancer drug patent

  June 20, 2016

• Doubling down on biosimilars, Novartis plans five launches by 2020

  June 20, 2016

• NIH panel to review proposal for first in human test of CRISPR

  June 17, 2016

• Pfizer begins construction on $200 million biologics plant in MA

  June 16, 2016

• Merck's Keytruda beats out chemotherapy in lung cancer study

  June 16, 2016

• Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT

  June 15, 2016

• Marathon Pharma latest company to try for approval of Duchenne drug

  June 15, 2016

• Shire buys rights to Pfizer bowel disease drug

  June 14, 2016

• FDA warns of kidney risks for diabetes drugs from Janssen, AstraZeneca

  June 14, 2016

• Former Dendreon CEO leads Alpine Immune to $48 million financing

  June 14, 2016

• Report: Oncology drove record pharma dealmaking in 2015

  June 9, 2016

• Small biotech Accera reinvents itself, takes aim at Alzheimer's treatment

  June 8, 2016

• FDA asks Sarepta for more data on muscular dystrophy drug

  June 7, 2016

• AbbVie lung cancer drug shows promise, but has high expectations to meet

  June 5, 2016

• With eye to growing Chinese market, Novartis opens major R&D hub in Shanghai

  June 2, 2016

• Global cancer drug spending rises, set to surpass $150 billion by 2020

  June 2, 2016

• FDA warns another Indian API supplier on manufacturing lapses

  June 1, 2016

• Activist investor Icahn acquires large stake in Allergan

  June 1, 2016

• Despite stock plunge, former Valeant CEO to collect $9 million in severance pay

  June 1, 2016

• BioMarin ends Duchenne program, withdraws EU application for drisapersen

  May 31, 2016

• Intercept shares climb on FDA approval of liver drug

  May 31, 2016

• Jazz Pharma snaps up leukemia drug with $1.5 billion deal for Celator

  May 31, 2016

• EMA knocks back multiple myeloma drug from Takeda

  May 27, 2016

• Roche's Gazyva notches early trial success

  May 27, 2016

• FDA rejects AstraZeneca hyperkalemia drug, boosting competitor Relypsa

  May 27, 2016

• Bristol-Myers attacks cost-effectiveness study of cancer drug

  May 26, 2016

• Sanofi diabetes drug wins adcomm support, keeping pace with Novo

  May 26, 2016

• Theranos hit with class-action lawsuit over blood-testing claims

  May 25, 2016

• Sarepta shares jump after FDA delays decision on Duchenne drug

  May 25, 2016

• Despite recent R&D setbacks, Lilly aims to launch 20 new drugs by 2023

  May 24, 2016

• Janssen's multiple myeloma drug passes muster in Europe

  May 24, 2016

• After setback, GSK's Breo gets boost from real-world data

  May 24, 2016

• Eyeing US market, Samsung applies for approval of biosimilar Remicade

  May 24, 2016

• EMA removes warning from Pfizer smoking cessation drug

  May 23, 2016

• Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug

  May 23, 2016

• Immunotherapies from Merck and Bristol-Myers help extend life, new data shows

  May 19, 2016

• Theranos corrects two years of test results: WSJ

  May 19, 2016

• Roche to shutter Clarecastle plant after it can't find buyer

  May 19, 2016

• Roche's much-anticipated immontherapy wins early approval for bladder cancer

  May 19, 2016

• New patent threat looms for AbbVie's blockbuster Humira

  May 18, 2016

• Bristol-Myers extends lead with new Opdivo indication

  May 17, 2016

• Novartis splits drugs unit, pharma chief to depart

  May 17, 2016

• AstraZeneca asthma drug clears phase 3 studies, boosting respiratory pipeline

  May 17, 2016

• Biogen unveils gene therapy collaboration with UPenn experts

  May 16, 2016

• After criticism, Valeant details plans for hospital discounts on heart drugs

  May 16, 2016

• With generics deal pending, Teva's Europe portfolio attracts buyers

  May 16, 2016

• Pfizer adds eczema drug in $5.2 billion deal for Anacor

  May 16, 2016

• Aegerion to plead guilty to misbranding cholesterol drug, will pay $40 million

  May 12, 2016

• After shutting down cancer drug, Clovis now facing government investigations

  May 12, 2016

• Baxter reportedly top suitor for Indian injectables maker

  May 12, 2016

• Amid losses, Endo plans cutbacks at Par manufacturing facilities

  May 12, 2016

• U.K. cost agency rejects Bristol-Myer's Opdivo for lung cancer

  May 12, 2016

• Theranos president to leave company as federal scrutiny continues

  May 12, 2016

• Colombian diplomat warns of fallout from Novartis patent battle

  May 11, 2016

• Drugmakers hit with federal investigations of PBM contracts

  May 11, 2016

• India awards patent to Gilead's Sovaldi

  May 10, 2016

• Allergan plans $10 billion stock buyback as it waits for Teva cash

  May 10, 2016

• FDA flags potential safety risk for Lilly antipsychotic drug

  May 10, 2016

• 'The sharks are circling:' 5 insights from the Valeant documents

  May 10, 2016

• Medicines Co. sells off cardiovascular drugs to Italy's Chiesi

  May 9, 2016

• Lower sales of generic drugs weigh on Teva's first-quarter revenue

  May 9, 2016

• As new CEO takes over, Valeant forms committee to oversee drug pricing

  May 6, 2016

• As Big Pharma circles, Medivation makes case for independence

  May 6, 2016

• FDA reaches agreement with Xellia on troubled manufacturing plant

  May 5, 2016

• Biogen spinoff set to build out hemophilia pipeline

  May 5, 2016

• Sanofi threatens Medivation board with hostile bid

  May 5, 2016

• Merck sales hit by generic competition in US, Europe

  May 5, 2016

• Report: Pfizer considering takeover offer for sought-after Medivation

  May 4, 2016

• Israeli pharma company provides rare disease drug for free after it can't find patients

  May 3, 2016

• Pfizer revenues surge as vaccines, new drugs rack up sales

  May 3, 2016

• Boosting focus on neurology, Biogen to spin off hemophilia business

  May 3, 2016

• Eagle Pharma hits FDA with lawsuit after cancer drug denied orphan exclusivity

  May 2, 2016

• Gene editing biotech Homology Med launches with $44 million in financing

  May 2, 2016

• Federal judge reopens high-stakes patent case between Merck and Gilead

  May 1, 2016

• As profits drop, AstraZeneca trims costs and sharpens focus on R&D

  April 29, 2016

• With CEO Pearson set to bow out, Valeant files much-delayed annual report

  April 29, 2016

• As new drugs take hold, Lilly ramps up R&D spend

  April 28, 2016

• Adding to changes at top, Valeant reportedly set to turn over board

  April 28, 2016

• Sanofi pressures Medivation to take $9.3 billion bid

  April 28, 2016

• Valeant officials apologize to Senate panel for steep price hikes

  April 27, 2016

• Valeant increased prices too aggressively, CEO expected to tell Senate panel

  April 27, 2016

• FDA demands additional studies for Catalyst's firdapse

  April 26, 2016

• Seven New York insurers end restrictions on coverage for hepatitis C drugs

  April 26, 2016

• New drug sales boost Lilly revenue, yet profits tumble

  April 26, 2016

• Despite efforts of advocates, FDA panel votes against Sarepta's Duchenne drug

  April 25, 2016

• Valeant names ex-Perrigo chief Joseph Papa as CEO

  April 25, 2016

• Inside the development of Venclexta, AbbVie's new leukemia drug

  April 22, 2016

• Adding to cosmetic portfolio, Allergan buys Topokine for $85 million

  April 22, 2016

• AstraZeneca launches massive drug discovery effort, aims to sequence 2 million genomes

  April 22, 2016

• Continuing scrutiny, FDA hits Sri Krishna with warning over 'serious' data violations

  April 21, 2016

• China investigates 3 drugmakers for manufacturing violations, orders recall

  April 21, 2016

• Novartis income falls as key cancer drug battles generic competition

  April 21, 2016

• Bluebird Bio gene therapy sees encouraging early results in treatment of rare brain disease

  April 21, 2016

• NIH suspends work at two facilities, including T-cell research

  April 19, 2016

• Bristol-Myers' Opdivo shows promise in head, neck cancers

  April 19, 2016

• Roche beats Q1 expectations on strong oncology sales

  April 19, 2016

• With new studies, Boehringer and Lilly to pit diabetes drug against heart failure

  April 19, 2016

• Theranos reportedly facing new federal investigations

  April 19, 2016

• Bristol-Myers' Opdivo gets boost from long-term survival data

  April 18, 2016

• Review of NCI facilities halts patient enrollment in Kite T-cell studies

  April 17, 2016

• Report: AstraZeneca considering bid for cancer biotech Medivation

  April 17, 2016

• Further downgrade to Valeant ratings reportedly could trigger forced selling

  April 15, 2016

• Swiss company Lonza Group seeking to acquire CRO Catalent: report

  April 14, 2016

• FDA advocates for adoption of speedier drug manufacturing technique

  April 14, 2016

• Report: U.S. drug spending hit $310 billion last year

  April 14, 2016

• Regulator proposes 2-year ban of Theranos founder Elizabeth Holmes

  April 13, 2016

• Biosimilars gain momentum — and pharma leaders are noticing

  April 13, 2016

• Large bondholder hits Valeant with default notice

  April 12, 2016

• Clovis' lung cancer drug fails to impress FDA panel

  April 12, 2016

• Japanese genomic analysis characterizes liver cancer into six types

  April 12, 2016

• CRISPR biotech Intellia strikes licensing deal with Regeneron, readies IPO

  April 11, 2016

• Life after Shkreli: KaloBios promises affordable drugs, no 'price gouging'

  April 11, 2016

• AbbVie and Roche team wins FDA approval for leukemia drug

  April 11, 2016

• Roche's anti-PDL1 immunotherapy granted fast track status

  April 11, 2016

• Valeant board asks CEO Pearson to cooperate with Senate panel subpoena

  April 10, 2016

• Amid questions on accuracy of blood tests, Theranos bulks up its medical board

  April 8, 2016

• After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3

  April 8, 2016

• Inspections by FDA hurting Indian drug exports, says Dr. Reddy's chairman

  April 7, 2016

• Why partnerships are crucial for pushing vaccine R&D forward

  April 7, 2016

• Allergan snaps up rights to Alzheimer's drugs in deal with Heptares

  April 7, 2016

• Lenders give Valeant a reprieve, agree to extend deadline for filing annual report

  April 7, 2016

• After merger with Pfizer implodes, Allergan's acquisition options open up

  April 6, 2016

• Pfizer calls off $160 billion merger with Allergan

  April 6, 2016

• Remicade copy clears FDA, becomes second biosim to win approval in U.S.

  April 5, 2016

• In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo

  April 5, 2016

• Valeant panel concludes Philidor investigation, finds no more misstatements

  April 5, 2016

• New US inversion rules could wreck Pfizer-Allergan deal

  April 5, 2016

• Report: Valeant cuts sales force for female libido drug

  April 4, 2016

• Gilead's new HIV formulation continues success with FDA approval of Descovy

  April 4, 2016

• Study shows no clinical benefit from Lilly's failed cholesterol drug

  April 4, 2016

• GSK gene therapy for rare immune disorder wins EMA approval

  April 3, 2016

• Samsung Bioepis' biosim of Remicade clears regulatory hurdle in EU

  April 1, 2016

• FTC alleges Endo struck illegal deals to delay release of generic drugs

  April 1, 2016

• Canadian securities regulator issues cease trade orders to Valeant management

  April 1, 2016

• As aging blockbusters come off patent, new opportunities emerge for biosim manufacturers

  March 31, 2016

• In quest to expand diabetes market share, Novo breaks ground on $1.8b U.S. plant

  March 31, 2016

• GSK won't file drug patents in low-income countries

  March 31, 2016

• Indian drug regulator to begin surprise inspections at manufacturing sites

  March 30, 2016

• FTC asks Pfizer, Allergan for more details on proposed mega-merger

  March 30, 2016

• With deadline looming, Valeant asks lenders for more time to file report

  March 30, 2016

• Cambridge-based Aveo settles fraud charges with SEC for $4 million

  March 30, 2016

• FDA panel says benefits outweigh risks for Acadia's Parkinson's drug

  March 29, 2016

• Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs

  March 29, 2016

• Sanders, other lawmakers urge NIH to consider patent override on cancer drug

  March 28, 2016

• New phase 2 data boosts prospects for Alder's migraine drug

  March 28, 2016

• Spending on Vertex's Kalydeco consumed 86% of Scottish rare disease fund's budget

  March 28, 2016

• Sprout investors reportedly allege Valeant overpriced Addyi

  March 27, 2016

• Gilead to pay Merck $200 million in damages for Hep C patents

  March 25, 2016

• Patent case in India highlights tensions between public health, protecting innovation

  March 24, 2016

• Head of Valeant's largest investor retires as drugmaker's troubles hit fund

  March 24, 2016

• A month after FDA spurned DMD drug, PTC laying off 18% of workforce

  March 23, 2016

• In major stroke study, AstraZeneca's Brilinta fails to beat aspirin

  March 23, 2016

• Merck wins major victory in hep C patent case against Gilead

  March 22, 2016

• Eli Lilly's ixekizumab gets green light from FDA

  March 22, 2016

• As stock crashed, Valeant's largest shareholder reportedly sold 1.5m shares

  March 22, 2016

• In response to crisis, FDA mandates new warnings for opioid painkillers

  March 22, 2016

• Citing 'improper conduct,' Valeant attempts to oust former CFO from board

  March 21, 2016

• Valeant's Pearson will step down as CEO; Ackman joins Board

  March 21, 2016

• U.K. cost regulator confirms final approval for Novartis' Entresto

  March 20, 2016

• Johnson & Johnson's psoriasis drug Stelara succeeds in Phase 3

  March 18, 2016

• In new deal, Kite Pharma partnering with Roche on cancer immunotherapy

  March 18, 2016

• McKesson laying off 1,600 employees

  March 17, 2016

• Scientists develop new type of stem cell with only half a genome

  March 17, 2016

• Amgen signs 'flexible manufacturing agreement' with CMO Patheon

  March 17, 2016

• GSK head Andrew Witty to step down in spring 2017

  March 17, 2016

• Jury rules in favor of Amgen in PCSK9 patent fight

  March 16, 2016

• After forecast cut, Valeant stock collapses as investors head for the exits

  March 16, 2016

• As EMA investigates, Gilead halts six clinical trials of cancer drug

  March 15, 2016

• Express Scripts: Growth in overall U.S. drug spending slowed in 2015

  March 15, 2016

• Teva's $40.5 billion generics deal with Allergan hits FTC snag

  March 15, 2016

• Roche signs potential $1 billion cancer immunotherapy deal with Cambridge biotech

  March 15, 2016

• Valeant cuts 2016 revenue projections by $1.5 billion

  March 15, 2016

• Amid investor criticism, AstraZeneca considers link between executive pay and revenue goal

  March 14, 2016

• Doctors Without Borders moves to block Pfizer patent in India

  March 11, 2016

• Sanofi's sarilumab bests blockbuster Humira in Phase 3 study

  March 11, 2016

• EC approves Teva's $40.5B deal for Allergan generics arm

  March 10, 2016

• House Oversight committee presses Valeant on details of withheld documents

  March 10, 2016

• First generic version of Viagra in the U.S. approved by FDA

  March 10, 2016

• Death from French drug trial likely due to high doses of compound

  March 10, 2016

• Senate bill adding Zika to priority review program highlights R&D incentives

  March 10, 2016

• VA broadens Hep C coverage to all veterans, not just the sickest

  March 10, 2016

• FDA accepts new Keytruda data, opening door for wider indication

  March 9, 2016

• Report: Theranos continued blood tests even as quality checks revealed flaws

  March 9, 2016

• Hoping for rebound, Valeant adds three new members to board

  March 9, 2016

• US prescription drug spending increases to an estimated $457 billion in 2015

  March 9, 2016

• CMS proposes overhaul to Part B drug reimbursement

  March 8, 2016

• India will reportedly refrain from issuing compulsory drug licenses

  March 8, 2016

• Ending 20-year partnership, Sanofi and Merck close down joint vaccines venture

  March 8, 2016

• Bayer, Novartis, Sanofi lose big on Venezuelan bonds

  March 7, 2016

• EMA debuts new program to speed up review of innovative drugs

  March 7, 2016

• In high-profile failure, Celldex's cancer vaccine crashes in phase 3

  March 7, 2016

• AbbVie paying Boehringer $595M upfront to gain access to psoriasis drug

  March 7, 2016

• Janssen, AbbVie's Imbruvica approved by FDA for first line treatment of CLL

  March 4, 2016

• Moody's downgrades pharma industry outlook, cites lower pricing

  March 4, 2016

• UK Autolus reels in £40 million for CAR-T development

  March 4, 2016

• Much-anticipated trial shows Novo's Victoza reduces CV risk

  March 4, 2016

• Kite, Juno ramping up commercial manufacturing capacity for CAR-T

  March 3, 2016

• Valeant dermatology exec resigns, company cites 'personal reasons'

  March 3, 2016

• Express Scripts unimpressed by insulin data on Novo's Tresiba

  March 3, 2016

• FDA opposes re-authorization of pediatric priority review program: GAO report

  March 3, 2016

• Animated drug ads prompt FDA study into effect on consumer behavior

  March 2, 2016

• UK cost regulator rejects promising cancer med Imbruvica

  March 2, 2016

• Second TAF-based HIV treatment from Gilead wins FDA approval

  March 1, 2016

• PhRMA sues to challenge Ohio ballot initiative limiting drug prices

  March 1, 2016

• Biotech Exelixis scores $200M from Ipsen for cancer drug rights

  March 1, 2016

• Hearings begin in India on validity of Gilead patent for hep C med

  Feb. 29, 2016

• On the heels of CEO's return, Valeant under new investigation by the SEC

  Feb. 29, 2016

• Amid calls for breakup, Glaxo reportedly begins search for successor to CEO Witty

  Feb. 29, 2016

• Valeant's Pearson returns from medical leave, resumes post as CEO

  Feb. 29, 2016

• Gilead's new HIV combo drug inches closer to EU approval

  Feb. 26, 2016

• DNA sequencer Illumina sues competitor over nanopore patents

  Feb. 25, 2016

• European pharma industry warns against 'Brexit,' urges Britain to remain in EU

  Feb. 25, 2016

• First human trial of optogenetics to treat blindness set to launch

  Feb. 25, 2016

• KaloBios asking bankruptcy court approval to buy rights to Chagas drug

  Feb. 25, 2016

• Senate confirms Califf as FDA commissioner by an 89-4 vote

  Feb. 24, 2016

• PTC stock falls off a cliff after biotech slapped with FDA 'refusal to file'

  Feb. 24, 2016

• 7 big pharma companies sign on to Parkinson's development group

  Feb. 24, 2016

• How the opioid crisis convinced these senators to oppose advancing Califf's nomination, in charts

  Feb. 23, 2016

• FDA chief nominee Califf likely to be confirmed after clearing key Senate vote

  Feb. 23, 2016

• CVS reports dramatic drop in Rx spending growth after 2014's double-digit spike

  Feb. 23, 2016

• Novartis, Broad researchers find hope in potential gene target for intractable cancers

  Feb. 22, 2016

• Sandoz to Supreme Court: Don't let branded drugmakers have extra leg up on biosims

  Feb. 19, 2016

• Sun Pharma to seek re-inspection of non-compliant Halol plant

  Feb. 18, 2016

• FDA 'refusal to file' letter sends Catalyst tumbling

  Feb. 17, 2016

• New, emotional BIO ad highlights innovation in effort push back on pricing critics

  Feb. 17, 2016

• Next-gen T-cell cancer therapy hopes buoyed by promising new data

  Feb. 17, 2016

• Looking ahead at orphan drugs' future: More breakthroughs, exploding sales

  Feb. 16, 2016

• Disappointment for Incyte as phase 3 failure prompts halt on Jakafi solid tumor trials

  Feb. 12, 2016

• Update: Sandoz continues biosim streak, acquires rights to Pfizer's Remicade copy in Europe

  Feb. 11, 2016

• Report: US CMO market set to rebound as foreign quality concerns grow

  Feb. 11, 2016

• From 'hit' to candidate: Inside Sanofi's massive compound sharing agreement with AZ

  Feb. 11, 2016

• Imprimis marches on with price cut strategy, will offer cheaper version of Retrophin's kidney stone med

  Feb. 11, 2016

• CMS pulls memo detailing possible changes to Medicare's drug reimbursements for docs

  Feb. 10, 2016

• Juno CEO, CFO snag bonuses after $1 billion Celgene deal

  Feb. 10, 2016

• Novartis strikes rare P4P deals with Aetna & Cigna, will price heart med based on outcomes

  Feb. 9, 2016

• Obama asks Congress for $1.8 billion to counter Zika ahead of mosquito season

  Feb. 8, 2016

• An Indian biotech is already developing two Zika vaccine candidates

  Feb. 8, 2016

• LA county doctor sentenced to 30 years to life for over-prescribing addictive drugs

  Feb. 5, 2016

• FDA, Califf to overhaul opioid approval process following intense public pressure

  Feb. 4, 2016

• UK to funnel $160 million into clinical research infrastructure

  Feb. 4, 2016

• AstraZeneca's potential lung cancer blockbuster nabs EU approval

  Feb. 4, 2016

• Gilead hunting for deals as Q4 earnings beat expectations

  Feb. 3, 2016

• Damaging House memos reveal calculated drug price increases at Turing, Valeant

  Feb. 2, 2016

• Sanofi reportedly planning to cut 600 jobs over 3 years in France

  Feb. 2, 2016

• WHO declares Zika a global health emergency, calls for greater collaboration

  Feb. 1, 2016

• Valeant hits back at Clinton's 'predatory pricing' accusations

  Feb. 1, 2016

• Senators Manchin, Ayotte join growing opposition to Califf FDA nomination

  Jan. 29, 2016

• Looking ahead at Lilly's 2016 prospects after a challenging 2015

  Jan. 29, 2016

• Pfizer recalls 3 lots of Lyrica after heat damage

  Jan. 28, 2016

• WHO warns of Zika's 'explosive spread,' convenes emergency committee

  Jan. 28, 2016

• Pharma titans seek out tech partnerships to bring big data to healthcare

  Jan. 26, 2016

• Akashi suspends Duchenne trial in another blow to treatment hopes

  Jan. 26, 2016

• Bristol-Myers' Opdivo notches two key regulatory victories in US, UK

  Jan. 25, 2016

• Powerhouse pharma coalition promises more antibiotics R&D, but calls for better incentives

  Jan. 22, 2016

• Reviewing Gilead's formidable 2015: A year marked by higher sales and new criticism

  Jan. 22, 2016

• Chinese pharma company slapped with import ban by FDA

  Jan. 21, 2016

• WebMD: We're not in negotiations to be bought

  Jan. 20, 2016

• Multiple violations cause production halt at Mylan-owned Agila's Polish plant

  Jan. 20, 2016

• Amidst falling sales, Medicines Co. reportedly mulling sale

  Jan. 20, 2016

• Watchdog report spotlights significant failures in FDA postmarket drug tracking

  Jan. 20, 2016

• Gavi commits $5 million in advance for Merck's Ebola vaccine

  Jan. 20, 2016

• Biotech Acorda buys Finnish firm Biotie & its Parkinson's candidates for $363M

  Jan. 19, 2016

• Novartis' psoriasis mega-blockbuster hopeful Cosentyx nabs 2 new indications

  Jan. 19, 2016

• CORRECTED: French drug trial suspended after participant left brain dead, five others critically ill

  Jan. 15, 2016

• Pfizer partners with nonprofit Calibr to develop heart failure drugs

  Jan. 14, 2016

• Bayer opens OTC drug manufacturing plant in China

  Jan. 14, 2016

• WHO declares Liberia free of Ebola, ending West African outbreak

  Jan. 14, 2016

• Warning letters reveal some of the FDA's biggest problems with Indian drugmakers

  Jan. 13, 2016

• Express Scripts shares slide as Anthem threatens to ditch PBM over drug savings

  Jan. 13, 2016

• Pharma battling ballot measures designed to limit drug prices

  Jan. 13, 2016

• FDA flags manufacturing deficiencies of Chinese drug supplier

  Jan. 13, 2016

• Health committee sends Califf FDA nom to full Senate as Sanders mulls hold

  Jan. 12, 2016

• Struggling Mannkind appoints new CEO after withdrawing offer to previous choice

  Jan. 11, 2016

• Shire buys Baxalta for $32 billion, ending months-long pursuit

  Jan. 11, 2016

• UK investor Woodford reiterates call for Glaxo to be split four ways

  Jan. 11, 2016

• Flurry of venture deals hits biopharma ahead of JPMorgan healthcare conference

  Jan. 7, 2016

• India's Cadila to snap up plant, animal health products from Pfizer spinoff Zoetis

  Jan. 7, 2016

• Biotech startup Vtesse granted FDA breakthrough designation for orphan NPC drug

  Jan. 6, 2016

• Gilead grabs priority review for pangenotype hep C combo; Hep B med shown to be safe

  Jan. 6, 2016

• MannKind CFO: We're searching for a new Afrezza marketing partner after Sanofi's departure

  Jan. 6, 2016

• Shkreli's former company KaloBios files for bankruptcy

  Dec. 31, 2015

• Valeant CEO Pearson on medical leave, company being run by 3-man exec group

  Dec. 28, 2015

• Bristol-Myers spinning off its entire HIV pipeline to Glaxo for $1.5 billion

  Dec. 18, 2015

• Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar

  Dec. 17, 2015

• Kallyope raises $44M in Series A to launch NYC-based 'gut-brain' biotech

  Dec. 11, 2015

• Clinton plan would pump brakes on Pfizer-Allergan deal, other major inversion mergers

  Dec. 10, 2015

• Senators mull speedier generics pathway amid outrage over Turing, Valeant price hikes

  Dec. 9, 2015

• The 5 pharma vets and 3 newcomers that made BCG's '50 most innovative' firms list

  Dec. 4, 2015

• Senators grilled Obama's nominee for FDA chief. Here's how he responded

  Nov. 18, 2015